<SEC-DOCUMENT>0001013762-25-002793.txt : 20250326
<SEC-HEADER>0001013762-25-002793.hdr.sgml : 20250326
<ACCEPTANCE-DATETIME>20250326170312
ACCESSION NUMBER:		0001013762-25-002793
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20250320
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250326
DATE AS OF CHANGE:		20250326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41277
		FILM NUMBER:		25774166

	BUSINESS ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		16772 WEST BERNARDO DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0235502-8k_modular.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:MODD="http://modularmedical.com/20250320">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_037_MODD_modularmedical.com_20250320 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20250320_20250320 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001074871 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000004" name="dei:EntityCentralIndexKey">0001074871</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="modd-20250320.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-03-20">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-20</xbrli:startDate>
        <xbrli:endDate>2025-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20250320__20250320_zVEaM7qrgbSk"><ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event Reported):
<span id="xdx_903_edei--DocumentPeriodEndDate_c20250320__20250320_zskEfqW1ZfJj"><ix:nonNumeric contextRef="AsOf2025-03-20" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">March 20, 2025</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20250320__20250320_zqAwKLj7r0S9"><ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000011" name="dei:EntityRegistrantName">MODULAR MEDICAL, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityFileNumber_c20250320__20250320_zFw6yXaCD4cb"><ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000012" name="dei:EntityFileNumber">001-41277</ix:nonNumeric></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20250320__20250320_zQNsN0aFc7Uf"><ix:nonNumeric contextRef="AsOf2025-03-20" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 49%"><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20250320__20250320_zjkEY5uzGO34"><ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000014" name="dei:EntityTaxIdentificationNumber">87-0620495</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(State or Other Jurisdiction<br/>
of Incorporation)</td>
    <td>&#160;</td>
    <td style="text-align: center">(I.R.S. Employer<br/>
Identification Number)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityAddressAddressLine1_c20250320__20250320_z1TshUgPODL4"><ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000015" name="dei:EntityAddressAddressLine1">10740 Thornmint Road</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityAddressCityOrTown_c20250320__20250320_zbfg3BHwv8W1"><ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000016" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20250320__20250320_zFDhVrTbxyhj"><ix:nonNumeric contextRef="AsOf2025-03-20" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20250320__20250320_zn0vpiJNWC8d"><ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000018" name="dei:EntityAddressPostalZipCode">92127</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices, with zip
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_904_edei--CityAreaCode_c20250320__20250320_zzI5FjFLpyO1"><ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000019" name="dei:CityAreaCode">858</ix:nonNumeric></span>) <span id="xdx_90D_edei--LocalPhoneNumber_c20250320__20250320_zOXZEE0q9B96"><ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000020" name="dei:LocalPhoneNumber">800-3500</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--WrittenCommunications_c20250320__20250320_zBYG0ILd1k0c"><ix:nonNumeric contextRef="AsOf2025-03-20" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--SolicitingMaterial_c20250320__20250320_zoVtSCradITg"><ix:nonNumeric contextRef="AsOf2025-03-20" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90B_edei--PreCommencementTenderOffer_c20250320__20250320_zx4wTS3dlds1"><ix:nonNumeric contextRef="AsOf2025-03-20" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20250320__20250320_zo4Q2tHfWe91"><ix:nonNumeric contextRef="AsOf2025-03-20" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%">Title of each class</td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%">Trading Symbol(s)</td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; padding-left: 11.9pt; text-align: center; width: 32%">Name of each exchange on which registered</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span id="xdx_90F_edei--Security12bTitle_c20250320__20250320_z4s1uTqMLla2"><ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000025" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_edei--TradingSymbol_c20250320__20250320_ztNsDc1otd6k"><ix:nonNumeric contextRef="AsOf2025-03-20" id="Fact000026" name="dei:TradingSymbol">MODD</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center">The <span id="xdx_907_edei--SecurityExchangeName_c20250320__20250320_znxX1At6r7Ne"><ix:nonNumeric contextRef="AsOf2025-03-20" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR&#167;230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20250320__20250320_zA7Do22hYsfh"><ix:nonNumeric contextRef="AsOf2025-03-20" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 1.01 Entry into
a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Private Placement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2025, Modular Medical, Inc. (the
&#8220;Company&#8221;) entered into Securities Purchase Agreements (the &#8220;Purchase Agreements&#8221;) with investors (the &#8220;Investors&#8221;)
for the&#160;private placement&#160;(the &#8220;Private Placement&#8221;) of 6,247,656&#160;units&#160;(each a &#8220;Unit&#8221;), with
each Unit consisting of (A) two shares of the Company&#8217;s common stock, par value $0.001 per share (&#8220;Common Stock&#8221;) and
(B) one warrant (a &#8220;Warrant&#8221;) to purchase one share of Common Stock, at an offering price of $1.92 per Unit. Certain affiliates,
officers and directors of the Company purchased a total of 374,478 Units in the Private Placement. The Common Stock and the Warrants included
in the&#160;Units&#160;and the Common Stock underlying the Warrants are collectively referred to herein as the &#8220;Securities.&#8221;
The Private Placement closed on March 26, 2025 with aggregate gross proceeds totaling approximately $12 million, before deducting placement
agent fees and other expenses. The Company intends to use the proceeds from the Private Placement for general corporate and working capital
purposes and supply-chain optimization and margin improvement on its MODD1 product in preparation for broad commercial availability and
preparing the submission to the FDA of a tubeless version of the MODD1 product, which the Company currently believes it will submit to
the FDA in the third quarter of 2025, along with ongoing work to obtain the CE mark required for overseas markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Warrants have an
exercise price of $1.12 per share. Each Warrant is exercisable immediately and will expire four years from the date of issuance. <span style="background-color: white">The
exercise price and number of shares of Common Stock issuable upon exercise of the warrants is subject to appropriate adjustment in the
event of stock dividends, stock splits, reorganizations or similar events affecting the Common Stock and the exercise price. Subject to
limited exceptions, an Investor may not exercise any portion of its warrants to the extent that the Investor would beneficially own more
than 4.99% (or, at the election of the holder prior to the date of issuance, 9.99%) of the Company&#8217;s outstanding Common Stock after
exercise.</span> In the event of certain fundamental transactions, the holder of the Warrants will have the right to receive the&#160;Black
Scholes&#160;Value (as defined in the Warrants) of its Warrants calculated pursuant to a formula set forth in the Warrants, payable in
cash. There is no trading market available for the Warrants on any securities exchange or nationally recognized trading system. The Company
does not intend to list the Warrants on any securities exchange or nationally recognized trading system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="background-color: white">In
addition, pursuant to the terms of the Purchase Agreement, the officers and directors of the Company have entered into agreements providing
that each such person may not, without the prior written consent of the Placement Agent (as defined below), subject to certain exceptions,
offer, issue, sell, transfer or otherwise dispose of the Company&#8217;s securities for a period of 60 days following the date of closing
of the Private Placement. </span>Also, pursuant to the Purchase Agreement, the Company agreed not to effect or agree to effect any Variable
Rate Transaction (as defined in the Purchase Agreement) until one year after the date of <span style="background-color: white">closing
of the Private Placement</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Newbridge Securities Corporation
(the &#8220;Placement Agent&#8221;) acted as the Company&#8217;s placement agent in connection with the Private Placement, pursuant to
that certain engagement letter, dated as of February 10, 2025, between the Company and the Placement Agent, pursuant to which the Company
paid the Placement Agent (i) a cash fee equal to 7.25% of the aggregate gross proceeds from the&#160;sale of the Securities in the Private
Placement and (ii) reimbursement for certain of out-of-pocket expenses, including for reasonable expenses and legal fees of $50,000. In
addition, the Company issued to the Placement Agent or its designees warrants (the &#8220;Placement Agent Warrants&#8221;) to purchase
up to an aggregate of 874,672 shares of Common Stock (7.0% of the Common Stock sold in the Private Placement). The Placement Agent Warrants
have substantially the same terms as the Warrants except the Placement Agent Warrants will have an exercise price equal to $1.40 per share
(125% of the exercise price of the Warrants). The Placement Agent Warrants will be exercisable six months from the date of issuance and
expire on the fourth anniversary of the issuance date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Titan Partners Group,
a division of American Capital Partners, acted as financial advisor to the Company and was paid a fee of $100,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Securities have not
been registered under the&#160;Securities Act of 1933, as amended (the "Securities Act"), and were offered pursuant to the exemption
from registration provided in Section 4(a)(2) under the&#160;Securities Act, and Rule 506(b) promulgated thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b><i>Concurrent Direct
Placement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Concurrently with the
Private Placement, on March 20, 2025, the Company entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) with
a foreign investor (the &#8220;Purchaser&#8221;), pursuant to which the Company completed a direct private placement of 260,417 Units
for additional aggregate gross proceeds of approximately $0.5 million on the same terms as the Private Placement (the &#8220;Concurrent
Direct Placement&#8221;). The Purchaser is reasonably believed to be a qualified institutional buyer pursuant to Regulation S under the
Securities Act. The Concurrent Direct Placement closed on March 25, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the Purchase
Agreement and the Subscription Agreement, the Company has agreed to use commercially reasonable efforts to prepare and file with the Securities
and Exchange Commission (the &#8220;SEC&#8221;) a registration statement covering the resale of the shares of Common Stock and shares
of Common Stock underlying the Warrants issued in the Private Placement and the Concurrent Direct Placement (the &#8220;Registration Statement&#8221;)
within 30 days of the Closing Date, and to cause the SEC to declare effective the Registration Statement as promptly as possible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The foregoing summary
of the terms and conditions of each of the Warrant, Placement Agent Warrant, the Purchase Agreement and the Subscription Agreement is
subject to, and qualified in its entirety by reference to the full text of such agreement, forms of which are filed as Exhibits 4.1, 4.2,
10.1 and 10.2, respectively, to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item 3.02. Unregistered Sales of Equity
Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information set
forth under Item 1.01 is incorporated by reference into this Item 3.02. The Securities being sold pursuant to the Purchase Agreement are being sold and issued without registration under the Securities Act, in reliance on the exemptions provided
by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering and/or Rule 506 promulgated thereunder, and
in reliance on similar exemptions under applicable state laws. For the Securities being sold pursuant to the Subscription Agreement,
the Company replied upon the exemption from the registration requirements of the Securities Act provided by Regulation S promulgated under
the Securities Act.<b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 9.01 Financial
Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>(d) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following exhibits
are filed with this report:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 9%"><b>Exhibit<br/>
Number</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 90%"><b>Exhibit Description</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>4.1</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea023550201ex4-1_modular.htm">Form of Common Stock Purchase Warrant</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>4.2</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea023550201ex4-2_modular.htm">Form of Placement Agent Warrant</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.1</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea023550201ex10-1_modular.htm">Form of Securities Purchase Agreement</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">10.2</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea023550201ex10-2_modular.htm">Form of Subscription Agreement</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">104</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>MODULAR MEDICAL, INC.</b></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 36%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Date: March 26, 2025</td>
    <td>By:</td>
    <td style="border-bottom: Black 1.5pt solid"><i>/s/ James E. Besser</i></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>James E. Besser</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Chief Executive Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwjAQRU/QOwxZi8ZoF3Zp0SJWkSLiNtpRgm2mTKLWI3lLY4s4DAzD/+9/IQYio6WpkOE4L3LYY91U2iMUeEFGe8bgSFfrBMIt8GqcZ2199/7AlAKDgYmHKj4FobM+jMMyATkZqelIxSBniYxhtxHRV0/JXkyJ1htdgbYl7JgaNug1v/qEvW7JUv3qqg7IzpBNYDyUvfwGJccKtvTQT+KbgzxPRTToJhIZ070JrkXr0X5JWFRYhzrX0/+NPgtWSpQ= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea023550201ex4-1_modular.htm
<DESCRIPTION>FORM OF COMMON STOCK PURCHASE WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS
EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY
NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE
SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE
MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COMMON STOCK PURCHASE WARRANT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MODULAR MEDICAL, INC. </B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Warrant Shares: [&#9679;]</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Issue Date: March 25, 2025</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;)
certifies that, for value received, [&#9679;] or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject
to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the &ldquo;<U>Initial
Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on March 25, 2029 (the &ldquo;<U>Termination Date</U>&rdquo;)
but not thereafter, to subscribe for and purchase from Modular Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
one share (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share
of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>. Capitalized
terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &ldquo;<U>Purchase
Agreement</U>&rdquo;), dated March 20, 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">a) <U>Exercise of Warrant</U>. Exercise of the
purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date
and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or
e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier
of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i)
herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified
in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise
procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.<B>&nbsp;</B>No ink-original Notice of Exercise
shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case,
the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice
of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of
Warrant Shares available hereunder shall have the automatic effect of lowering the outstanding number of Warrant Shares purchasable hereunder
in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the
number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within
one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that,
by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant
Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">b) <U>Exercise Price</U>. The exercise price per
share of Common Stock under this Warrant shall be $1.12 subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">c) <U>Cashless Exercise</U>. If at the time of
exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for, the
resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">(A)&thinsp;</FONT></TD>
    <TD STYLE="text-align: center; vertical-align: top; width: 0.15in">=</TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">(B)&thinsp;</FONT></TD>
    <TD STYLE="text-align: center; width: 0.15in; vertical-align: top">=</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">the Exercise Price of this Warrant, as adjusted hereunder; and </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: left; font-size: 10pt; vertical-align: top; width: 0.25in">(X)</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 0.15in"><FONT STYLE="font-size: 10pt">&thinsp;=</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If Warrant Shares are issued in such a cashless
exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take
on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to
the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo; means, for any
date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading
Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the
Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m.
(New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB
or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases,
the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a
majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall
be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo; means, for any date,
the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading
Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market
on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time)
to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for
trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency
succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders
of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">d) <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">i. <U>Delivery of Warrant Shares Upon Exercise</U>.
The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the
account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there is an effective
registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant
Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise
of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of
the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise by the date that is the later of (i) the earlier of (a) two (2) Trading Days after the
delivery to the Company of the Notice of Exercise and (b) the number of Trading Days comprising the Standard Settlement Period after the
delivery to the Company of the Notice of Exercise, and (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the
Company (provided the foregoing clause (ii) shall not apply in the event of a cashless exercise) (such date, the &ldquo;<U>Warrant Share
Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become
the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following
delivery of the Notice of Exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long
as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard
settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock
as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ii. <U>Delivery of New Warrants Upon Exercise</U>.
If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate,
at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the
unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">iii. <U>Rescission Rights</U>. If the Company
fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery
Date, then the Holder will have the right to rescind such exercise by providing the Company with written notice of rescission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">iv. <U>Compensation for Buy-In on Failure to Timely
Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer
Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise
on or before the Warrant Share Delivery Date (other than any such failure that is solely due to any action or inaction by the Holder with
respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise)
or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A)
pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if
any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that
the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order
giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant
and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded)
or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover
a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder
shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the
Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">v. <U>No Fractional Shares or Scrip</U>. No fractional
shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which
the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round down to the next whole
share.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">vi. <U>Charges, Taxes and Expenses</U>. Issuance
of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the
issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued
in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that, in the event
that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be
accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the
payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required
for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation
performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">vii. <U>Closing of Books</U>. The Company will
not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">e) <U>Holder&rsquo;s Exercise
Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any
portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons
acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution
Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such
determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the
remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and
(ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without
limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation
contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the
preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not
representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely
responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this
Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole
discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of
whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and
Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership
Limitation. To ensure compliance with this restriction, each Holder shall be deemed to represent to the Company each time it
delivers a Notice of Exercise that such Notice of Exercise has not violated the restrictions set forth in this paragraph, and the
Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises
of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other than to the extent that information on
the number of outstanding shares of Common Stock of the Company is provided by the Company and relied upon by the Holder), provided
that any exercise of this Warrant and issuance of Common Stock in excess of the applicable Beneficial Ownership Limitation shall be
null and void. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder and the Company shall have no obligation to
verify or confirm the accuracy of such determination and shall have no liability for purported exercises of this Warrant that are
not in compliance with the Beneficial Ownership Limitation. For purposes of this Section 2(e), in determining the number of
outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the
Company&rsquo;s most recent periodic or annual report filed with the Securities and Exchange Commission, as the case may be, (B) a
more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting
forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one
Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the
number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of
the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall initially be
4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial
Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 19.99%
of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in
the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is delivered to the Company. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of
this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to
such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. For purposes of
clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Beneficial Ownership Limitation
shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of Section 13(d) of the Exchange
Act or Rule 16a-1(a)(1) promulgated under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section 3</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">a) <U>Stock Dividends and Splits</U>. If the Company,
at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares
of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt,
shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares
of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common
Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of
the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares
of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the
number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant
shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">b) <U>Subsequent Rights Offerings</U>. In
addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock
Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of
shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a &nbsp;record is
taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record
holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>,
that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the
Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or
beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to
such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">c) <U>Pro Rata Distributions</U>. During such
time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights
to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent
that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares
of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">d) <U>Fundamental Transaction</U>. If, at any
time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger
or consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the stockholders
of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power
of the surviving entity immediately after such merger or consolidation (excluding a merger effected solely to change the Company&rsquo;s
name), (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition
of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted
to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of
the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or
other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of
this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in <U>Section 2(e)</U>
on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction, other than in clause (i) above in connection with a merger or consolidation of the Company with any Subsidiary
or Affiliate whereby the stockholders of the Company do not own at least (x) 50.0% of the outstanding shares of Common Stock and (y) 50.0%
of the voting power of the surviving entity immediately after such merger or consolidation, the Company or any Successor Entity (as defined
below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the
Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant
from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised
portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental Transaction
is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, Holder shall only be entitled
to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black
Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company
in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or
whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the
Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in
such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which
Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;Black Scholes Value&rdquo; means
the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (i) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of such date of request, (ii) an expected
volatility equal to the remaining term of this Warrant obtained from the HVT function on Bloomberg as of the Trading Day immediately prior
to the public announcement of the applicable Fundamental Transaction or, if the Fundamental Transaction is not publicly announced, the
date the Fundamental Transaction is consummated, (iii) the underlying price per share used in such calculation shall be the greater of
(A) the sum of the price per share being offered in cash, if any, plus the per share value of any non-cash consideration, if any, being
offered in such Fundamental Transaction and (B) the greater of (x) the last VWAP of the Common Stock immediately prior to the public announcement
of such Fundamental Transaction and (y) the last VWAP of the Common Stock immediately prior to the consummation of such Fundamental Transaction,
(iv) a zero cost of borrow and (v) a 360 day annualization factor. The payment of the Black Scholes Value will be made by wire transfer
of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election
and (ii) the date of consummation of the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company shall cause any successor entity in a Fundamental Transaction
in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the
Company under this Warrant prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this
Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent
to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the Exercise Price hereunder to such
shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall
succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring
to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the
Company herein. For clarity, the provisions of this <U>Section 3(d)</U> shall only apply if and to the extent the Fundamental Transaction
occurs while this Warrant is outstanding and exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">e) <U>Calculations</U>. All calculations under
this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3,
the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of
Common Stock (excluding treasury shares, if any) issued and outstanding. Notwithstanding the foregoing, in no event may the Exercise Price
be adjusted below the par value of the Common Stock then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">f) <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">i. <U>Adjustment to Exercise Price</U>. Whenever
the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile
or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares
and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">ii. <U>Notice to Allow Exercise by Holder</U>.
If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare
a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders
of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the
approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation
or merger to which the Company is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange
whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile
or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least
10 calendar days prior to the applicable record or effective date hereinafter specified, a notice (unless such information is filed with
the Securities and Exchange Commission, in which case a notice shall not be required) stating (x) the date on which a record is to be
taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of
which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to
be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become
effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their
shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale,
transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not
affect the validity of the corporate action required to be specified in such notice. The Holder shall remain entitled to exercise this
Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may
otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">iii. <U>Voluntary Adjustment By Company</U>. Subject
to the rules and regulations of the Trading Market, the Company may at any time during the term of this Warrant reduce the then current
Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">a) <U>Transferability</U>. Subject to compliance
with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase
Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or
in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to
pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">b) <U>New Warrants</U>. This Warrant may be divided
or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying
the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance
with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new
Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued
on transfers or exchanges shall be dated the original Issue Date and shall be identical with this Warrant except as to the number of Warrant
Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">c) <U>Warrant Register</U>. The Company shall
register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;), in the
name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice
to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">d) <U>Transfer Restrictions</U>. If, at the time
of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i)
registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky
laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to
Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case
may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">e) <U>Representation by the Holder</U>. The Holder,
by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant
Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or
any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">a) <U>No Rights as Stockholder Until Exercise;
No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of
the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting
any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to receive cash payments
pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this
Warrant.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">b) <U>Loss, Theft, Destruction or Mutilation of
Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction
or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity
or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender
and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate
of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">c) <U>Saturdays, Sundays, Holidays, etc</U>. If
the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading
Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">d) <U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company covenants that, during the period
the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for
the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its
issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant
Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary
to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon
the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant
and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free
from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer
occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Except and to the extent as waived or consented
to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through
any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in
the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder
as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the
par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value,
(ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations
under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Before taking any action which would result in
an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain
all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">e) <U>Jurisdiction</U>. All questions concerning
the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the
Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">f) <U>Restrictions</U>. The Holder acknowledges
that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise,
will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">g) <U>Nonwaiver and Expenses</U>. No course of
dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise
prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement,
if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the
Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited
to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant
hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">h) <U>Notices</U>. Any notice, request or other
document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice
provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">i) <U>Limitation of Liability</U>. No provision
hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration
herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common
Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">j) <U>Remedies</U>. The Holder, in addition to
being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights
under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach
by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance
that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">k) <U>Successors and Assigns</U>. Subject to applicable
securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors
and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to
be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">l) <U>Amendment</U>. This Warrant may be modified
or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">m) <U>Severability</U>. Wherever possible, each
provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision
of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition
or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">n) <U>Headings</U>. The headings used in this
Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Page Follows) </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company has caused this
Common Stock Purchase Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>MODULAR MEDICAL, INC.</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Page to Common Stock Warrant] </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.75in"><FONT STYLE="font-size: 10pt">TO:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">MODULAR MEDICAL, INC. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.75in">(1) The undersigned hereby elects to purchase
________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith
payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.75in">(2) Payment shall take the form of (check applicable
box):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#9744; in lawful money of the United States; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#9744; if permitted the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number
of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.75in">(3) Please issue said Warrant Shares in the name
of the undersigned or in such other name as is specified below:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;</U>&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrant Shares shall be delivered to the following DWAC Account
Number:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;</U>&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;</U>&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;</U>&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.75in">(4) <U>Accredited Investor</U>. The undersigned
is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Signature of Authorized Signatory of Investing Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><I>(To assign the foregoing Warrant, execute this
form and supply required information. Do not use this form to purchase shares.) </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, the foregoing Warrant and
all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 45%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">______________________________________</FONT></TD>
    <TD STYLE="width: 40%; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">______________________________________</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD>______________________________________</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD>______________________________________</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Dated:</TD>
    <TD>______________________________________</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Holder&rsquo;s Signature:</TD>
    <TD>______________________________________</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Holder&rsquo;s Address:</TD>
    <TD>______________________________________</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">13</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ea023550201ex4-2_modular.htm
<DESCRIPTION>FORM OF PLACEMENT AGENT WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THE REGISTERED HOLDER OF THIS WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR
HYPOTHECATE THIS WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE INITIAL ISSUE DATE (DEFINED BELOW) TO ANYONE OTHER THAN
(I) NEWBRIDGE SECURITIES CORPORATION OR A PLACEMENT AGENT OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER
OR PARTNER OF NEWBRIDGE SECURITIES CORPORATION OR OF ANY SUCH PLACEMENT AGENT OR SELECTED DEALER.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR
TO SEPTEMBER [&#9679;], 2025. VOID AFTER 5:00 P.M., EASTERN TIME, MARCH [&#9679;], 2029.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">PLACEMENT AGENT
WARRANT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">MODULAR MEDICAL,
Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60%">Warrant Shares: _______</TD><TD STYLE="text-align: justify; width: 40%">Initial Issue Date:
March __, 2025</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">Initial Exercise Date: September __, 2025<SUP>1</SUP></TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS PLACEMENT AGENT WARRANT
(the &ldquo;<B>Warrant</B>&rdquo;) certifies that, for value received, [Newbridge Securities Corporation] [other designee] or its assigns
(the &ldquo;<B>Holder</B>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date set forth above (the &ldquo;<B>Initial Exercise Date</B>&rdquo;) and, in accordance with FINRA
Rule 5110(f)(2)(G)(i), prior to 5:00 p.m. (New York City time) on the date that is four (4) years following the Initial Issue Date set
forth above (the &ldquo;<B>Termination Date</B>&rdquo;) but not thereafter, to subscribe for and purchase from Modular Medical, Inc.,
a company incorporated under the laws of the State of Nevada (the &ldquo;<B>Company</B>&rdquo;), up to ___ shares of Common Stock (as
subject to adjustment hereunder, the &ldquo;<B>Warrant Shares</B>&rdquo;). The purchase price of one share of Common Stock under this
Warrant shall be equal to the Exercise Price, as defined in <U>Section 2(b)</U>. This Warrant is one of a series of similar warrants provided
as compensation to Newbridge Securities Corporation (&ldquo;<B>Newbridge</B>&rdquo;) and its permitted designees for Newbridge acting
as placement agent in connection with the Company&rsquo;s private placement of securities (the &ldquo;<B>Private Placement</B>&rdquo;)
pursuant to the Securities Purchase Agreement dated as of March [__], 2025 between the Company and each of the purchasers identified on
the signature pages thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this <U>Section 1</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify">NTD: To be six months after the Initial Issue Date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Bid Price</B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined in good faith by an independent appraiser
selected in good faith by the Board of Directors of the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business
Day</B>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;&nbsp;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Commission</B>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common
Stock</B>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common
Stock Equivalents</B>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange
Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Rule 144</B>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities
Act</B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trading
Day</B>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Trading
Market</B>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>VWAP</B>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price per share of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price per share of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the
Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink
Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share
of the Common Stock so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<B>Warrants</B>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company as placement agent compensation pursuant to the engagement
letter between the Company and Newbridge dated as of February 10, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)  <U>Exercise
of Warrant</U>. Subject to the provisions of <U>Section 2(e)</U> herein, exercise of the purchase rights represented by this Warrant may
be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery
to the Company (or such other office or agency of the Company as it may designate by notice in writing to the registered Holder at the
address of the Holder appearing on the books of the Company) of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<B>Notice of Exercise</B>&rdquo;), and, unless the cashless
exercise procedure specified in <U>Section 2(c)</U> below is specified in the applicable Notice of Exercise, delivery of the aggregate
Exercise Price of the Warrant Shares specified in the applicable Notice of Exercise as specified in this <U>Section 2(a)</U>. Within the
earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in <U>Section
2(d)(i)</U> herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant
Shares specified in the applicable Notice of Exercise by wire transfer of immediately available funds or cashier&rsquo;s check drawn on
a United States bank unless the cashless exercise procedure specified in <U>Section 2(c)</U> below is specified in the applicable Notice
of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)
of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has
been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading
Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases
of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant
Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)  <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $1.12, subject to adjustment hereunder (the &ldquo;<B>Exercise
Price</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c)  <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may only be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing ((A-B)(X)) by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(A) =</TD><TD STYLE="text-align: justify">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to <U>Section 2(a)</U> hereof on a day that is not
a Trading Day or (2) both executed and delivered pursuant to <U>Section 2(a)</U> hereof on a Trading Day prior to the opening of &ldquo;regular
trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day,
(ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise
or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s
execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a
Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading
hours&rdquo; on a Trading Day) pursuant to <U>Section 2(a)</U> hereof or (iii) the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to <U>Section
2(a)</U> hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(B) =</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(X) =</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the
terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not
to take any position contrary to this <U>Section 2(c)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything herein
to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this <U>Section
2(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d)  <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.  <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Company&rsquo;s
transfer agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<B>DWAC</B>&rdquo;) if the Company is then a participant in
such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder, or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144, and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name
of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) two (2)&nbsp;Trading Days after the delivery
to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<B>Warrant Share Delivery Date</B>&rdquo;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, then the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until
such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<B>Standard Settlement Period</B>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.  <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.  <U>Rescission
Rights</U>. If the Company fails to cause the Company&rsquo;s transfer agent to transmit to the Holder the Warrant Shares pursuant to
<U>Section 2(d)(i)</U> by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.  <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Company&rsquo;s transfer agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of <U>Section 2(d)(i)</U> above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases,
shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving
upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which
(x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at
the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts
payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common
Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.  <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.  <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <I><U>provided</U></I>, <I><U>however</U></I>,
that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all the Company&rsquo;s
transfer agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another
established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.  <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">viii  <U>Signature</U>.
This <U>Section 2</U> and the exercise form attached hereto set forth the totality of the procedures required of the Holder in order to
exercise this Warrant. Without limiting the preceding sentences, no ink-original exercise form shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any exercise form be required in order to exercise this Warrant. No additional
legal opinion, other information or instructions shall be required of the Holder to exercise this Warrant. The Company shall honor exercises
of this Warrant and shall deliver Shares underlying this Warrant in accordance with the terms, conditions and time periods set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e)  <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to <U>Section 2</U> or otherwise, to the extent that after giving effect to such issuance after
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons
acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties to the extent such issuance would exceed such limitation.&nbsp; Except as set forth in the preceding
sentence, for purposes of this <U>Section 2(e)</U>, beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to
the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation contained in this <U>Section 2(e)</U> applies,
the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates
and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission
of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall not have any obligation to verify or confirm the accuracy
of such determination and neither of them shall have any liability for any error made by the Holder or any other Person. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this <U>Section 2(e)</U>, in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Company&rsquo;s transfer agent setting forth the number of shares of Common
Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants,
9.99%) of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this <U>Section 2(e)</U>, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant
held by the Holder and the provisions of this <U>Section 2(e)</U> shall continue to apply. Any increase in the Beneficial Ownership Limitation
will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this <U>Section 2(e)</U> to correct this
paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained
or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this
paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)  <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this <U>Section 3(a)</U> shall become effective immediately after the record date
for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)  <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to <U>Section 3(a)</U> above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<B>Purchase Rights</B>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant,
issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the grant, issue or sale of such Purchase Rights; <I><U>provided</U></I>, <I><U>however</U></I>, to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c)  <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend (other than
cash dividends) or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<B>Distribution</B>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<I><U>provided</U></I>,
<I><U>however</U></I>, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation). To the extent this Warrant has not been partially or completely exercised at
the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder
has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d)  <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power
of the then outstanding common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects
any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common
Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in
one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other
Person or group acquires more than 50% of the outstanding shares of Common Stock or 50% or more of the voting power of the then outstanding
common equity of the Company (not including any shares of Common Stock held by the other Person or other Persons making or party to, or
associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
(each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction (without regard to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant), the number of shares of Common
Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(together, the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard
to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance
with the provisions of this <U>Section 3(d)</U> pursuant to written agreements in form and substance reasonably satisfactory to the Company
and the holders of Warrants representing at least a majority of the shares of Common Stock underlying the Warrants then outstanding (the
&ldquo;<B>Required Holders</B>&rdquo;) and approved by the Required Holders (without unreasonable delay) prior to such Fundamental Transaction
and shall deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without
regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and
power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e)  <U>Calculations</U>.
All calculations under this <U>Section 3</U> shall be made by the Company to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this <U>Section 3</U>, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">f)  <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.  <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this <U>Section 3</U>, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.  <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)  <U>Transferability</U>.
Pursuant to FINRA Rule 5110(g)(1), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred,
assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result
in the effective economic disposition of the securities by any person for a period of 180 days immediately following the Initial Issue
Date or commencement of sales of the offering pursuant to which this Warrant is being issued, except the transfer of any security:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">i.  by
operation of law or by reason of reorganization of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">ii.  to
any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject
to the lock-up restriction in this <U>Section 4(a)</U> for the remainder of the time period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iii.  if
the aggregate amount of securities of the Company held by the Holder or related person do not exceed 1% of the securities being offered;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">iv.  that
is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or
otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">v.  the
exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this <U>Section 4(a)</U>
for the remainder of the time period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the foregoing restriction,
the Securities Act and any other applicable securities laws, and the conditions set forth in <U>Section 4(d)</U>, this Warrant and all
rights hereunder are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Warrant and the Warrant
Shares or any other securities (&ldquo;<B>Other Securities</B>&rdquo;) received upon exercise of this Warrant shall be subject to restrictions
on transferability until registered under the Securities Act, unless an exemption from registration is available. Until this Warrant and
the Warrant Shares or Other Securities are so registered, this Warrant and any certificate for Warrant Shares or Other Securities issued
or issuable upon exercise of this Warrant shall contain a legend on the face thereof, in form and substance satisfactory to counsel for
the Company, stating that this Warrant, the Warrant Shares or Other Securities may not be sold, transferred or otherwise disposed of unless
this Warrant, the Warrant Shares or Other Securities are registered under the Securities Act or may be transferred pursuant to an available
exemption from the Securities Act. This Warrant and the Warrant Shares or Other Securities may also be subject to restrictions on transferability
under applicable state securities or blue sky laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)  <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with <U>Section 4(a)</U>, as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c)  <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<B>Warrant
Register</B>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d)  <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">e)  <U>&ldquo;Piggy-Back&rdquo;
Registration</U>. If at any time after the Initial Issue Date, there is no effective registration covering, or no current prospectus available
for, the issuance of the Warrant Shares to the Holder, the Holder shall have the right, for a period of no more than seven (7) years from
the commencement of the offering in accordance with FINRA Rule 5110(g)(8)(D), to include the Warrant Shares as part of any other registration
statement filed by the Company to register the resale of securities issued to the purchasers in the Private Placement; <U>provided that</U>,
if the SEC informs the Company that all of the Warrant Shares cannot, as a result of the application of Rule 415 or other applicable regulations,
be registered for resale as a secondary offering on a single registration statement with all of the securities issued to the purchasers
in the Private Placement, the Company agrees to promptly inform the Holder thereof and use its reasonable efforts to file amendments to
the registration statement as required by the SEC, covering the maximum number of Warrant Shares permitted to be registered by the SEC..
The Company shall give written notice of such proposed filing to the Holder as soon as practicable but in no event less than ten (10)
days before the anticipated filing date and offer to the Holder in such notice the opportunity to register the sale of such number of
Warrant Shares as such Holder may request in writing within five (5) days following receipt of such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">a)  <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in <U>Section 2(d)(i)</U>, except as expressly
set forth in <U>Section 3</U>. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo;
pursuant to <U>Section 2(c)</U> or to receive cash payments pursuant to <U>Section 2(d)(i)</U> and <U>Section 2(d)(iv)</U> herein, in
no event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">b)  <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">c)  <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">d)  <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">The Company covenants that,
during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares
to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants
that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary
Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be
necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or
of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which
may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Except and to the extent as
waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times
in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company
will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such
increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally
issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain
all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable
the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">e)  <U>Governing
Law; Jurisdiction</U>. Any questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether
of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the
State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in New
York, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue
of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under
this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES
ANY RIGHT TO A JURY TRIAL, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH
OR ARISING OUT OF THIS WARRANT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">f)  <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">g)  <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. No provision of this Warrant shall be construed
as a waiver by the Holder of any rights that the Holder may have under U.S. federal securities laws and the rules and regulation of the
Commission thereunder. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as
shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of
appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">h)  <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be deemed to have
been duly given, if delivered in person or mailed, certified, return-receipt requested, postage prepaid to the address previously provided
to the other party, or sent by fax or email (to the extent stated below). The address for such notice or communication to the Holder shall
be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Newbridge Securities Corporation<BR>
1200 North Federal Highway, Suite 400<BR>
Boca Raton, Florida 33432<BR>
Attn: Chad D. Champion, Head of Capital Markets &amp; Investment Banking<BR>
Email: cchampion@newbridgesecurities.com<BR>
Tel. No: (561) 453-2270</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">With a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">McGuireWoods LLP<BR>
1251 Avenue of the Americas, 20th Floor<BR>
New York, New York 10020<BR>
Attn: Stephen Older, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.375in; text-indent: 0in">Andrew Terjesen, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">Email: solder@mcguirewoods.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.375in; text-indent: 0in">aterjesen@mcguirewoods.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Either party hereto may from
time to time, by written notice to the other party, designate a different address. If any notice or other document is sent by certified
or registered mail, return receipt requested, postage prepaid, properly addressed as aforementioned, the same shall be deemed delivered
seventy-two (72) hours after mailing thereof. If any notice is sent by fax or email, it will be deemed to have been delivered on the date
the fax or email thereof is actually received, provided the original thereof is sent by certified mail, in the manner set forth above,
within twenty-four (24) hours after the fax or email is sent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">i)  <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">j)  <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">k)  <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">l)  <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Required Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">m)  <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">n)  <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="3" STYLE="text-align: left">MODULAR MEDICAL, INC.</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60%">&nbsp;</TD><TD STYLE="text-align: left; width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD><TD STYLE="text-align: justify; width: 31%">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left"></TD>
    <TD>Name:  </TD><TD STYLE="text-align: justify">James
Besser</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>Title:</TD><TD STYLE="text-align: justify">Chief
Executive Officer</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature
Page]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Modular
Medical, Inc. &ndash; Placement Agent&rsquo;s Warrant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="text-transform: uppercase">TO:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-transform: uppercase">modular medical, inc.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">_________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(1)  The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(2)  Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">in lawful money of the United States; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9744;</TD><TD STYLE="text-align: justify">if permitted the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number
of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(3)  Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrant Shares shall be delivered to the following DWAC Account
Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(4)  <U>Accredited
Investor</U>. If the Warrant is being exercised via cash exercise and there is no effective registration statement registering the issue
of the shares under the Warrant, the undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under
the Securities Act of 1933, as amended, and, the undersigned understands that the undersigned must bear the economic risk of the investment
for an indefinite period of time since the securities cannot be sold, transferred or assigned to any person or entity without compliance
with the provisions of the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: _______________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Phone Number:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Email Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify; width: 12%">Holder&rsquo;s Signature:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify; width: 37%"><U></U></TD>
    <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ea023550201ex10-1_modular.htm
<DESCRIPTION>FORM OF SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>SECURITIES PURCHASE AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">This Securities Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;)
is dated as of March 20, 2025, between Modular Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), and each of the
purchasers identified on the signature pages hereto (each, including its successors and assigns, an &ldquo;<U>Purchaser</U>&rdquo; and
collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>RECITALS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">A. The Company and each Purchaser is executing
and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities
Act of 1933, as amended (together with the rules and regulations thereunder, the &ldquo;<U>Securities Act</U>&rdquo;) and/or Rule 506
of Regulation D promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">B. The Purchasers, severally and not jointly,
wish to purchase from the Company, and the Company wishes to sell and issue to the Purchasers, upon the terms and subject to the conditions
stated in this Agreement, an aggregate of $11,995,499.52 (the &ldquo;<U>Financing Amount</U>&rdquo;) of units the &ldquo;<U>Units</U>&rdquo;),
each Unit comprised of (A) either (i) two shares of the Company&rsquo;s common stock, par value $0.001 per share (&ldquo;<U>Common Stock</U>&rdquo;),
or (ii) two pre-funded warrants in the form attached hereto as <U>Exhibit B</U> (the &ldquo;<U>Pre-Funded Warrants</U>&rdquo;) to purchase
one share of Common Stock per Pre-Funded Warrant, and (B) one warrant to purchase one share of Common Stock in the form attached hereto
as <U>Exhibit C</U> (the &ldquo;<U>Common Warrant</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">In consideration of the mutual covenants contained
in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company
and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>ARTICLE I. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">1.1 <U>Definitions</U>. In addition to the terms defined elsewhere
in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Action</U>&rdquo; shall have the meaning ascribed to such
term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Affiliate</U>&rdquo; means any Person that, directly or indirectly
through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and
construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Agreement</U>&rdquo; has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Authorizations</U>&rdquo; shall have the meaning ascribed
to such term in Section 3.1(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Board of Directors</U>&rdquo; means the board of directors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Business Day</U>&rdquo; means any day except any Saturday,
any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New
York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Closing</U>&rdquo; means the closing of the purchase and
sale of the Securities pursuant to Section 2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Closing Date</U>&rdquo; means the first (1st) Trading Day
after the date hereof or, if later, the date on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) each Purchaser&rsquo;s obligation to pay its aggregate Purchase Price, as set forth
on the signature page of such Purchaser attached hereto and (ii) the Company&rsquo;s obligation to deliver the Securities, in each case,
have been satisfied or waived, but in no event later than the fifth (5th) Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Commission</U>&rdquo; means the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Common Stock</U>&rdquo; shall have the meaning ascribed to
such term in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Common Stock Equivalents</U>&rdquo; means any securities
of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred
stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Common Warrant</U>&rdquo; means collectively, the Common
Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, in the form of <U>Exhibit
C</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Common Warrant Shares</U>&rdquo; means the shares of Common
Stock issuable upon exercise of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Company</U>&rdquo; has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Company Counsel</U>&rdquo; means Lucosky Brookman LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Company Covered Person</U>&rdquo; means, with respect to
the Company as an &ldquo;issuer&rdquo; for purposes of Rule 506 promulgated under the Securities Act, any Person listed in the first paragraph
of Rule 506(d)(1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Covered Action</U>&rdquo; shall have the meaning ascribed
to such term in Section 4.6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Disclosure Time</U>&rdquo; means, (i) if this Agreement is
signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading
Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof and (ii) if this Agreement is signed between
midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the
date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Disqualification Event</U>&rdquo; shall have the meaning
ascribed to such term in Section 3.1(ll).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Environmental Laws</U>&rdquo; shall have the meaning ascribed
to such term in Section 3.1(m).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Exchange Act</U>&rdquo; means the Securities Exchange Act
of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Exempt Issuance</U>&rdquo; means the issuance of (a) shares
of Common Stock or options to employees, officers, consultants or directors of the Company pursuant to any equity incentive plan duly
adopted for such purpose by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee
of non-employee directors established for such purpose for services rendered to the Company, (b) shares of Common Stock issued to consultants
in exchange for services rendered or to be rendered to the Company, (c) shares issuable upon the exercise or exchange of or conversion
of any securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this
Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities
or to decrease the exercise price, exchange price or conversion price of such securities or to extend the term of such securities, and
(d) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the
Company, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration
rights that require or permit the filing of any registration statement in connection therewith within 60 days following the Closing Date,
and provided that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>FCPA</U>&rdquo; means the Foreign Corrupt Practices Act of
1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>FDA</U>&rdquo; shall have the meaning ascribed to such term
in Section 3.1(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>GAAP</U>&rdquo; shall have the meaning ascribed to such term
in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Health Care Laws</U>&rdquo; means (i) the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. &sect;&sect; 301 et Seq.), and the regulations promulgated thereunder, (ii) the Public Health Service Act
(42 U.S.C. &sect;&sect; 201 et seq.) and the regulations promulgated thereunder, (iii) all federal and state fraud and abuse laws, including,
without limitation, the federal Anti-Kickback Statute (42 U.S.C. &sect;1320a7b(b)), the civil False Claims Act (31 U.S.C. &sect;3729 et
seq.), the criminal False Claims Law (42 U.S.C. &sect; 1320a-7b(a)), Sections 1320a-7 and 1320a-7a of Title 42 of the United States Code,
all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287, 1035, 1347 and 1349,
the Physician Payments Sunshine Act (42 U.S.C. &sect; 1320a-7h), and the regulations promulgated pursuant to such statutes, (iv) the Health
Insurance Portability and Accountability Act of 1996 (18 U.S.C. &sect;&sect;669, 1035, 1347 and 1518; 42 U.S.C. &sect;1320d et seq.) and
the regulations promulgated thereunder, (v) Titles XVIII (42 U.S.C. &sect;1395 et seq.) and XIX (42 U.S.C. &sect;1396 et seq.) of the
Social Security Act and the regulations promulgated thereunder, (vi) the Patient Protection and Affordable Care Act, (vii) all applicable
statutes, rules or regulations relating to the ownership, testing, development, manufacture, quality, safety, accreditation, packaging,
use, distribution, labeling, promotion, sale, offer for sale, import, export or disposal of any product manufactured or distributed by
the Company, each of (i) through (vi) as may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Intellectual Property Rights</U>&rdquo; shall have the meaning
ascribed to such term in Section 3.1(o).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Purchaser</U>&rdquo; has the meaning set forth in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Purchaser Party</U>&rdquo; shall have the meaning ascribed
to such term in Section 4.6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Liens</U>&rdquo; means a lien, charge, pledge, security interest,
encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Lock-Up Agreement</U>&rdquo; means the Lock-Up Agreement,
dated as of the date hereof, by and among the Company and the directors and officers of the Company, in the form reasonably acceptable
to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Material Adverse Effect</U>&rdquo; shall have the meaning
ascribed to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Material Contract</U>&rdquo; means any contract, instrument
or other agreement to which the Company is a party or by which it is bound which is material to the business of the Company, including
those that have been filed as an exhibit to the SEC Reports pursuant to Item 601(b)(10) of Regulation S-K.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Material Permits</U>&rdquo; shall have the meaning ascribed
to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Money Laundering Laws</U>&rdquo; shall have the meaning ascribed
to such term in Section 3.1(dd).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>New Securities</U>&rdquo; shall have the meaning ascribed
to such term in Section 4.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Offer Notice</U>&rdquo; shall have the meaning ascribed to
such term in Section 4.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Officer&rsquo;s Certificate</U>&rdquo; a certificate signed
by the Chief Executive Officer or the Chief Financial Officer to the effect that (i) the representations and warranties of the Company
in Section 3.1 hereof are true and correct as of the date of this Agreement, and as of and as if made on the Closing Date, (ii) all obligations,
covenants and agreements to be performed or complied with by the Company at or prior to the Closing have been performed or complied with
by it, and (iii) all of the conditions set forth in Section 2.3 have been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Person</U>&rdquo; means an individual or corporation, partnership,
trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency
or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Placement Agent</U>&rdquo; means Newbridge Securities Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>PPM</U>&rdquo; means the Company&rsquo;s confidential Private
Placement Memorandum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Pre-Funded Warrant</U>&rdquo; means collectively, the pre-funded
Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, in the form of <U>Exhibit
A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Pre-Funded Warrant Shares</U>&rdquo; means the shares of
Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Proceeding</U>&rdquo; means an action, claim, suit, arbitration,
hearing, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition),
whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Pro Rata Share</U>&rdquo; shall have the meeting ascribed
to it in Section 4.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Purchase Price</U>&rdquo; shall have the meaning ascribed
to it in Section 2.1(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Registrable Securities</U>&rdquo; means, as of any date of
determination, (i) the Shares and the Warrant Shares and (ii) any securities issued or then issuable upon any stock split, dividend or
other distribution, recapitalization or similar event with respect to the foregoing; provided, however, that any such Registrable Securities
shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another,
registration statement hereunder with respect thereto) (x) if such Registrable Securities have been disposed of by the Purchaser in accordance
with such effective registration statement, (y) if such Registrable Securities have been previously sold in accordance with Rule 144,
or (z) for so long as such securities are eligible for resale without volume or manner-of-sale restrictions and current public information
being available pursuant to Rule 144 as reasonably determined by the Company, upon the advice of counsel to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Resale Registration Statement</U>&rdquo; means a registration
statement on Form S-1 or Form S-3 covering the resale of the Shares and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Rule 144</U>&rdquo; means Rule 144 promulgated by the Commission
pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter
adopted by the Commission having substantially the same purpose and effect as such rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>SEC Reports</U>&rdquo; shall have the meaning ascribed to
such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Securities</U>&rdquo; means the Units, the Shares, the Warrant
Shares and the Warrants, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Securities Act</U>&rdquo; shall have the meaning ascribed
to such term in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Selling Stockholder Questionnaire</U>&rdquo; shall have the
meaning ascribed to such term in Section 2.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Shares</U>&rdquo; means the shares of Common Stock included
in the Units purchased by Purchasers pursuant to the terms and conditions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Short Sales</U>&rdquo; means all &ldquo;short sales&rdquo;
as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of
Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Trading Day</U>&rdquo; means a day on which the principal
Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Trading Market</U>&rdquo; means the Nasdaq Global Market
(&ldquo;<U>Nasdaq</U>&rdquo;) or any of the following markets or exchanges on which the Common Stock is then listed or quoted for trading
on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market or the Nasdaq Global Select Market (or any successors to
any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Transaction Documents</U>&rdquo; means this Agreement, all
exhibits and schedules hereto, the Lock-Up Agreements, the Officer&rsquo;s Certificate, the Pre-Funded Warrants and the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Transfer Agent</U>&rdquo; means Colonial Stock Transfer Company,
Inc., with offices located at 7840 S 700 E, Sandy, Utah 84070, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Units</U>&rdquo; shall have the meaning given to such term
in the recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company issues or sells: (i) any debt or equity securities that are convertible into, exchangeable or exercisable for, or
include the right to receive additional shares of Common Stock either (A) at a conversion, exercise, or exchange rate or other price that
is based upon and/or varies with the trading prices of or quotations for Common Stock at any time after the initial issuance of such debt
or equity securities, or (B) with a conversion, exercise, or exchange price that is subject to being reset at some future date after the
initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related
to the business of the Company or the market for the Common Stock; or (ii) enters into any agreement, including, but not limited to, an
equity line of credit, whereby the Company may sell securities at a future determined price; <I>provided</I>, that any at-the-market offering
facility for equity securities entered into by the Company shall not be considered a Variable Rate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Warrants</U>&rdquo; means the Pre-Funded Warrants and the
Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;<U>Warrant Shares</U>&rdquo; means the shares of Common Stock
issuable upon exercise of the Pre-Funded Warrants and the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>ARTICLE II. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">2.1 <U>Closing</U>. (a) On the Closing Date, upon
the terms and subject to the conditions set forth herein, the Company will issue and sell to each Purchaser, and such Purchaser will purchase,
severally and not jointly with each other Purchaser, the Units set forth opposite the name of such Purchaser on its signature page hereto,
inclusive of the number of shares of Common Stock and/or Pre-Funded Warrants indicated thereon. The purchase price per Unit shall be (a)
if the Unit consists of shares of Common Stock, $1.92; and (b) if the Unit consists of Pre-Funded Warrants, $1.919 (collectively, the
&ldquo;<U>Purchase Price</U>&rdquo;). The Pre-Funded Warrants shall have an exercise price equal to $0.001 per Pre-Funded Warrant Share.
The Common Warrants shall have an exercise price equal to $1.12 per Common Warrant Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(b) Upon the satisfaction or waiver of the conditions
set forth in <U>Section 2.3</U>, the closing of the purchase and sale of the Units pursuant to this Agreement (the &ldquo;<U>Closing</U>&rdquo;)
shall occur remotely via the exchange of documents and signatures. At or prior to the Closing, each Purchaser shall execute any related
agreements or other documents required to be executed hereunder, dated on or before the Closing Date, including but not limited to the
Selling Stockholder Notice and Questionnaire, in the form attached hereto as Appendix I (the &ldquo;<U>Selling Stockholder Questionnaire</U>&rdquo;)
(or similar form or information reasonably satisfactory to the Company and sufficient in substance for the Company to obtain the information
necessary to effect the transactions contemplated by the Transaction Documents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">2.2 <U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(a) On or prior to the Closing Date, the Company
shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(i) this Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(ii) a legal opinion of Company Counsel, dated
as of the Closing Date, in form and substance reasonably satisfactory to the Purchasers, which the Purchasers and the Placement Agent
shall be entitled to rely upon;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(iii) the Officer&rsquo;s Certificate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(iv) a certificate of an officer of the Company,
dated as of the Closing Date, certifying (x) the Company&rsquo;s Certificate of Incorporation; (y) the Company&rsquo;s Bylaws; (z) resolutions
of the Board of Directors (or an authorized committee thereof) approving the Transaction Documents and the transactions contemplated thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(v) a good standing certificate for the Company,
issued by the Secretary of State of the State of Nevada, dated not less than five (5) Business Days prior to the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(vi) the Company&rsquo;s wire instructions, on
Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer which shall be provided at least one (1) Trading
Day prior to the Closing Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(vii) a copy of the irrevocable instructions to
the Transfer Agent instructing the Transfer Agent to deliver to each Purchaser (or nominee as instructed by such Purchaser), at the Closing,
the number of Units set forth on the signature page of such Purchaser attached hereto next to the heading &ldquo;Number of Units&rdquo;
comprised of an equal number of Shares, registered in the name of the Purchaser (or its nominee as instructed by such Purchaser);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(viii) a Pre-Funded Warrant, registered in the
name of the Purchaser (or its nominee as instructed by such Purchaser), to purchase up to the number of Pre-Funded Warrant Shares equal
to the product of (a) the number of Units with Pre-Funded Warrants set forth on the signature page of such Purchaser attached hereto next
to the heading &ldquo;Number of Units with Pre-funded Warrants (if applicable),&rdquo; if any, <I>multiplied by </I>(b) two; and a Common
Warrant, registered in the name of the Purchaser (or its nominee as instructed by such Purchaser), to purchase up to a number of Common
Warrant Shares equal to the number of Units set forth on the signature page of such Purchaser attached hereto next to the heading &ldquo;Number
of Units&rdquo;; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(ix) the Company shall have received the Financing
Amount at Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(b) On or prior to the Closing Date, each Purchaser
shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(i) this Agreement duly executed by such Purchaser;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(ii) such Purchaser&rsquo;s aggregate Purchase
Price via wire transfer of immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">2.3 <U>Closing Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(a) The obligations of the Company hereunder in
connection with the Closing are subject to the satisfaction (or waiver in writing by the Company) of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(i) the representations and warranties of the
Purchasers contained herein shall be true and correct as of the Closing Date as if made as of the Closing Date (unless such representation
or warranty was made as of a specific date, in which case such representation and warranty shall be true and correct as of such date);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(ii) all obligations, covenants and agreements
to be performed or complied with by each Purchaser on or prior to the Closing shall have been performed or complied with by it in all
material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(b) The respective obligations of the Purchasers
hereunder in connection with the Closing are subject to satisfaction (or waiver in writing by each Purchaser solely as to such Purchaser)
of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(i) the representations and warranties of the
Company contained herein shall be true and correct as of the date hereof and as of the Closing Date as if made as of the Closing Date
(unless such representation or warranty was made as of a specific date, in which case such representation and warranty shall be true and
correct as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(ii) all obligations, covenants and agreements
to be performed or complied with by the Company on or prior to the Closing shall have been performed or complied with by it;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(iii) the delivery by the Company of the items
set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(iv) no Material Adverse Effect shall have occurred
since the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(v) from the date hereof to the Closing Date,
trading in the Common Stock shall not have been suspended by the Commission or the Trading Market, and, at any time prior to the Closing
Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall
not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium
have been declared either by the United States or New York State authorities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(vi) the Company shall have filed with the Trading
Market a Notification Form: Listing of Additional Shares for the listing of the Shares and the Warrant Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(vii) no governmental authority shall have issued
any order, decree or ruling, and no law shall be in effect, enjoining, restraining or otherwise prohibiting any of the transactions contemplated
hereby, and the Company shall have obtained all governmental, regulatory or third-party consents and approvals, if any, necessary for
the sale and issuance of the Securities, including without limitation, those required by Nasdaq; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(viii) the Closing of the purchase of Securities
by each Purchaser shall occur substantially concurrently, <I>provided</I> that a failure by any Purchaser to provide the deliverables
set forth in Section 2.2(b) or satisfy the requirements in Section 2.3(a) shall not affect the timing of the Closing in respect of any
other Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(ix) The Company shall have delivered Lock-Up
Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>ARTICLE III. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">3.1 <U>Representations and Warranties of the Company</U>.
The Company hereby makes the following representations and warranties to each Purchaser and the Placement Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(a) <U>Subsidiaries</U>. The Company owns, directly
or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued
and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive
and similar rights to subscribe for or purchase securities. If the Company has no Subsidiaries, all other references to the Subsidiaries
or any of them in the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(b) <U>Organization and Qualification</U>. The
Company is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction
of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on
its business as currently conducted. The Company is not in violation nor default of any of the provisions of its certificate or articles
of incorporation, bylaws or other organizational or charter documents. The Company is duly qualified to conduct business and is in good
standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned
by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not
have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction
Document, (ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise)
of the Company or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis
its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;), and no Proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(c) <U>Authorization; Enforcement</U>. The Company
has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each
of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of
this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated
hereby and thereby have been duly authorized by all necessary action on the part of the Company, and no further action is required by
the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith. This Agreement and each other
Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered
in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company, enforceable against
the Company in accordance with its terms except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(d) <U>No Conflicts</U>. The execution, delivery
and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of
the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or
violate any provision of the Company&rsquo;s certificate or articles of incorporation, bylaws or other organizational or charter documents,
(ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result
in the creation of any Lien upon any of the properties or assets of the Company, or give to others any rights of termination, amendment,
anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement,
credit facility, debt or other instrument (evidencing a Company debt or otherwise) to which the Company is a party or by which any property
or asset of the Company is bound or affected, or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court or governmental authority to which the Company is subject (including federal and
state securities laws and regulations), or by which any property or asset of the Company is bound or affected; except in the case of each
of clauses (ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(e) <U>Filings, Consents and Approvals</U>. The
Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration
with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery
and performance by the Company of the Transaction Documents, other than (i) the filing of the registration statement required to be filed
by Section 4.11 and (ii) the submission of the Listing of Additional Shares Notification Form with the Trading Market in the time and
manner required thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(f) <U>Issuance of the Securities</U>. The Shares
are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued,
fully paid and nonassessable, free and clear of all Liens imposed by the Company, except for restrictions on transfer imposed by applicable
securities laws. The Warrant Shares have been duly and validly authorized and reserved for issuance and, upon exercise of the applicable
Warrants in accordance with their terms, including the payment of any exercise price therefor, will be validly issued, fully paid and
nonassessable and will be free and clear of all encumbrances and restrictions (other than those created by the Purchasers), except for
restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws. Assuming the accuracy of the
representations and warranties of each Purchaser in <U>Section 3.2</U> hereof, the Warrant Shares will be issued in compliance with all
applicable federal and state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(g) <U>Capitalization</U>. The capitalization
of the Company as of the date hereof is as set forth in the SEC Reports. The Company has not issued any capital stock since its most recently
filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&rsquo;s
stock option plans, the issuance of shares of Common Stock (the &ldquo;Plan Shares&rdquo;) to employees, directors and consultants pursuant
to the Company&rsquo;s equity incentive plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as
of the date of the most recently filed periodic report under the Exchange Act, shares of Common Stock issued to consultants in exchange
for services rendered or to be rendered to the Company, and as provided in the SEC Reports. No Person has any right of first refusal,
preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents
that has not been waived. Except as set forth in the SEC Reports, and except for the Plan Shares and equity awards granted to employees,
directors and consultants pursuant to the Company&rsquo;s equity incentive plans, there are no outstanding options, warrants, scrip rights
to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or
exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock, or contracts,
commitments, understandings or arrangements by which the Company is or may become bound to issue additional shares of Common Stock or
Common Stock Equivalents. The issuance and sale of the Securities will not obligate the Company to issue shares of Common Stock or other
securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company with any provision
that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company.
There are no outstanding securities or instruments of the Company that contain any redemption or similar provisions, and there are no
contracts, commitments, understandings or arrangements by which the Company is or may become bound to redeem a security of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(h) <U>SEC Reports: Financial Statements</U>.
The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities
Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two (2) years preceding the date hereof (or such
shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits
thereto and documents incorporated by reference therein, being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;)
on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities
Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in
all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as
in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified
in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required
by GAAP, and fairly present in all material respects the financial position of the Company as of and for the dates thereof and the results
of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end
audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(i) <U>Material Changes: Undisclosed Events, Liabilities
or Developments</U>. Since the date of the latest audited financial statements included within the SEC Reports, (i) there has been no
event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect and (ii) the
Company has not incurred any liabilities (contingent or otherwise) that are material to the Company other than (A) trade payables and
accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected
in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission. Except for the issuance
of the Securities contemplated by this Agreement at the time this representation is made or deemed made, no event, liability, fact, circumstance,
occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its business,
properties, operations, assets, financial condition or prospects that would be required to be disclosed by the Company under applicable
securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one (1) Trading Day
prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(j) <U>Litigation</U>. Except as disclosed in
the SEC Reports, there is no action, suit, inquiry, notice of violation, Proceeding or investigation pending or, to the knowledge of the
Company, threatened in writing against the Company or any of its properties before or by any court, arbitrator, governmental or administrative
agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;) which (i) adversely
affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if
there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. The Company is not and has
not been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of
breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending, any investigation by the Commission
involving the Company or, to the Company&rsquo;s knowledge, any current or former director or officer of the Company. The Commission has
not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company under the Exchange
Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(k) <U>Labor Relations</U>. No labor dispute exists
or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which would reasonably be expected
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(l) <U>Compliance</U>. Except as disclosed in
the SEC Reports, the Company: (i) is not in default under or in violation of (and no event has occurred that has not been waived that,
with notice or lapse of time or both, would result in a default by the Company), nor has the Company received notice of a claim that it
is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which
it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is not
in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is not and has not been
in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal,
state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment
and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(m) <U>Regulatory Permits</U>. The Company possesses
all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary
to conduct its business as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected
to result in a Material Adverse Effect (&ldquo;<U>Material Permits</U>&rdquo;), and the Company has not received any notice of Proceedings
relating to the revocation or modification of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(n) <U>Title to Assets</U>. The Company has good
and marketable title in all personal property owned by them that is material to the business of the Company, in each case free and clear
of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the use
made and proposed to be made of such property by the Company and (ii) Liens for the payment of federal, state or other taxes, for which
appropriate reserves have been made therefor in accordance with GAAP and the payment of which is neither delinquent nor subject to penalties.
Any real property and facilities held under lease by the Company are held by them under valid, subsisting and enforceable leases with
which the Company are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(o) <U>Intellectual Property</U>. To the Company&rsquo;s
knowledge, the Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so do could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement,
except for Intellectual Property Rights that are within two years of the end of their term or the abandonment of which would not have
a Material Adverse Effect. To the knowledge of the Company, no action or use by the Company or the Subsidiary necessary for the conduct
of its business as currently carried on and as described in the SEC Reports will involve or give rise to any infringement of, or license
or similar fees for, any Intellectual Property Rights of others. Neither the Company nor any Subsidiary has received, since the date of
the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that
the Intellectual Property violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not
have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no
existing infringement by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable
security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do
so could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(p) <U>Insurance</U>. The Company is insured by
insurers of recognized financial responsibility against such losses and risks and in such amounts as the Company believes to be prudent
and customary in the businesses in which the Company is engaged, including, but not limited to, directors and officers insurance coverage.
The Company does not have any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(q) <U>Transactions With Affiliates and Employees</U>.
To the Company&rsquo;s knowledge, none of the Company&rsquo;s stockholders, officers or directors or any family member or affiliate of
any of the foregoing, has either directly or indirectly an interest in, or is a party to, any transaction that would be required to be
disclosed as a related party transaction pursuant to Item 404 of Regulation S-K promulgated under the Securities Act that is not so disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(r) <U>Sarbanes-Oxley; Internal Accounting Controls</U>.
Except as disclosed in the SEC Reports, the Company is in material compliance with any applicable provision of the Sarbanes-Oxley Act
of 2002 that are effective as of the date hereof, and the rules and regulations promulgated in connection therewith that are effective
as of the date hereof. The Company maintains internal accounting controls designed to provide reasonable assurances regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including, but not limited
to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management&rsquo;s
general or specific authorization, (ii) transactions are recorded as necessary to permit preparation of the Company&rsquo;s financial
statements in conformity with GAAP and to maintain accountability for its assets, (iii) access to the Company&rsquo;s assets is permitted
only in accordance with management&rsquo;s general or specific authorization and (iv) the recorded accountability for the Company&rsquo;s
assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(s) <U>Certain Fees</U>. Other than the Placement
Agent&rsquo;s fees, no brokerage or finder&rsquo;s fees or commissions are or will be payable by the Company to any broker, financial
advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated
by the Transaction Documents. The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or
on behalf of other Persons for fees of a type contemplated in this Section 3.1(t) that may be due in connection with the transactions
contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(t) <U>Investment Company</U>. The Company is
not, and is not an Affiliate of, and immediately after receipt of payment for the Securities will not be or be an Affiliate of, an &ldquo;investment
company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner
so that it will not become an &ldquo;investment company&rdquo; subject to registration under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(u) <U>Registration Rights</U>. Except as provided
for in Section 4.11 of this Agreement, no Person has any right to cause the Company to effect the registration under the Securities Act
of any securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(v) <U>Listing and Maintenance Requirements</U>.
The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to,
or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor
has the Company received any notification that the Commission is contemplating terminating such registration. The Common Stock is currently
eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current
in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic
transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(w) <U>Disclosure</U>. All of the disclosure furnished
by or on behalf of the Company to the Purchasers regarding the Company, its business and the transactions contemplated hereby is true
and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. The Company
acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 3.2 hereof. Except with respect to the material terms and conditions of the
transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf
has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material,
non-public information which is not or will not be otherwise disclosed pursuant to Section 4.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(x) <U>No Integrated Offering</U>. Assuming the
accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither the Company, nor, to the Company&rsquo;s
knowledge, any of its Affiliates, nor any Person acting on its or, to the Company&rsquo;s knowledge, their behalf has, directly or indirectly,
made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions
of any Trading Market on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(y) <U>Solvency</U>. Except as disclosed in the
SEC Reports, based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by
the Company of the proceeds from the sale of the Securities hereunder, (i) the fair saleable value of the Company&rsquo;s assets exceeds
the amount that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its business
as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of
the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the
current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking
into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or
circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws
of any jurisdiction within six months from the Closing Date. The SEC Reports sets forth as of the date hereof all outstanding secured
and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. Neither the Company
nor any Subsidiary is in default with respect to any Indebtedness. For purposes of this Agreement, &ldquo;Indebtedness&rdquo; means (x)
any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course
of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the
same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement
of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the present value
of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor
any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(z) <U>Tax Status</U>. Except for matters that
would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company has filed
all federal, state, local and foreign tax returns required to be filed by it through the date hereof, subject to permitted extensions,
and has paid all taxes due, and no tax deficiency has been determined adversely to the Company, nor does the Company have any knowledge
of any tax deficiencies that have been, or could reasonably be expected to be asserted against the Company, that could, in the aggregate,
reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(aa) <U>Foreign Corrupt Practices</U>. Neither
the Company nor any of the Company&rsquo;s directors or officers, nor, to the knowledge of the Company, any agents or employees of the
Company, has in the course of its actions for, or on behalf of, the Company: (i) made any unlawful contribution, gift, entertainment or
other unlawful expense relating to foreign or domestic political activity; (ii) made any direct or indirect bribe, kickback, improper
rebate, payoff, influence payment, or otherwise unlawfully provided anything of value, to any &ldquo;foreign official&rdquo; (as defined
in the FCPA) or domestic government official; (iii) failed to disclose fully any contribution made by the Company (or made by any person
acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any applicable
provision of the FCPA. The Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to
cause the Company to comply in all material respects with the FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(bb) <U>Office of Foreign Assets Control</U>.
Neither the Company nor, to the knowledge of the Company, any of the Company&rsquo;s directors or officers, nor, to the knowledge of the
Company, any agents or employees of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(cc) <U>Money Laundering</U>. The operations of
the Company are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements
of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules
and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;), and no Action or Proceeding by or before any
court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending
or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(dd) <U>Accountants</U>. The Company&rsquo;s accounting
firm is Farber Hass Hurley LLP. To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting
firm as required by the Exchange Act and (ii) expressed its opinion with respect to the financial statements included in the Company&rsquo;s
Annual Report on Form 10-K for the fiscal year ended March 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(ee) <U>Acknowledgment Regarding Purchasers&rsquo;
Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&rsquo;s
length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges
that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction
Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of its representatives or agents in connection
with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&rsquo; purchase of the
Securities. The Company further represents to each Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other
Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its
representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(ff) <U>Acknowledgment Regarding Purchaser&rsquo;s
Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(h) and 4.10
hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor
has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo;
securities based on securities issued by the Company or to hold the Securities for any specified term; (ii) past or future open market
or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions,
before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&rsquo;s
publicly- traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser
is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall
not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction.
The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during
the period that the Securities are outstanding, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&rsquo;
equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such
aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(gg) <U>Regulation M Compliance</U>. The Company
has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result
in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities,
(ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to
pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of
clauses (ii) and (iii), compensation paid to the Company&rsquo;s placement agent in connection with the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(hh) <U>FDA</U>. As to each product subject to
the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal Food, Drug and Cosmetic Act, as
amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged, labeled, tested, distributed, sold,
and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Regulated Product</U>&rdquo;), such Regulated
Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable
requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure,
or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling,
advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect.
There is no pending, completed or, to the Company&rsquo;s knowledge, threatened, action (including any lawsuit, arbitration, or legal
or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none
of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental
entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing
or packaging of, the testing of, the sale of, or the labeling and promotion of any Regulated Product, (ii) withdraws its approval of,
requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating
to, any Regulated Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv)
enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of
permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations
by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The
properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable
laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license
or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any
concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(ii) <U>Stock Option Plans</U>. Each stock option
granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance with the terms of the Company&rsquo;s
stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option
would be considered granted under GAAP and applicable law. No stock option granted under the Company&rsquo;s stock option plan has been
backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock
options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material
information regarding the Company or its financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(jj) <U>Private Placement</U>. Assuming the accuracy
of the Purchaser&rsquo;s representations and warranties set forth in Section 3.2, the offer and sale of the Securities to the Purchasers
as contemplated hereby is exempt from the registration requirements of the Securities Act. Neither the Company nor any other person or
entity authorized by the Company to act on its behalf has engaged in a general solicitation or general advertising (within the meaning
of Regulator D of the Securities Act) of investors with respect to offers or sales of Securities pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(kk) <U>No Rule 506 Disqualifying Activities</U>.
With respect to the Warrants and Warrant Shares to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none
of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating
in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding voting equity securities, calculated
on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company
in any capacity at the time of sale (each, a &ldquo;Company Covered Person&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications
described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;Disqualification Event&rdquo;), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3). No &ldquo;bad actor&rdquo; disqualifying event described in Rule 506(d)(1)(i)-(viii) of the
Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;) is applicable to the Company or, to the Company&rsquo;s knowledge, any
Company Covered Person, except for a Disqualification Event as to which Rule 506(d)(2)(ii&ndash;iv) or (d)(3), is applicable. Other than
the Placement Agent, the Company is not aware of any Person (other than any Company Covered Person) that has been or will be paid (directly
or indirectly) remuneration for solicitation of purchasers in connection with the sale of the Securities pursuant to this Agreement. The
Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Placement
Agent a copy of any disclosures provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(ll) <U>Cybersecurity</U>. (i)(x) To the Company&rsquo;s
knowledge, there has been no material security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s
information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees,
suppliers, vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems
and Data</U>&rdquo;) and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition
that would reasonably be expected to result in, any material security breach or other compromise to its IT Systems and Data; (ii) the
Company and the Subsidiaries are presently in compliance in all material respects with all applicable laws or statutes and all judgments,
orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations
relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access,
misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company
and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential
information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the
Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(mm) <U>Compliance with Data Privacy Laws</U>.
(i) To the Company&rsquo;s knowledge, the Company and the Subsidiaries are, and at all times during the last three (3) years were, in
compliance with all applicable state, federal and foreign data privacy and security laws and regulations, including, without limitation,
the European Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy Laws</U>&rdquo;);
(ii) the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance
with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis
of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii) the Company provides accurate notice of its applicable
Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws; and (iv) applicable Policies
provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating to its subject matter, and do not
contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by Privacy Laws. &ldquo;<U>Personal
Data</U>&rdquo; means (i) a natural person&rsquo;s name, street address, telephone number, email address, photograph, social security
number, bank information, or customer or account number; (ii) any information which would qualify as &ldquo;personally identifying information&rdquo;
under the Federal Trade Commission Act, as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR; and (iv) any other piece of
information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any
identifiable data related to an identified person&rsquo;s health or sexual orientation. (i) None of such disclosures made or contained
in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii) the execution, delivery
and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies. Neither the Company nor the
Subsidiaries (i) to the knowledge of the Company, has received written notice of any actual or potential liability of the Company or the
Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy Laws; (ii) is currently
conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any regulatory request
or demand pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement by or with any court or arbitrator or governmental
or regulatory authority that imposed any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(nn) <U>No Additional Agreements</U>. Other than
as specified in the Transaction Documents, the Company does not have any agreement or understanding with any Purchaser with respect to
the transactions contemplated by the Transaction Documents. For the avoidance of doubt, the Company has not entered into any other purchase
agreement with any other Person on or around the date hereof, or any other agreement in connection with any Person&rsquo;s direct or indirect
equity investment in the Company that includes terms and conditions that are materially more advantageous to such Person than to any Purchaser
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(oo) <U>Placement Agent</U>. The Company hereby
acknowledges and agrees that (i) the Placement Agent is acting solely as placement agent in connection with the execution, delivery and
performance of the Transaction Documents and is not acting as an underwriter or in any other capacity and is not and shall not be construed
as a fiduciary for such Purchaser, the Company or any other person or entity in connection with the execution, delivery and performance
of the Transaction Documents, (ii) the Placement Agent has not made nor will make any representation or warranty, whether express or implied,
of any kind or character and the Placement Agent has not provided any advice or recommendation in connection with the execution, delivery
and performance of the Transaction Documents and (iii) the Placement Agent will not have any responsibility with respect to (A) any representations,
warranties or agreements made by any person or entity under or in connection with the execution, delivery and performance of the Transaction
Documents, or the execution, legality, validity or enforceability (with respect to any person) thereof, or (B) the business, affairs,
financial condition, operations or properties of, or any other matter concerning the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">3.2 <U>Representations and Warranties of the Purchasers</U>.
Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date
to the Company and the Placement Agent that the statements contained in this Section 3.2 are true and correct as of the date hereof and
as of the Closing Date (unless as of a specific date therein, in which case they shall be accurate as of such date):</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(a) <U>Organization; Authority</U>. Such Purchaser
is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction
of its incorporation or formation with full right, corporate, partnership limited liability company or similar power and authority to
enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder
and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated
by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action,
as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser,
and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of
such Purchaser, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights
generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies
and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(b) <U>Understandings or Arrangements</U>. Such
Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with
any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser&rsquo;s
right to sell the Securities in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities
hereunder in the ordinary course of its business. Notwithstanding the foregoing, if such Purchaser is purchasing the Securities as a fiduciary
or agent for one or more Purchaser accounts, such Purchaser has full investment discretion with respect to each such account, and the
full power and authority to make the acknowledgements, representations and agreements herein on behalf of each owner of each such account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(c) <U>Purchaser Status</U>. At the time such
Purchaser was offered the Securities, it was, and as of the date hereof it is an &ldquo;accredited investor&rdquo; as defined in Rule
501(a)(1), (a)(2), (a)(3), (a)(4), (a)(5), (a)(6), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(d) <U>Experience of Such Purchaser</U>. Such
Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the
merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present
time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(e) <U>Disclosure of Information; Exculpation</U>.
Such Purchaser or its advisor has had an opportunity to receive, review and understand all information related to the Company in the PPM,
as applicable, and otherwise requested by it and to ask questions of and receive answers from the Company regarding the Company, its business
and the terms and conditions of the offering of the Securities, and has conducted and completed its own independent due diligence. Such
Purchaser acknowledges that copies of the SEC Reports are available on the EDGAR reporting system. Based on the information such Purchaser
or its advisor has deemed appropriate, and without reliance on the Placement Agent, the Purchaser has independently made its own analysis
and decision to enter into the Transaction Documents. Such Purchaser or its advisor is relying exclusively on the representations and
warranties of the Company contained in the Transaction Documents, the SEC Reports, the PPM (as applicable) and its own sources of information,
investment analysis and due diligence (including professional advice it deems appropriate) with respect to the execution, delivery and
performance of the Transaction Documents, the Securities and the business, condition (financial and otherwise), management, operations
and properties of the Company, including all business, legal, regulatory, accounting, credit and tax matters. Neither such inquiries nor
any other due diligence investigation conducted by such Purchaser or its advisor shall modify, limit or otherwise affect such Purchaser&rsquo;s
right to rely on the Company&rsquo;s representations and warranties contained in this Agreement. Such Purchaser acknowledges and agrees
that the Placement Agent shall have no liability or obligation on or with respect to the accuracy or completeness, as of any date, of
any information set forth in, or any omission from, any valuation or other materials that may have been provided or made available to
such Purchaser in connection with the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(f) <U>Restricted Securities</U>. Such Purchaser
understands that the Securities are characterized as &ldquo;restricted securities&rdquo; under the U.S. federal securities laws inasmuch
as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations
such securities may be resold (i) pursuant to an effective registration statement or (ii) pursuant to an exemption from registration under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(g) <U>Legends</U>. It is understood that, except
as provided below, book entries or certificates evidencing the Securities may bear the following or any similar legend:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&ldquo;THE OFFER AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE
NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION
FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS THEREUNDER (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (I) THE RESALE OF SUCH SECURITIES HAS BEEN REGISTERED PURSUANT TO THE SECURITIES ACT,
(II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144 OR ANOTHER APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES
ACT, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT
REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN AGREEMENT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">If required by the authorities of any state in connection with the
issuance of sale of the Securities, the legend required by such state authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(h) <U>Certain Transactions and Confidentiality</U>.
Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant
to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities
of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the
Company, the Placement Agent or any other Person representing the Company setting forth the material terms of the transactions contemplated
hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, (i) in the case of a Purchaser that is
a multi- managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and
the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of
such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the
portfolio manager that made the investment decision to purchase the Securities covered by this Agreement and (ii) in the case of a Purchaser
that is affiliated with other funds or investment vehicles or whose investment advisor or sub-advisor that routinely acts on behalf of
or pursuant to an understanding with such Purchaser is also an investment advisor or sub-advisor to other funds or investment vehicles,
the representation set forth above shall only apply with respect to the personnel of such other funds or investment vehicles or such investment
advisor or sub- advisor who had knowledge of the transaction contemplated hereby and not with respect to any personnel who have been effectively
walled off by appropriate information barriers. Other than to other Persons party to this Agreement or to such Purchaser&rsquo;s representatives,
including, without limitation, its officers, directors, partners, legal and other advisors, employees, and agents, such Purchaser has
maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of
this transaction). In the case of a Purchaser whose investment advisor utilized an information barrier with respect to the information
regarding the transactions contemplated hereunder after first receiving such term sheet (written or oral) from the Company or such other
Person representing the Company, the representation set forth above in this Section 3.2 (h) shall only apply after the point in time when
the portfolio manager who manages such Purchaser&rsquo;s assets was informed of the information regarding the transactions contemplated
hereunder and, with respect to the Purchaser&rsquo;s investment advisor, the representation set forth above shall only apply with respect
to any purchases or sales, including Short Sales, of the securities of the Company on behalf of other funds or investment vehicles for
which Purchaser&rsquo;s investment advisor is also an investment advisor or sub-advisor after the point in time when the portfolio manager
who manages the assets of such other funds or investment vehicles for which Purchaser&rsquo;s investment advisor is also an investment
advisor or sub-advisor was informed of the information regarding the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Notwithstanding anything contained herein or otherwise
to the contrary, in constructing the application of this Agreement, it is understood and agreed that this paragraph will not restrict
the activities of any person, including person affiliated with or within the Purchaser or the manager of the Purchaser that do not have
access or knowledge of the information or awareness discussed in this Section 3.2(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(i) <U>Placement Agent</U>. Such Purchaser hereby
acknowledges and agrees that it has independently evaluated the merits of its decision to purchase the Securities and that (i) the Placement
Agent is acting solely as placement agent in connection with the execution, delivery and performance of the Transaction Documents and
is not acting as an underwriter or in any other capacity and is not and shall not be construed as a fiduciary for such Purchaser, the
Company or any other person or entity in connection with the execution, delivery and performance of the Transaction Documents, (ii) the
Placement Agent has not made nor will make any representation or warranty, whether express or implied, of any kind or character and the
Placement Agent has not provided any advice or recommendation in connection with the execution, delivery and performance of the Transaction
Documents and (iii) the Placement Agent will not have any responsibility with respect to (A) any representations, warranties or agreements
made by any person or entity under or in connection with the execution, delivery and performance of the Transaction Documents, or the
execution, legality, validity or enforceability (with respect to any person) thereof, or (B) the business, affairs, financial condition,
operations or properties of, or any other matter concerning the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(j) <U>No General Solicitation</U>. Such Purchaser
did not learn of the investment in the Securities as a result of any general solicitation or general advertising.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(k) <U>Brokers and Finders</U>. No Person will
have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon the
Company or a Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into
by or on behalf of such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(l) <U>No Government Recommendation or Approval</U>.
Such Purchaser understands that no United States federal or state agency, or similar agency of any other country, has reviewed, approved,
passed upon, or made any recommendation or endorsement of the Company or the purchase of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(m) <U>No Intent to Effect a Change of Control;
Ownership</U>. Such Purchaser has no present intent to effect a &ldquo;change of control&rdquo; of the Company as such term is understood
under the rules promulgated pursuant to Section 13(d) of the 1934 Act and under the rules of Nasdaq Stock Market. Notwithstanding the
foregoing, in the case of a Purchaser that is a multi- managed investment vehicle whereby separate portfolio managers manage separate
portions of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets managed
by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Except as set forth in
its Selling Stockholder Questionnaire or as reflected in a Schedule 13G or Schedule 13D filed with the Commission, as of the date hereof,
such Purchaser is not the owner of record or the beneficial owner of shares of Common Stock or securities convertible into or exchangeable
for Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(n) <U>No Conflicts</U>. The execution, delivery
and performance by such Purchaser of the Transaction Documents and the consummation by such Purchaser of the transactions contemplated
hereby and thereby will not (i) result in a violation of the organizational documents of such Purchaser or (ii) conflict with, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture or instrument to which such Purchaser is a party, or (iii) result
in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such
Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually
or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Purchaser to perform its obligations
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(o) <U>No Rule 506 Disqualifying Activities</U>.
If such Purchaser is a Company Covered Person, such Purchaser has not taken any of the actions set forth in, and is not subject to, any
Disqualification Events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(p) <U>Residency</U>. Such Purchaser is a resident
of or an entity organized under the jurisdiction specified below its address on the Schedule of Purchasers, except as otherwise communicated
to the Company by the Purchaser prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(q) <U>Regulation Best Interest</U>. If such Purchaser
is a customer or client of the Placement Agent, such Purchaser acknowledges that the Placement Agent is registered with the SEC as a Broker-Dealer
and is a member of the Financial Industry Regulatory Authority, Inc., and that an affiliate of the Placement Agent is a registered investment
advisor with the SEC. Such Purchaser understands that brokerage and investment advisory services and fees differ. Such Purchaser acknowledges
that the Placement Agent&rsquo;s Form CRS (Customer Relationship Summary) and Best Interest Disclosure is available on the Placement Agent&rsquo;s
website at www.newbridgesecurities.com/disclosures and that the Purchaser has been advised by the Placement Agent, and has had the opportunity,
to review such disclosure carefully before purchasing any Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The Company acknowledges and agrees that the representations
contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on the Company&rsquo;s representations
and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other
document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated
hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>ARTICLE IV. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.1 <U>Furnishing of Information</U>. Until the
earlier of (i) the time that no Purchaser owns Securities or (ii) twenty-four (24) month anniversary of the Closing Date, the Company
covenants to use commercially reasonable best efforts to timely file (or obtain extensions in respect thereof and file within the applicable
grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.2 <U>Integration</U>. The Company shall not
sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities
Act) that the Company believes, acting in good faith and after consultation with the Trading Market, would be integrated with the offer
or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval
prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.3 <U>Securities Laws Disclosure; Publicity</U>.
The Company shall (a) by the Disclosure Time, issue a press release and/or file a Current Report on Form 8-K disclosing (x) the material
terms of the transactions contemplated hereby, which shall have been previously reviewed by counsel for the Placement Agent, and (y) material
data from the Company&rsquo;s INB-100 Phase 1 clinical trial previously conveyed to Purchasers, and (b) in respect of any information
in clause (a) that is issued in a press release, file a Current Report on Form 8-K, which shall have been previously reviewed by counsel
for the Placement Agent, including this Agreement as an exhibit thereto, within the time required by the Exchange Act. From and after
the issuance of such press release, the Company represents to the Purchasers and the Placement Agent that it shall have publicly disclosed
all material, non-public information delivered to any of the Purchasers by the Company or any of its officers, directors, employees or
agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such
press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under this Agreement, or an
agreement entered into in connection with the transactions contemplated by the Transaction Documents, whether written or oral, between
the Company or any of its officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchasers or any of their
respective officers, directors, agents, employees or investment advisers, on the other hand, shall terminate. The Company and each Purchaser
shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the
Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of
the Company and the Placement Agent, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser
and the Placement Agent, with respect to any press release of the Company. To the extent any disclosure is required by law or the regulations
of the Trading Market, the Company shall provide such Purchaser with prompt prior notice of such requirement so that the Purchaser may
(a) seek appropriate relief to prevent or limit such disclosure, (b) furnish only that portion of the information which is legally required
to be furnished or disclosed, and to the extent reasonably feasible, (c) consult with the Company on content and timing prior to any such
disclosure. Notwithstanding anything to the contrary contained herein, without the prior written consent of any applicable Purchaser,
the Company shall not (and shall cause each of its affiliates and representatives not to) disclose the name of such Purchaser or its investment
adviser in any filing, announcement, release or otherwise, except as required by law in which case the Company shall comply with the provisions
of this Section 4.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.4 <U>Reservation of Common Stock</U>. As of
the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive
rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue all of the Warrant Shares upon
conversion of any Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.5 <U>Non-Public Information</U>. Except with
respect to the material terms and conditions of the transactions contemplated by the Transaction Documents and other material information,
which in each case shall be disclosed pursuant to Section 4.3, the Company covenants and agrees that neither it, nor any other Person
acting on its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably
believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the receipt of such
information and agreed with the Company to keep such information confidential. The Company understands and confirms that each Purchaser
shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company delivers
any material, non-public information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that
such Purchaser shall not have any duty of confidentiality to the Company or any of its officers, directors, agents, employees or Affiliates,
or a duty to the Company or any of its officers, directors, agents, employees or Affiliates not to trade on the basis of such material,
non-public information, <I>provided</I> that the Purchaser shall remain subject to applicable law. To the extent that any notice provided
pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company, the Company shall
simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that
each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.6 <U>Indemnification of Purchasers</U>. Subject
to the provisions of this Section 4.6, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders, members,
partners, investment advisers, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such
titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section
15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or
employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title
or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and
reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating
to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other
Transaction Documents or (b) any action or claim instituted or made against the Purchaser Parties in any capacity, by any stockholder
of the Company who is not an affiliate of such Purchaser Party or any other third party (including a derivative action brought on behalf
of the Company) (a &ldquo;<U>Covered Action</U>&rdquo;), with respect to, or arising out of or resulting from, any of the transactions
contemplated by the Transaction Documents. If any Covered Action shall be brought against any Purchaser Party in respect of which indemnity
may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have
the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party
shall have the right to employ separate counsel in any such Covered Action and participate in the defense thereof, but the fees and expenses
of such counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically
authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ
counsel or (iii) in such Covered Action there is, in the reasonable opinion of counsel, a material conflict on any material issue between
the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable
fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement
(y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably
withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser
Party&rsquo;s willful misconduct, gross negligence or breach of any of the representations, warranties, covenants or agreements made by
such Purchaser Party in this Agreement or in the other Transaction Documents. The Company shall not, without the prior written consent
of the Purchaser Party (which consent shall not be unreasonably withheld), consent to entry of any judgment or enter into any settlement
or other compromise which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Purchaser
Party of a release from all liability in respect to such Covered Action, and such settlement shall not include any admission as to fault
on the part of the Purchaser Party. The indemnification required by this Section 4.6 shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained
herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities
the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.7 <U>Listing of Common Stock</U>. The Company
hereby agrees to use reasonable best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it
is currently listed. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it
will then include in such application all of the Shares and Warrant Shares and will use its reasonable best efforts to take such other
action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as
possible. The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading
Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the
Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust
Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust
Company or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.8 <U>Subsequent Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 55.1pt">(a) From the date hereof until the later of (a)
sixty (60) days from the Closing Date or (b) thirty (30) days after the effective date of the Resale Registration Statement, the Company
shall not (i) other than in an Exempt Issuance, issue, enter into any agreement to issue or announce the issuance or proposed issuance
of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement thereto,
in each case other than as contemplated pursuant to Section 4.11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 55.1pt">(b) From the date hereof until one (1) year after
the date hereof, the Company shall not enter into a Variable Rate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.9 <U>Certain Transactions and Confidentiality</U>.
Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Person acting on its behalf or
pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company&rsquo;s securities
during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement
are first publicly announced pursuant to the initial press release as described in Section 4.3. Each Purchaser, severally and not jointly
with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by
the Company pursuant to the initial press release as described in Section 4.3, such Purchaser will maintain the confidentiality of the
existence and terms of this transaction. Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the
contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that
it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the initial press release as described in Section 4.3, (ii) no Purchaser shall be restricted
or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release
as described in Section 4.3 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the
Company to the Company after the issuance of the initial press release as described in Section 4.3. Notwithstanding the foregoing, in
the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such
Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of
assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.10 <U>Removal of Legends</U>. In connection
with any sale, assignment, transfer or other disposition of the Shares or the Warrant Shares by a Purchaser pursuant to Rule 144, pursuant
to any other exemption under the Securities Act or pursuant to sale under an effective registration statement such that the purchaser
acquires freely tradable shares and upon compliance by the Purchaser with the requirements of this <U>Section 4.10</U>, if requested by
the Purchaser, the Company shall cause the Transfer Agent to timely remove any restrictive legends related to the book entry account holding
such Shares or Warrant Shares and make a new, unlegended entry for such book entry Shares or Warrant Shares sold or disposed of without
restrictive legends, <I>provided</I> that the Company has received customary representations and other documentation reasonably acceptable
to the Company in connection therewith. Subject to receipt by the Company of customary representations and other documentation reasonably
acceptable to the Company in connection therewith, upon the earlier of such time as the Shares or Warrant Shares, (i) have been sold or
transferred pursuant to an effective registration statement, (ii) have been sold pursuant to Rule 144 or (iii) are eligible for resale
under Rule 144(b)(1) or any successor provision (without the requirement for the Company to comply with the current public information
obligations of Rule 144(c)), the Company shall promptly, after receipt of any request therefor from a Purchaser accompanied by such customary
and reasonably acceptable documentation referred to above (A) deliver to the Transfer Agent irrevocable instructions that the Transfer
Agent shall make a new, unlegended entry for such book entry Shares or Warrant Shares and (B) use commercially reasonable efforts to cause
its counsel to cooperate with the Transfer Agent to effect the removal of such legends under the Securities Act. From and after the earlier
of such dates, upon a Purchaser&rsquo;s written request, the Company shall promptly cause certificates or book entries evidencing the
Purchaser&rsquo;s Shares or Warrant Shares to be replaced with certificates or book entries, as the case may be, which do not bear such
restrictive legends, provided the provisions of either clauses (i), (ii) or (iii) above, as applicable, are satisfied with respect to
such Shares or Warrant Shares. The Company shall be responsible for the fees of its Transfer Agent associated with such issuance. Notwithstanding
the foregoing, promptly following the effectiveness of the Resale Registration Statement, upon receipt by the Company of an executed representation
letter from a Purchaser, the form of which is attached as <U>Exhibit E</U> (the &ldquo;<U>Representation Letter</U>&rdquo;), the Company
shall remove any legend from the book entry position evidencing the applicable Securities then held by such Purchaser, <I>provided</I>
that they are not an affiliate of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">4.11 <U>Registration Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(a) The Company shall use commercially reasonable
efforts to prepare and file with the United States Securities and Exchange Commission (the &ldquo;<U>SEC</U>&rdquo;), within thirty (30)
days after the Closing Date, and cause the SEC to declare effective, as promptly as possible, after the filing thereof, the Resale Registration
Statement, covering the resale of all of the Registrable Securities for an offering to be made on a continuous basis pursuant to Rule
415 promulgated under the Securities Act (&ldquo;<U>Rule 415</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(b) Notwithstanding the registration obligations
set forth in Section 5(a), if the SEC informs the Company that all of the Registrable Securities cannot, as a result of the application
of Rule 415 or other applicable regulations, be registered for resale as a secondary offering on a single registration statement, the
Company agrees to promptly inform the Purchaser thereof and use its reasonable efforts to file amendments to the registration statement
as required by the SEC, covering the maximum number of Registrable Securities permitted to be registered by the SEC. If the SEC or any
publicly available written or oral guidance of the SEC staff sets forth a limitation on the number of Registrable Securities permitted
to be registered on a particular registration statement as a secondary offering, the Company shall reduce the Registrable Securities on
a pro rata basis among the participating Purchasers (the &ldquo;Holders&rdquo;) in this Offering, in proportion to the aggregate amount
of Registrable Securities to be registered on behalf of each.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">(c) In connection with the Company&rsquo;s registration
obligations hereunder, the Company shall, as promptly as reasonably possible under the circumstances, taking into account the Company&rsquo;s
good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure of such event, prepare
a supplement or amendment, including a post-effective amendment, to a registration statement or a supplement to the related prospectus
or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter
delivered, neither a registration statement nor such prospectus, included therein, will contain an untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Company notifies the Holders to suspend the use of any prospectus until the requisite
changes to such prospectus have been made, then the Holders shall suspend use of such prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>ARTICLE V. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.1 <U>Termination</U>. This Agreement may be
terminated (a) by written agreement of a Purchaser as to such Purchaser&rsquo;s obligations and the Company, or (b) by any Purchaser,
as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the
other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the fifth (5th) Trading
Day following the date hereof; <I>provided</I>, <I>however</I>, that no such termination will affect the right of any party to sue for
any breach by any other party (or parties). The Company shall provide prompt notice of any such termination to each other Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.2 <U>Fees and Expenses</U>. Each party shall
pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party
incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent
fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company), stamp
taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers. The Company shall pay all
Placement Agent fees relating to or arising out of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.3 <U>Entire Agreement</U>. The Transaction Documents,
together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject matter hereof
and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge
have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.4 <U>Notices</U>. Any and all notices or other
communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective
on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email attachment at the email address
as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, with no rejection
notice received, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered via email attachment
at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, with no rejection notice received, (c) the second (2nd) Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices shall be as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Attention: James E. Besser</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">10740 Thornmint Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">San Diego, California 92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">E-Mail: ir@modular-medical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">with a copy (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Lucosky Brookman LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Attention: Lawrence Metelitsa</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">101 Wood Avenue South</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Woodbridge, New Jersey 08830</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">E-Mail: lmetelitsa@lucbro.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.5 <U>Amendments; Waivers</U>. No amendment,
modification, alteration, or change in any of the terms of this Agreement shall be valid or binding upon the parties hereto unless made
in writing and duly executed by the Company and the Major Stockholders holding at least 85% in interest of the Securities then-held; <I>provided</I>
that prior to Closing the consent of all Purchasers shall be required. No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver
of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.6 <U>Headings</U>. The headings herein are for
convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.7 <U>Successors and Assigns</U>. This Agreement
shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may not assign this
Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser
may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, <I>provided</I>
that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents
that apply to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.8 <U>Third-Party Beneficiaries</U>. The Placement
Agent shall be the express third-party beneficiary of the representations and warranties of the Company in Section 3.1 and the representations
and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit of the parties hereto, the Placement Agent,
the parties named in Section 4.6, and their respective successors and permitted assigns and is not for the benefit of, nor may any provision
hereof be enforced by, any other Person, except as otherwise set forth in this Section 5.8 or Section 4.6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.9 <U>Governing Law</U>. All questions concerning
the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced
in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof (other than
Sections 5-1401 and 5-1402 of the General Obligations Law). Each party agrees that all Actions or Proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against
a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any
of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it
is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue
for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such
Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.10 <U>Survival</U>. The representations and
warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.11 <U>Execution</U>. This Agreement may be executed
in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign
the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;pdf&rdquo; format data file (including
any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures
and Records Act or other applicable law, e.g., www.docusign.com), such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such &ldquo;pdf&rdquo; signature page were
an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.12 <U>Severability</U>. If any term, provision,
covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable,
the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in
no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ
an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction.
It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions,
covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.13 <U>Rescission and Withdrawal Right</U>. Notwithstanding
anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Documents, whenever
any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related
obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time
upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions
and rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.14 <U>Replacement of Securities</U>. If any
certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued
in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a
new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction.
The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including
customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.15 <U>Remedies</U>. In addition to being entitled
to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will be
entitled to seek specific performance under the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.16 <U>Payment Set Aside</U>. To the extent that
the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its
rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated,
declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise
restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state
or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally
intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement
or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.17 <U>Independent Nature of Purchasers&rsquo;
Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations
of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non- performance of the obligations of
any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken
by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture
or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to
such obligations or the transactions contemplated by the Transaction Documents, and the Company acknowledges that the Purchasers are not
acting in concert or as a group. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation,
the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal
counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers with the same terms
and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers.
It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between
the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.18 <U>Exculpation of the Placement Agent. </U>Each
party hereto agrees for the express benefit of the Placement Agent, its affiliates and its representatives that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Neither the Placement Agent nor its affiliates or representatives (i) have any duties or obligations other than those specifically set forth herein or in the engagement letter, dated as of February 10, 2025, between the Company and Placement Agent (the &ldquo;<U>Engagement Letter</U>&rdquo;); (ii) shall be liable for any improper payment made in accordance with the information provided by the Company; (iii) make any representation or warranty, or have any responsibilities as to the validity, accuracy, value or genuineness of any information, certificates or documentation delivered by or on behalf of the Company pursuant to this Agreement or the Transaction Documents or in connection with any of the transactions; or (iv) shall be liable (A) for any action taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the discretion or rights or powers conferred upon it by this Agreement or any Transaction Document or (B) for anything which any of them may do or refrain from doing in connection with this Agreement or any Transaction Document, except for such party&rsquo;s own fraud, gross negligence, willful misconduct or bad faith. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">The Placement Agent, its affiliates and its representatives shall be entitled to (i) rely on, and shall be protected in acting upon, any certificate, instrument, opinion, notice, letter or any other document or security delivered to any of them by or on behalf of the Company, and (ii) be indemnified by the Company for acting as Placement Agent, hereunder pursuant the indemnification provisions set forth in the Engagement Letter. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.19 <U>Saturdays, Sundays, Holidays, etc</U>.
If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business
Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">5.20 <U>Construction</U>. The parties agree that
each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore,
the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed
in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to share prices and
shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends,
stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><B>5.21 <U>WAIVER OF JURY TRIAL. IN ANY ACTION,
SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO
THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY
JURY.</U>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties hereto have caused
this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>MODULAR MEDICAL, INC.</B> &nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 35%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By: &nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name: &nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title: &nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>[COMPANY SIGNATURE PAGE TO MODULAR MEDICAL
SECURITIES PURCHASE AGREEMENT]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>SIGNATURE PAGE TO THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>PURCHASE AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">By execution and delivery of this signature page, you are (a) agreeing
to become (i) a Purchaser, as defined in this Purchase Agreement, by and among Modular Medical, Inc., a Delaware corporation (the &ldquo;Company&rdquo;),
and each of the Purchasers, and (b) acknowledging that you have read and acknowledge each of the representations in the Purchase Agreement
section entitled &ldquo;Representations and Warranties,&rdquo; and (c) hereby representing that the statements contained therein are complete
and accurate with respect to the undersigned as a Purchaser. The Company&rsquo;s countersignature will be delivered to each Purchaser
as part of the closing of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Purchaser hereby elects to subscribe under the Purchase Agreement
for a total of $<U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;</U> in consideration for the following number of Units: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Number of Units: <U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;</U>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>Number of Units with Pre-funded Warrants (if applicable): <U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;</U>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">If the Purchaser is an INDIVIDUAL, and if purchased as JOINT TENANTS,
as TENANTS IN COMMON/ COMMUNITY PROPERTY, or if the Purchaser is a REVOCABLE TRUST:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>PURCHASER:</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>JOINT PURCHASER (if any):</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">Print Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 10%">Print Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>SSN#:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>SSN#:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Signature:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Signature:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Address:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">If the Purchaser is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY
or IRREVOCABLE TRUST:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>Name of Entity:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Federal Tax Payer ID:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Print&nbsp;Name&nbsp;(Signatory):</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Additional&nbsp;Name&nbsp;(if&nbsp;any):</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Signature:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Signature:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Date:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Address:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%">State of Organization:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 30%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>EXHIBIT A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Form of Pre-Funded Warrant </B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>EXHIBIT B </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Form of Common Warrant </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>EXHIBIT C </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Form of Lock-Up Agreement</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>APPENDIX I </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Purchaser Questionnaire</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><IMG SRC="ex10-1_001.jpg" ALT="" STYLE="width: 48px; height: 783px"></TD><TD STYLE="text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><B>PURCHASERQUESTIONNAIRE</B></P>
                                                                                                            <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><B>The Purchaser
                                            makes the following representations regarding its status as an &ldquo;accredited investor&rdquo;
                                            and certain related matters, <I><U>and has initialed all of the applicable representations</U></I>:</B></P></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top; width: 15%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P></TD>
    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt; width: 85%"><FONT STYLE="font-size: 10pt">1.&emsp;&thinsp;The Purchaser is any bank as defined in section 3(a)(2) of the Securities Act, or any savings and loan association or other institution as defined in section 3(a)(5)(A) of the Securities Act whether acting in its individual or fiduciary capacity; any broker or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934; any investment adviser registered pursuant to section 203 of the Investment Advisers Act of 1940 or registered pursuant to the laws of a state; any investment adviser relying on the exemption from registering with the Commission under section 203(l) or (m) of the Investment Advisers Act of 1940; any insurance company as defined in section 2(a)(13) of the Act; any investment company registered under the Investment Company Act of 1940 or a business development company as defined in section 2(a)(48) of that act; any Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c) or (d) of the Small Business Investment Act of 1958; any Rural Business Investment Company as defined in section 384A of the Consolidated Farm and Rural Development Act; any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974 if the investment decision is made by a plan fiduciary, as defined in section 3(21) of such act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors.</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">2.&emsp;&thinsp;Any private business development company as defined in section 202(a)(22) of the Investment Advisers Act of 1940.</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">3.&emsp;&thinsp;Any organization described in section 501(c)(3) of the Code, corporation, Massachusetts or similar business trust, or partnership, or limited liability company, not formed for the specific purpose of acquiring the securities offered, with total assets in excess of $5,000,000.</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;_____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">4.&emsp;&thinsp;Any director, executive officer, or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or general partner of a general partner of that issuer.</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;&nbsp;____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">5.&emsp;&thinsp;Any natural person whose individual net worth, or joint net worth with that person&rsquo;s spouse or spousal equivalent, exceeds $1,000,000.</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;&nbsp;____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">6.&emsp;&thinsp;Any natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person&rsquo;s spouse or spousal equivalent in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income level in the current year.</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;&nbsp;____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">7.&emsp;&thinsp;Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii).</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: left; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;____________</FONT></TD>
    <TD STYLE="vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">8.&emsp;&thinsp;Any entity in which all of the equity owners are accredited investors.</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">9.&emsp;&thinsp;Any entity, of a type not listed in paragraph (1), (2), (3), (7), or (8), not formed for the specific purpose of acquiring the securities offered, owning investments in excess of $5,000,000. &ldquo;Investments&rdquo; means investments as defined in Rule 2a51-1(b) under the Investment Company Act of 1940.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: center; vertical-align: top; width: 14%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: justify; vertical-align: top; width: 86%; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">10.&ensp;&thinsp;Any natural person holding in good standing one or more professional certifications or designations or credentials from an accredited educational institution that the Commission has designated as qualifying an individual for accredited investor status.</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">11.&ensp;&thinsp;Any natural person who is a &ldquo;knowledgeable employee,&rdquo; as defined in rule 3c&ndash;5(a)(4) under the Investment Company Act of 1940 (17 CFR 270.3c&ndash;5(a)(4)), of the issuer of the securities being offered or sold where the issuer would be an investment company, as defined in section 3 of such act, but for the exclusion provided by either section 3(c)(1) or section 3(c)(7) of such act.</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">12.&ensp;&thinsp;Any &ldquo;family office,&rdquo; as defined in rule 202(a)(11)(G)&ndash;1 under the Investment Advisers Act of 1940 (17 CFR 275.202(a)(11)(G)&ndash;1).</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: justify; vertical-align: top; padding-left: 20pt; font-size: 10pt; text-indent: -20pt"><FONT STYLE="font-size: 10pt">13.&ensp;&thinsp;Any &ldquo;family client,&rdquo; as defined in rule 202(a)(11)(G)&ndash;1 under the Investment Advisers Act of 1940 (17 CFR 275.202(a)(11)(G)&ndash;1)), of a family office meeting the requirements in paragraph (a)(12) of this section and whose prospective investment in the issuer is directed by such family office pursuant to paragraph (a)(12)(iii).</FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;____________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: justify; vertical-align: top">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 20pt; text-indent: -20pt">14.&ensp;&thinsp;The Subscriber cannot
    make any of the representations set forth in subparagraphs &ldquo;1&rdquo; through &ldquo;13&rdquo; above.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 20pt">Note: If the Purchaser (1) was formed solely for the purpose
    of making an investment in the Company or (2) is an &ldquo;investment company&rdquo; as defined under the Investment Company Act of 1940
    (including those excepted from the definition pursuant to Section 3(c)(1) and 3(c)(7) thereof), the Purchaser represents that it has <U>&emsp;&emsp;&emsp;&emsp;</U>
    &thinsp;equity owners and that each of the equity owners is an accredited investor as described above. If this paragraph (l) is applicable
    to the Purchaser, please list all equity owners and attach such list to this Purchaser Agreement.</P></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>APPENDIX II </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Form W-9&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>APPENDIX III </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Form of Selling Stockholder Questionnaire </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;<FONT STYLE="font-size: 10pt"><B>SELLING
STOCKHOLDER NOTICE AND QUESTIONNAIRE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.625in; text-align: right"><U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;
</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">Name of Selling Stockholder (please print)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>Modular Medical, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>QUESTIONNAIRE FOR SELLING STOCKHOLDERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>IMPORTANT: IMMEDIATE ATTENTION REQUIRED </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">This Questionnaire is being furnished to all persons
or entities (the &ldquo;<I>Purchasers</I>&rdquo;) electing to purchase shares of common stock, par value $0.001 per share (the &ldquo;<I>Common
Stock</I>&rdquo;), of Modular Medical, Inc., a Nevada corporation (the &ldquo;<I>Company</I>&rdquo;), and pre-funded warrants and warrants
to purchase Common Stock (the &ldquo;Warrants&rdquo; and, together with the Common Stock, the &ldquo;<I>Securities</I>&rdquo;), pursuant
to the Securities Purchase Agreement by and among the Company and the Purchasers (the &ldquo;<I>Purchase Agreement</I>&rdquo;) to which
this Questionnaire is an Appendix. This Questionnaire relates to certain information required to be disclosed in the registration statement
(the &ldquo;<I>Registration Statement</I>&rdquo;) being prepared by the Company for filing with the United States Securities and Exchange
Commission (the &ldquo;<I>SEC</I>&rdquo;) pursuant to Section 4.11 of the Purchase Agreement. <B><U>The Company must receive a completed
Questionnaire from each</U>&nbsp;<U>Purchaser in order to include such Purchaser&rsquo;s shares of Common Stock (including shares of Common
Stock issuable upon exercise of the Warrants) in the Registration Statement.</U></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The furnishing of accurate and complete responses
to the questions posed in this Questionnaire is an extremely important part of the registration process. The inclusion of inaccurate or
incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and
to the individuals who furnish the information. Accordingly, Purchasers are advised to consult their own securities law counsel regarding
the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><U>PLEASE GIVE A RESPONSE TO EVERY QUESTION</U>,
indicating &ldquo;None&rdquo; or &ldquo;Not Applicable&rdquo; where appropriate. <B><U>Please complete, sign, and return one copy of this
Questionnaire by email or overnight</U>&nbsp;<U>courier as soon as possible</U>.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in">Lucosky Brookman LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in">101 Wood Avenue South</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in">Woodbridge, New Jersey 08830</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in">Attention: Lawrence Metelitsa</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5in">E-Mail: lmetelitsa@lucbro.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Unless stated otherwise, answers should be given
as of the date you complete this Questionnaire. However, it is your responsibility to inform us of any changes that may occur to your
situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this
Questionnaire, please contact Lawrence Metelitsa at lmetelitsa@lucbro.com or [&#9679;].&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>PART I - STOCK OWNERSHIP </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B><U>Item&thinsp;1</U>. <U>Beneficial Ownership</U>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Deemed Beneficial Ownership</U>. Please state the amount of securities of the Company you own on the date you complete this Questionnaire. (If none, please so state in each case.) </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt; width: 49%"><FONT STYLE="font-size: 10pt">Amount Beneficially Owned1</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center; width: 49%"><FONT STYLE="font-size: 10pt">Number of Shares of Common Stock Owned</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Please state the number of shares owned by you
or by family members, trusts and other organizations with which you have a relationship, and any other shares of which you may be deemed
to be the &ldquo;beneficial owner&rdquo;1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 60%"><FONT STYLE="font-size: 10pt">Total Shares:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-size: 10pt; width: 40%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Of such shares:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 40pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Shares as to which you have <U>sole</U> voting power:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 40pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Shares as to which you have <U>shared</U> voting power:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 40pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Shares as to which you have <U>sole</U> investment power:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 40pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Shares as to which you have <U>shared</U> investment power:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    </TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 40pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Shares which you will have a right to acquire before 60 days after the date you complete this questionnaire through the exercise of options, warrants or otherwise:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Do you have any present plans to exercise options
or otherwise acquire, dispose of or to transfer shares of Common Stock of the Company between the date you complete this Questionnaire
and the date which is 60 days after the date in which the Registration Statement is filed?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Answer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">If so, please describe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Pledged Securities</U>. If any of such securities have been pledged or otherwise deposited as collateral or are the subject matter of any voting trust or other similar agreement or of any contract providing for the sale or other disposition of such securities, please give the details thereof. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Answer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Disclaimer of Beneficial Ownership</U>. Do you wish to disclaim beneficial ownership1 of any of the shares reported in response to Item 1(a)? </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Answer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">If the answer is &ldquo;Yes&rdquo;, please furnish
the following information with respect to the person or persons who should be shown as the beneficial owner(s)1 of the shares in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Name and Address of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Beneficial Owner</P></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Relationship of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Such Person To You</P></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Number of Shares</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Beneficially Owned</P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Shared Voting or Investment Power over Securities</U>. Will any person be deemed to have beneficial ownership over any of the Securities purchased by you pursuant to the Purchase Agreement? </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Answer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">If the answer is &ldquo;Yes&rdquo;, please furnish
the following information with respect to the person or persons who should be shown as the beneficial owner(s)1 of the Securities in question.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Name and Address of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Beneficial Owner</P></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Relationship of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Such Person To You</P></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 32%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Number of Shares</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Beneficially Owned</P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B><U>Item 2</U>. <U>Major Shareholders</U></B>. Please state below
the names of persons or groups known by you to own beneficially1 more than 5% of the Company&rsquo;s Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Answer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B><U>Item 3</U>. <U>Change of Control</U>.</B> Do you know of any
contractual arrangements, including any pledge of securities of the Company, the operation of which may at a subsequent date result in
a change of control of the Company?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Answer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B><U>Item 4</U>. <U>Relationship with the Company</U>.</B> Please
state the nature of any position, office or other material relationship you have, or have had within the past three years, with the Company
or its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; white-space: nowrap; font-size: 10pt; width: 15%"><FONT STYLE="font-size: 10pt">Name</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center; width: 84%"><FONT STYLE="font-size: 10pt">Nature of Relationship</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; white-space: nowrap; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B><U>Item 5</U>. <U>Broker-Dealer Status</U>.</B> Is the Purchaser
a broker-dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
No.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">If so, please answer the remaining questions under this Item 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><I>Note that the Company will be required to identify
any registered broker-dealer as an underwriter in the Registration Statement and related prospectus. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">If the Purchaser is a registered broker-dealer, please indicate whether the Purchaser purchased its Common Stock for investment or acquired them as transaction-based compensation for investment banking or similar services. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Answer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><I>Note that if the Purchaser is a registered
broker-dealer and received its Common Stock other than as transaction-based compensation, the Company is required to identify the Purchaser
as an underwriter in the Registration Statement and related prospectus. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Is the Purchaser an affiliate of a registered broker-dealer? For purposes of this Question, an &ldquo;affiliate&rdquo; of a specified person or entity means a person or entity that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the person or entity specified. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
No.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">If so, please answer questions (i)-(iii) below under this Item 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">i. Please describe the affiliation between the
Purchaser and any registered broker-dealers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">ii. If the Common Stock was received by the Purchaser
other than in the ordinary course of business, please describe the circumstances:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">iii. If the Purchaser, at the time of its receipt
of Common Stock, has had any agreements or understandings, directly or indirectly, with any person to distribute the Common Stock, please
describe such agreements or understandings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"><I>Note that if the Purchaser is an affiliate
of a broker-dealer and did <B><U>not</U>&nbsp;</B>receive its Common Stock in the ordinary course of business or at the time of receipt
had any agreements or understandings, directly or indirectly, to distribute the securities, the Company must identify the Purchaser as
an underwriter in the Registration Statement and related prospectus. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B><U>Item 6</U>. <U>Nature of Beneficial Holding</U>.</B> The purpose
of this question is to identify the ultimate natural person(s) or publicly held entity that exercise(s) sole or shared voting or dispositive
power over the Registrable Securities (as defined in the Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Is the Purchaser a natural person? </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
No.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Is the Purchaser required to file, or is it a wholly owned subsidiary of a company that is required to file, periodic and other reports (for example, Form 10-K, 10-Q, 8-K) with the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act? </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
No.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Is the Purchaser an investment company, or a subsidiary of an investment company, registered under the Investment Company Act of 1940, as amended? </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
Yes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
No.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">If a subsidiary, please identify the publicly held parent entity:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">If you answered &ldquo;no&rdquo; to questions (a), (b) and (c) above, please identify the controlling person(s) of the Purchaser (the &ldquo;Controlling Entity&rdquo;). If the Controlling Entity is not a natural person or a publicly held entity, please identify each controlling person(s) of such Controlling Entity. This process should be repeated until you reach natural persons or a publicly held entity that exercises sole or shared voting or dispositive power over the Registrable Securities: </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>***PLEASE NOTE THAT THE SEC REQUIRES THAT THESE NATURAL PERSONS
BE NAMED IN THE PROSPECTUS*** </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>PART II - CERTAIN TRANSACTIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B><U>Item 7</U>. <U>Transactions with the Company</U></B>. If you,
any of your associates, or any member of your immediate family had or will have any direct or indirect material interest in any transactions
or series of transactions to which the Company or any of its subsidiaries was a party at any time since [April 1, 2022] or in any currently
proposed transactions or series of transactions in which the Company or any of its subsidiaries will be a party, in which the amount involved
exceeds $120,000, please specify (a) the names of the parties to the transaction(s) and their relationship to you, (b) the nature of the
interest in the transaction, (c) the amount involved in the transaction, and (d) the amount of the interest in the transaction. If the
answer is &ldquo;none&rdquo;, please so state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Answer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><B><U>Item 8</U>. <U>Third Party Payments.</U></B> Please describe
any compensation paid to you by a third party pursuant to any arrangement between the Company and any such third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Answer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>PART III &ndash; PLAN OF DISTRIBUTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The selling securityholders and any of their pledgees,
donees, transferees, assignees or other successors-in- interest may, from time to time, sell, transfer or otherwise dispose of any or
all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which
the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of
sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. The
selling securityholders may use one or more of the following methods when disposing of the shares or interests therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">through brokers or dealers that may act solely as agents; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">to or through underwriters; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">an exchange distribution in accordance with the rules of the applicable exchange; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">privately negotiated transactions; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">through the writing or settlement of options or other hedging transactions entered into after the effective date of the registration statement of which this prospectus is a part, whether through an options exchange or otherwise; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">broker-dealers may agree with the selling securityholders to sell a specified number of such shares at a stipulated price per share; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">a combination of any such methods of disposition; and </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">any other method permitted pursuant to applicable law. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The selling securityholders may also sell shares
under Rule 144 or Rule 904 under the Securities Act of 1933, as amended, or Securities Act, if available, or Section 4(a)(1) under the
Securities Act, rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Broker-dealers engaged by the selling securityholders
may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling securityholders
(or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling securityholders
do not expect these commissions and discounts to exceed what is customary in the types of transactions involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The selling securityholders may, from time to
time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance
of their secured obligations, the pledgees or secured parties may offer and sell shares of common stock from time to time under this prospectus,
or under a supplement or amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending
the list of selling securityholders to include the pledgee, transferee or other successors in interest as selling securityholders under
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Upon being notified in writing by a selling securityholder
that any material arrangement has been entered into with a broker-dealer for the sale of common stock through a block trade, special offering,
exchange distribution or secondary distribution or a purchase by a broker or dealer, we will file a supplement to this prospectus, if
required, pursuant to Rule 424(b) under the Securities Act, disclosing (i) the name of each such selling securityholder and of the participating
broker-dealer(s), (ii) the number of shares involved, (iii) the price at which such shares of common stock were sold, (iv) the commissions
paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any
investigation to verify the information set out or incorporated by reference in this prospectus, and (vi) other facts material to the
transaction. In addition, upon being notified in writing by a selling securityholder that a donee or pledgee intends to sell more than
500 shares of common stock, we will file a supplement to this prospectus if then required in accordance with applicable securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The selling securityholders also may transfer
the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the
selling beneficial owners for purposes of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">In connection with the sale of the shares of common
stock or interests in shares of common stock, the selling securityholders may enter into hedging transactions with broker-dealers or other
financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume.
The selling securityholders may also sell shares of common stock short and deliver these securities to close out their short positions,
or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling securityholders may also enter
into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities
which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The selling securityholders and any broker-dealers
or agents that are involved in selling the shares may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities
Act in connection with such sales. In such event, any profits realized by such selling securityholders or compensation received by such
broker-dealers or agents may be deemed to be underwriting commissions or discounts under the Securities Act. The maximum commission or
discount to be received by any member of the Financial Industry Regulatory Authority (FINRA) or independent broker-dealer will not be
greater than 8% of the initial gross proceeds from the sale of any security being sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">We have advised the selling securityholders that
they are required to comply with Regulation M promulgated under the Securities Exchange Act of 1934, as amended, during such time as they
may be engaged in a distribution of the shares. The foregoing may affect the marketability of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The aggregate proceeds to the selling securityholders
from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any.
Each of the selling securityholders reserves the right to accept and, together with their agents from time to time, to reject, in whole
or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from
this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">We are required to pay all fees and expenses incident
to the registration of the shares. We have agreed to indemnify the selling securityholders against certain losses, claims, damages and
liabilities, including liabilities under the Securities Act or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">We have agreed with the selling securityholders
to keep the registration statement of which this prospectus constitutes a part effective until the earlier of (a) such time as all of
the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement and (b) such
time as none of the shares covered by this prospectus constitute &ldquo;registrable securities&rdquo;, as such term is defined in the
purchase agreement by and among us and the selling securityholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">*&emsp;*&emsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The undersigned has reviewed the Plan of Distribution
set forth above and does not have a present intention of effecting a sale in a manner not described therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">Agree&ensp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&emsp;&emsp;&emsp;Disagree&ensp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">(If left blank, response will be deemed to be &ldquo;Agree&rdquo;.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The undersigned hereby represents that the undersigned
is familiar with Interpretation A.65 in the Securities and Exchange Commission, Division of Corporation Finance, Manual of Publicly Available
Telephone Interpretations dated July 1997, a copy of which is attached hereto as <U>Exhibit I</U>, and that the undersigned will comply
with all applicable laws in respect of its sales of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><U>SIGNATURE </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The undersigned understands that the Company anticipates
filing the Registration Statement within the time frame set forth in Section 4.11 of the Purchase Agreement. If at any time any of the
information set forth in my responses to this Questionnaire has materially changed due to passage of time (other than due to the receipt
of the Common Stock or Warrants set forth opposite the undersigned&rsquo;s name in the Schedule of Purchasers in the Purchase Agreement),
or any development occurs which requires a change in any of my answers, or has for any other reason become incorrect, the undersigned
agrees to furnish as soon as practicable to the individual to whom a copy of this Questionnaire is to be sent, as indicated and at the
address shown on the first page hereof, any necessary or appropriate correcting information. Otherwise, the Company is to understand that
the above information continues to be, to the best of my knowledge, information and belief, complete and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Upon any sale of Common Stock (including Common
Stock issuable upon exercise of Warrants) pursuant to the Registration Statement, the undersigned hereby agrees to deliver to the Company
and the Company&rsquo;s transfer agent the Certificate of Subsequent Sale set forth in <U>Exhibit II</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The undersigned understands that the information
that the undersigned is furnishing to the Company herein will be used by the Company in the preparation of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Name of Purchaser:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="border-top: black 0.75pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Date: <U>&emsp;&emsp;&emsp;&emsp;&emsp;</U>, 2025</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="border-top: black 0.75pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Print Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="border-top: black 0.75pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title (if applicable):</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="border-top: black 0.75pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Address:</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="border-top: black 0.75pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Street</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="border-top: black 0.75pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Street</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="border-top: black 0.75pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">City</FONT></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">State &emsp;&emsp;&emsp;&emsp;&emsp;&emsp;Zip Code</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="border-top: black 0.75pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Telephone Number</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="4">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top">
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="border-top: black 0.75pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page --></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-size: 10pt">Email Address</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><B>FOOTNOTES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Beneficial Ownership</U>. You are the beneficial owner of a security, as defined in Rule 13d-3 under the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;), if you, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise have or share: (1) voting power, which includes the power to vote, or to direct the voting of, such security, and/or (2) investment power, which includes the power to dispose, or to direct the disposition of, such security. You are also the beneficial owner of a security if you, directly or indirectly, create or use a trust, proxy, power of attorney, pooling arrangement or any other contract, arrangement or device with the purpose or effect of divesting yourself of beneficial ownership of a security or preventing the vesting of such beneficial ownership. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in">You are deemed to be the beneficial owner of a security if you have
the right to acquire beneficial ownership of such security at any time <U>within 60 days including</U>, but not limited to, any right
to acquire such security (a) through the exercise of any option, warrant or right, (b) through the conversion of a security, or (c) pursuant
to the automatic termination of, or the power to revoke a trust, discretionary account, or similar arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in">Ordinarily, shares held in the name of your spouse or minor child should
be considered as beneficially owned by you absent special circumstances to indicate that you do not have, as a practical matter, voting
power or investment power over such shares. Similarly, absent countervailing facts, securities held in the name of relatives who share
your home are to be reported as being beneficially owned by you. In addition, securities held for your benefit in the name of others,
such as nominees, trustees and other fiduciaries, securities held by a partnership of which you are a partner, and securities held by
a corporation controlled by you should be regarded as beneficially owned by you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in">This definition of beneficial ownership is very broad; therefore, even
though you may not actually have or share voting or investment power with respect to securities owned by persons in your family or living
in your home, you should include such shares in your beneficial ownership disclosure and may then disclaim beneficial ownership of such
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Associate</U>. The term &ldquo;associate&rdquo;, as defined in Rule 14a-1 under the Exchange Act, means (a) any corporation or organization (other than the Company or any of its majority owned subsidiaries) of which you are an officer or partner or are, directly or indirectly, the beneficial owner of 10% or more of any class of equity securities, (b) any trust or other estate in which you have a substantial beneficial interest or as to which you serve as trustee or in a similar capacity, and (c) your spouse, or any relative of yours or relative of your spouse living in your home or who is a director or officer of the Company or of any subsidiary. The term &ldquo;relative of yours&rdquo; as used in this Questionnaire refers to any relative or spouse of yours, or any relative of such spouse, who has the same home as you or who is a director or officer of any subsidiary of the Company. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Please identify your associate referred to in your answer and indicate
your relationship.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Immediate Family</U>. The members of your &ldquo;immediate family&rdquo; are deemed to include the following: your spouse; your parents; your children; your siblings; your mother-in-law or father-in-law; your sons- and daughters-in- law; and your brothers- and sisters-in-law.&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt"><U>Transactions</U>. The term &ldquo;transaction&rdquo; is to be understood in its broadest sense, and includes the direct or indirect receipt of anything of value. Please note that indirect as well as direct material interests in transactions are to be disclosed. Transactions in which you would have a direct interest would include your purchasing or leasing anything (stock in a business acquired by the Company, office space, plants, Company apartments, computers, raw materials, finished goods, etc.) from or selling or leasing anything to, or borrowing or lending cash or other property from or to, the Company, or any subsidiary. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><U>Exhibit I </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Securities Act Sections Compliance and Disclosure
Interpretations Section 239.10: &ldquo;An issuer filed a registration statement for a secondary offering of common stock which is not
yet effective. One of the selling shareholders wanted to do a short sale of common stock &ldquo;against the box&rdquo; and cover the short
sale with registered shares after the effective date. The issuer was advised that the short sale could not be made before the registration
statement becomes effective, because the shares underlying the short sale are deemed to be sold at the time such sale is made. There would,
therefore, be a violation of Section 5 if the shares were effectively sold prior to the effective date.&rdquo;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right">&nbsp;<FONT STYLE="font-size: 10pt"><U>Exhibit II
</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><U>CERTIFICATE OF SUBSEQUENT SALE </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Colonial Stock Transfer Company, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">7840 S 700 E</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Sandy, Utah 84070</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">RE: Sale of Shares of Common Stock of Modular Medical, Inc. (the &ldquo;<I>Company</I>&rdquo;)
pursuant to the Company&rsquo;s Prospectus dated <U>&emsp;</U>, <U>&emsp;&emsp;&emsp;</U> (the &ldquo;<I>Prospectus</I>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Dear Sir/Madam:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">The undersigned hereby certifies, in connection
with the sale of shares of Common Stock of the Company included in the table of Selling Stockholders in the Prospectus, that the undersigned
has sold the shares pursuant to the Prospectus and in a manner described under the caption &ldquo;Plan of Distribution&rdquo; in the Prospectus
and that such sale complies with all securities laws applicable to the undersigned, including, without limitation, the Prospectus delivery
requirements of the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Selling Stockholder (the beneficial owner): <U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Record Holder (e.g., if held in name of nominee):
<U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;</U>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Book Entry Position or Restricted Stock Certificate
No.(s): _______________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Number of Shares Sold: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">Date of Sale: ____________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">In the event that you receive a stock certificate(s)
or evidence of a book entry position representing more shares of Common Stock than have been sold by the undersigned, then you should
return to the undersigned a newly issued certificate or book entry position for such excess shares in the name of the Record Holder and
<B>BEARING A RESTRICTIVE LEGEND</B>. Further, you should place a stop transfer on your records with regard to such certificate. Notwithstanding
the foregoing, in the event that the undersigned executes and delivers to you and to the Company the certification set forth on <U>Annex
I</U>, upon instructions from the Company, you should return to the undersigned a newly issued certificate or book entry position for
such excess shares of Common Stock in the name of the Record Holder without any restrictive legend. In addition, no subsequent certification
will be required to be delivered to you by the undersigned provided that the representations and warranties set forth on <U>Annex I</U>
have been delivered to you and continue to be accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">Very truly yours,</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 5%">Dated: <U></U></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 35%">&#8239;</TD>
    <TD STYLE="vertical-align: top; width: 20%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 35%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Print&nbsp;Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom">&nbsp;&#8239;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">cc:</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Modular Medical, Inc. </FONT></TD></TR>

<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD STYLE="text-align: justify">10740 Thornmint Road, San Diego, California 92127</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"></TD><TD STYLE="text-align: justify">Attn: Chief Financial Officer</TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><U>Annex I </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">In connection with any excess shares to be returned
to the Selling Stockholder upon a sale of shares of Common Stock of Modular Medical, Inc. (the &ldquo;<I>Company</I>&rdquo;) included
in the table of Selling Stockholders in the Prospectus, the undersigned hereby certifies to the Company and transfer agent, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">1. In connection with the sale by the undersigned stockholder of any
of the shares of Common Stock, the undersigned stockholder will deliver a copy of the Prospectus included in the Registration Statement
to the purchaser directly or through the undersigned stockholder&rsquo;s broker-dealer in compliance with the requirements of the Securities
Act of 1933 and the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">2. Any such sale will be made only in the manner described under &ldquo;Plan
of Distribution&rdquo; in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">3. The undersigned stockholder will only sell the shares of Common
Stock while the Registration Statement is effective, unless another exemption from registration is available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">4. The Company and its attorneys may rely on this letter to the same
extent as if it were addressed to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">5. The undersigned stockholder agrees to notify you immediately of
any development or occurrence which to his, her or its knowledge would render any of the foregoing representations and agreements inaccurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">All terms not defined herein are as defined in
the Securities Purchase Agreement entered into in March 20, 2025 among the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">Very truly yours,</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 5%">Dated: <U></U></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 35%">&#8239;</TD>
    <TD STYLE="vertical-align: top; width: 20%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 35%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Print&nbsp;Name:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom">&nbsp;&#8239;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 48; Options: Last -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>ea023550201ex10-2_modular.htm
<DESCRIPTION>FORM OF SUBSCRIPTION AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MODULAR MEDICAL, INC.<BR>
SUBSCRIPTION AGREEMENT FOR UNITS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Canadian Subscribers)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>TO: Modular Medical, Inc. (the &ldquo;Corporation&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The undersigned
(the &ldquo;<B>Subscriber</B>&rdquo;) on its own behalf, and, if applicable, on behalf of the person for whom the undersigned is contracting
hereunder as trustee or agent (a &ldquo;<B>Beneficial Purchaser</B>&rdquo;), hereby irrevocably subscribes for and agrees to purchase
from the Corporation that number of units of the Corporation (the &ldquo;<B>Units</B>&rdquo;) set out below at a price of US$[&#9679;] per Unit.
Each Unit shall consist of (A) either (i) two shares of the Corporation&rsquo;s common stock (&ldquo;<B>Shares</B>&rdquo;), or (ii) to
certain subscribers at the sole discretion of the Corporation and in lieu of Shares, two Pre-Funded Warrants (as defined herein), and
(B) one warrant to purchase one Share (a &ldquo;<B>Warrant</B>&rdquo;). Each Pre-Funded Warrant shall entitle the holder thereof to acquire
on Share (&ldquo;<B>Pre-Funded Warrant Shares</B>&rdquo;) at a price of $0.001 subject to the terms and conditions set out in the Pre-Funded
Warrant Certificates (as defined herein). Each Warrant shall entitle the holder thereof to acquire one Share (&ldquo;<B>Warrant Shares</B>&rdquo;)
at a price of US$[</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT><FONT STYLE="font-size: 10pt">] until
5:00 p.m. (New York City time) on the date which is 48 months following the Closing Date (as defined herein), whereupon the Warrants
expire. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber agrees to be bound by the terms
and conditions set forth in the attached &ldquo;Terms and Conditions of Subscription for Units&rdquo; including without limitation the
representations, warranties and covenants set forth in the applicable schedules attached thereto. The Subscriber further agrees, without
limitation, that the Corporation may rely upon the Subscriber&rsquo;s representations, warranties and covenants contained in such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUBSCRIPTION AND SUBSCRIBER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Please print all information (other than signatures),
as applicable, in the space provided below</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-left: Black 1.5pt solid; border-top: Black 1.5pt solid; white-space: nowrap">&nbsp;</TD>
  <TD STYLE="border-top: Black 1.5pt solid; white-space: nowrap">&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-top: Black 1.5pt solid; white-space: nowrap">&nbsp;</TD>
  <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-left: Black 1.5pt solid; border-top: Black 1.5pt solid; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid; border-top: Black 1.5pt solid; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-left: Black 1.5pt solid; white-space: nowrap">Name of Subscriber:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&nbsp;&nbsp;&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1pt solid; white-space: nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
  <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-left: Black 1.5pt solid; white-space: nowrap">Number of Units:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid; white-space: nowrap">x US$[ &#9679; ]</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3" STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3" STYLE="border-left: Black 1.5pt solid; white-space: nowrap; text-align: left">Account Reference (if applicable):</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1pt solid; white-space: nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
  <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-left: Black 1.5pt solid; white-space: nowrap">= Aggregate Subscription Price:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3" STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-left: 1.375in; text-align: center">(the &ldquo;<B>Subscription Price</B>&rdquo;)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-left: Black 1.5pt solid; width: 2%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1pt solid; width: 33%">&nbsp;</TD>
  <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; width: 5%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1.5pt solid; width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="4" STYLE="border-left: Black 1.5pt solid; border-right: Black 1.5pt solid; text-align: center">Authorized Signature</TD>
  <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="4" STYLE="border-left: Black 1.5pt solid; border-right: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-top: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="4" STYLE="border-left: Black 1.5pt solid; border-right: Black 1.5pt solid; text-align: center">(Official Capacity or Title &ndash; if the Subscriber is not an individual)</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>If the Subscriber is signing as agent for a Beneficial Purchaser and is not purchasing as trustee or agent for accounts fully managed by it, complete the following:</B></P>

</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="4" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="4" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name of individual whose signature appears above if different than the name of the subscriber printed above.)</P>

</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Beneficial Purchaser)</P>

</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="4" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="4" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="4" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="4" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="4" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Subscriber&rsquo;s Residential Address, including Municipality and Province)</P>

</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(Beneficial Purchaser&rsquo;s Residential Address)</P>

</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3" STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3" STYLE="border-left: Black 1.5pt solid">Telephone Number:</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3" STYLE="border-left: Black 1.5pt solid">Email Address:</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3" STYLE="border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="3" STYLE="border-top: Black 1.5pt solid">&nbsp;</TD>
  <TD STYLE="border-top: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><I>[Modular
Medical, Inc. &ndash; Non-Brokered Private Placement Subscription Agreement]</I></FONT><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-top: Black 1.5pt solid; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Account Registration Information</U>:</B></P>
</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Delivery Instructions</U>:</B></P>
</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 5.4pt; border-left: Black 1.5pt solid; width: 2%">&#9744;</TD>
  <TD STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1.5pt solid; width: 48%">Same as Subscriber Information on prior page</TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="padding-left: 5.4pt; border-left: Black 1.5pt solid; width: 2%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#9744;</P></TD>
  <TD STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1.5pt solid; width: 48%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Same as Subscriber Information on
      prior page</P></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Name)</P>
</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Name)</P>
</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Account Reference, if applicable)</P>
</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Account Reference, if applicable)</P>
</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid"></TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">(Address, including Postal Code)</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">(Telephone Number)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Fax Number)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-bottom: Black 1pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="padding-left: 5.4pt; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid">(Contact Name)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-top: Black 1.5pt solid; text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Number
  and kind of securities of the Corporation held, directly or indirectly, or over which control or direction is exercised by the Subscriber,
  if any </U></B>(<B><U>if none, please state):</U></B></FONT></TD>
  <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; border-top: Black 1.5pt solid; text-align: justify; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>State
  whether Subscriber is an Insider* of the Corporation:</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9744; No &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</P>
</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid"><B><U>State whether Subscriber is a Registrant*:</U></B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-bottom: 1pt; border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-left: 0.25in">Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#9744; No &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid; padding-left: 0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1.5pt solid; border-bottom: Black 1pt solid; border-left: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-left: Black 1.5pt solid">(*definitions at Section 1.1 of the attached Terms and Conditions)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid; padding-bottom: 1pt">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; border-right: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B STYLE="font-style: normal; font-weight: normal"><I>[Modular Medical, Inc. &ndash; Non-Brokered
Private Placement Subscription Agreement]</I></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SUBSCRIPTION PROCEDURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All Subscribers shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">carefully review the Subscription Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">obtain independent legal, financial and tax advice regarding the Subscription Agreement and the Subscriber&rsquo;s
investment in the Units;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">complete and sign pages 1 and 2 of the Subscription Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">if the Subscriber is resident in or otherwise subject to the laws of any of the Provinces or Territories
of Canada and is purchasing the Units (the &ldquo;<B>Subscriber&rsquo;s Units</B>&rdquo;) as an &ldquo;accredited investor&rdquo; as defined
in NI 45-106 (as defined herein), provide a duly completed and executed copy of the Accredited Investor Status Certificate in the form
attached hereto as SCHEDULE &ldquo;A&rdquo;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">deliver the Aggregate Subscription Price (as defined herein) payable by the Subscriber for the Subscriber&rsquo;s
Units to the Corporation, on or before the Closing Date, by wire transfer in same day freely transferable United Sates dollars and payable
in such manner as may be specified by the Corporation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">provide and submit any other documents or information required by applicable securities laws that the
Corporation may request.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<DIV STYLE="border: Black 1.5pt solid; padding: 5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>A completed and executed copy of this Subscription
Agreement, including all applicable schedules hereto, must be delivered by no later than 5:00 p.m. (New York City time) on Thursday, March
13, 2025.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cassels Brock &amp; Blackwell LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Suite 3200, Bay Adelaide Centre &ndash; North
Tower</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>40 Temperance St</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Toronto, ON M5H 0B4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Attention: Shannon Scrocchi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>E-mail: sscrocchi@cassels.com</B></P>

</DIV>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TERMS AND CONDITIONS OF SUBSCRIPTION FOR UNITS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE&nbsp;1
<U><BR>
Interpretation</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">1.1</TD><TD STYLE="text-align: justify"><U>Definitions</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whenever used in this Subscription Agreement,
unless there is something in the subject matter or context inconsistent therewith, the following words and phrases shall have the respective
meanings ascribed to them as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;<B>Beneficial Purchaser</B>&rdquo; has
the meaning given to such term on the face page of this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Business Day</B>&rdquo;
means a day other than a Saturday, Sunday or any other day on which the principal chartered banks located in New York City are not open
for business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Closing</B>&rdquo;
has the meaning given to such term in Section 4.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Closing Date</B>&rdquo;
has the meaning given to such term in Section 4.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Closing Time</B>&rdquo;
has the meaning given to such term in Section 4.1;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Commission</B>&rdquo;
means the Securities and Exchange Commission;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Control Person</B>&rdquo;
means a person, company or combination of persons or companies described in clause (c) of the definition of &ldquo;distribution&rdquo;
in subsection 1(1) of the <I>Securities Act </I>(Ontario);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Corporation</B>&rdquo;
means Modular Medical, Inc. and includes any successor corporation to or of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Insider</B>&rdquo;
means (a) a director or officer of the Corporation (or a subsidiary of the Corporation), (b) any person who beneficially owns, directly
or indirectly, voting securities of the Corporation or who exercises control or direction over voting securities of the Corporation or
a combination of both carrying more than 10% of the voting rights attached to all voting securities of the Corporation for the time being
outstanding, (c) a person prescribed by regulation or designated as an insider by a regulatory authority or (d) a director or officer
of an Insider of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Lien</B>&rdquo; means
a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>NI 45-106</B>&rdquo;
means, collectively, (i) National Instrument 45-106 - <I>Prospectus Exemptions</I> as such instrument is in effect on the Closing Date
in the applicable Selling Jurisdictions, other than the Province of Quebec and (ii) the Regulation 45-106 respecting Prospectus Exemptions
as such regulation is applicable to Quebec Subscribers and in effect on the Closing Date in the Province of Quebec;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Offering</B>&rdquo;
means the offering of Units pursuant to this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>person</B>&rdquo;
means any individual (whether acting as an executor, trustee administrator, legal representative or otherwise), corporation, firm, partnership,
sole proprietorship, syndicate, joint venture, trustee, trust, unincorporated organization or association, and pronouns have a similar
extended meaning;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Pre-Funded Warrant</B>&rdquo;
means a pre-funded warrant to purchase one share of common stock of the Corporation at a price of US$0.001, subject to the terms and conditions
set out in the Pre-Funded Warrant Certificates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Pre-Funded Warrant
Certificate</B>&rdquo; has the meaning given to such term in Section 3.2 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Pre-Funded Warrant
Share</B>&rdquo; has the meaning given to such term on the face page of this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Purchased Securities</B>&rdquo;
means, the Units subscribed for and purchased by the Subscriber pursuant to this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Registrable Securities</B>&rdquo;
means, as of any date of determination, (i) the Shares, the Pre-Funded Warrant Shares and the Warrant Shares and (ii) any securities issued
or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing;
provided, however, that any such Registrable Securities shall cease to be Registrable Securities (and the Corporation shall not be required
to maintain the effectiveness of any, or file another, registration statement hereunder with respect thereto) (x) if such Registrable
Securities have been disposed of by the Subscriber in accordance with such effective registration statement, (y) if such Registrable Securities
have been previously sold in accordance with Rule 144, or (z) for so long as such securities are eligible for resale without volume or
manner-of-sale restrictions and current public information being available pursuant to Rule 144 as reasonably determined by the Corporation,
upon the advice of counsel to the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Registrant</B>&rdquo;
means a dealer, adviser, investment fund manager, an ultimate designated person or chief compliance officer as those terms are used pursuant
to applicable securities laws, or a person registered or otherwise required to be registered under applicable securities laws;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Resale Registration
Statement</B>&rdquo; means a registration statement on Form S-1 or Form S-3 covering the resale of the Shares, the Pre-Funded Warrant
Shares, if any, and the Warrant Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Rule 144</B>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the U.S. Securities Act, as such Rule may be amended or interpreted from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such
rule;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Shares</B>&rdquo;
has the meaning given to such term on the face page of this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Subscriber</B>&rdquo;
has the meaning given to such term on the face page of this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Subscription Agreement</B>&rdquo;
means this subscription agreement (including any schedules hereto) and any instrument amending this Subscription Agreement; &ldquo;<B>hereof</B>&rdquo;,
&ldquo;<B>hereto</B>&rdquo;, &ldquo;<B>hereunder</B>&rdquo;, &ldquo;<B>herein</B>&rdquo; and similar expressions mean and refer to this
Subscription Agreement and not to a particular Article or Section; and the expression &ldquo;<B>Article</B>&rdquo; or &ldquo;<B>Section</B>&rdquo;
followed by a number means and refers to the specified Article or Section of this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Subscription Price</B>&rdquo;
has the meaning given to such term on the face page of this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Underlying Securities</B>&rdquo;
means, collectively, the Shares, the Pre-Funded and the Warrants, as applicable, underlying the Units and the Pre-Funded Warrant Shares
and Warrant Shares, as applicable, issued or issuable to holders of Pre-Funded Warrants and Warrants pursuant to the terms of the Pre-Funded
Warrant Certificates and the Warrant Certificates, as applicable, and this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Unit</B>&rdquo; has
the meaning given to such term on the face page of this Subscription Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>United States</B>&rdquo;
means the United States of America, its territories and possessions, any State of the United States and the District of Columbia;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>U.S. Person</B>&rdquo;
has the meaning given to such term in Rule 902(k) of Regulation S under the U.S. Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>U.S. Securities Act</B>&rdquo;
means the <I>United States Securities Act of 1933</I>, as amended;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Warrant Certificate</B>&rdquo;
has the meaning given to such term in Section 3.2 hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Warrants</B>&rdquo;
has the meaning given to such term on the face page of this Subscription Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&ldquo;<B>Warrant Shares</B>&rdquo;
has the meaning given to such term on the face page of this Subscription Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">1.2</TD><TD STYLE="text-align: justify"><U>Gender and Number</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Words importing the singular number only shall
include the plural and vice versa, words importing the masculine gender shall include the feminine gender and words importing persons
shall include firms and corporations and vice versa.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">1.3</TD><TD STYLE="text-align: justify"><U>Currency</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specified, all dollar amounts
in this Subscription Agreement, including the symbol &ldquo;$&rdquo;, are expressed in Canadian dollars.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">1.4</TD><TD STYLE="text-align: justify"><U>Subdivisions, Headings and Table of Contents</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The division of this Subscription Agreement into
Articles, Sections, Schedules and other subdivisions, the inclusion of headings and the provision of a table of contents are for convenience
of reference only and shall not affect the construction or interpretation of this Subscription Agreement. The headings in this Subscription
Agreement are not intended to be full or precise descriptions of the text to which they refer. Unless something in the subject matter
or context is inconsistent therewith, references herein to an Article, Section, Subsection, paragraph, clause or Schedule are to the applicable
article, section, subsection, paragraph, clause or schedule of this Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE&nbsp;2
<U><BR>
SCHEDULES</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">2.1</TD><TD STYLE="text-align: justify"><U>Description of Schedules</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are the Schedules attached to and
incorporated in this Subscription Agreement by reference and deemed to be a part hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD STYLE="width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">Schedule A</TD>
    <TD STYLE="width: 67%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">Accredited Investor Certificate</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">Schedule B</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify; font-size: 10pt">Contact Information for Canadian Securities Commissions</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE&nbsp;3
<U><BR>
SUBSCRIPTION AND DESCRIPTION OF Units</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">3.1</TD><TD STYLE="text-align: justify"><U>Subscription for the Units</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber hereby confirms its irrevocable
subscription for and offer to purchase the Units from the Corporation, on and subject to the terms and conditions set out in this Subscription
Agreement, for the Subscription Price which is payable as described in Article 4 hereto.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">3.2</TD><TD STYLE="text-align: justify"><U>Description of Units</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each Unit shall consist of (A) either (i) two
Shares, or (ii) to certain subscribers at the sole discretion of the Corporation and in lieu of Shares, two Pre-Funded Warrants; and (B)
one Warrant. Each Warrant shall entitle the holder thereof to acquire one Warrant Share at a price of US$[<FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT>]
per Warrant Share until 5:00 p.m. (New York City time) on the date which is 48 months following the Closing Date, whereupon the Warrants
expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Pre-Funded Warrants, if any, will be governed
by the terms and conditions set out in the certificate representing the Pre-Funded Warrants (the &ldquo;<B>Pre-Funded Warrant Certificates</B>&rdquo;)
delivered to the Subscriber at Closing. The Pre-Funded Warrant Certificates will contain, among other things, provision for the appropriate
adjustment in a class, number and exercise price of the Pre-Funded Warrant Shares upon the occurrence of certain events, including any
subdivision, consolidation or re-classification of the common stock of the Corporation or payments of stock dividends or upon the merger
or re-organization of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrants will be governed by the terms and
conditions set out in the certificate representing the Warrants (the &ldquo;<B>Warrant Certificates</B>&rdquo;) delivered to the Subscriber
at Closing. The Warrant Certificates will contain, among other things, provision for the appropriate adjustment in a class, number and
exercise price of the Warrant Shares upon the occurrence of certain events, including any subdivision, consolidation or re-classification
of the common stock of the Corporation or payments of stock dividends or upon the merger or re-organization of the Corporation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">3.3</TD><TD STYLE="text-align: justify"><U>Acceptance and Rejection of Subscription by the Corporation</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber acknowledges and agrees that the
Corporation reserves the right, in its absolute discretion, to reject this subscription for Units, in whole or in part, at any time prior
to the Closing Time. If this subscription is rejected in whole, any cheques or other forms of payment delivered to the Corporation representing
the Subscription Price will be promptly returned to the Subscriber without interest or deduction. If this subscription is accepted only
in part, a cheque representing any refund of the Subscription Price for that portion of the subscription for the Units which is not accepted,
will be promptly delivered to the Subscriber without interest or deduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE&nbsp;4
<U><BR>
Closing</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">4.1</TD><TD STYLE="text-align: justify"><U>Closing</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delivery and sale of the Units and payment of
the Subscription Price will be completed (the &ldquo;<B>Closing</B>&rdquo;), in one or more tranches, at or around 10:00 a.m. (New York
City time) (the &ldquo;<B>Closing Time</B>&rdquo;), with the first tranche closing being on or about March 15, 2025 or such other date
or time as the Corporation determine (the &ldquo;<B>Closing Date</B>&rdquo;). If, prior to the Closing Time, the terms and conditions
contained in this Subscription Agreement have been complied with, against delivery of the Subscription Agreements and payment as prescribed
therein, the Corporation shall deliver certificates or direct registration system (&ldquo;<B>DRS</B>&rdquo;) statements representing the
Shares, the Pre-Funded Warrants, if any, and the Warrants underlying the Units and such other documentation as may be required pursuant
to the Subscription Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If, prior to the Closing Time, the terms and conditions
contained in this Subscription Agreement (other than delivery by the Corporation to the Subscriber of certificates or DRS statements representing
the Units) have not been complied with to the satisfaction of the Subscriber, the Corporation and the Subscriber will have no further
obligations under this Subscription Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">4.2</TD><TD STYLE="text-align: justify"><U>Conditions of Closing</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offering is conditional upon, among other
things, the Corporation having filed a Notification Form: Listing of Additional Shares for the listing of the Shares, the Pre-Funded Warrant
Shares, if any, and the Warrant Shares with the Nasdaq Global Market or any of the following markets or exchanges on which the Corporation&rsquo;s
common stock is then listed or quoted for trading on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market or the
Nasdaq Global Select Market (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber acknowledges and agrees that the
obligations of the Corporation hereunder are conditional on the accuracy of the representations and warranties of the Subscriber contained
in this Subscription Agreement as of the date of this Subscription Agreement, and as of the Closing Time as if made at and as of the Closing
Time, and the fulfillment of the following additional conditions as soon as possible and in any event not later than the Closing Time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">payment by the Subscriber of the Subscription Price by wire transfer (pursuant to the wire instruction
set out below) in United States dollars payable to &ldquo;Modular Medical, Inc.&rdquo;, or as the Corporation and the Subscriber may otherwise
agree:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the Subscriber having properly completed, signed and delivered this Subscription Agreement to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Cassels Brock &amp; Blackwell LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Suite 3200, Bay Adelaide Centre &ndash;
North Tower</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">40 Temperance St</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Toronto, ON M5H 0B4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Attention:  Shannon Scrocchi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Email: sscrocchi@cassels.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">the Subscriber having properly completed, signed and delivered Schedule &ldquo;A&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber and each Beneficial Purchaser,
if any, acknowledge and agree that as the sale of the Subscriber&rsquo;s Units will not be qualified by a prospectus, such sale is subject
to the condition that the Subscriber (or, if applicable each Beneficial Purchaser) sign and return to the Corporation all relevant documentation
required by applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber and each Beneficial Purchaser,
if any, acknowledge and agree that the Corporation will be required to provide to the securities regulators a list setting out the identities
of the Beneficial Purchasers of the Units. Notwithstanding that the Subscriber may be purchasing Units as an agent on behalf of an undisclosed
principal (if permissible under applicable securities laws), the Subscriber agrees to provide, on request, particulars as to the identity
of such undisclosed principal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE&nbsp;5
<U><BR>
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE CORPORATION</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">5.1</TD><TD STYLE="text-align: justify"><U>Representations, Warranties and Covenants of the Corporation</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation hereby represents and warrants
to, and covenants with the Subscriber as follows and acknowledges that the Subscriber is relying on such representations and warranties
in connection with the transactions contemplated herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Corporation is an entity duly incorporated or otherwise organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties
and assets and to carry on its business as currently conducted.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Corporation has full power and authority to enter into this Subscription Agreement and perform the
same and to do all other acts which may be necessary to consummate the transaction contemplated hereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Shares are duly authorized and, when issued and paid for in accordance with the provisions hereof,
will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Corporation, except for restrictions
on transfer imposed by applicable securities laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The Pre-Funded Warrant Shares have been duly and validly authorized and reserved for issuance and, upon
exercise of the applicable Pre-Funded Warrants, if any, in accordance with their terms, including the payment of any exercise price therefor,
will be validly issued, fully paid and nonassessable and will be free and clear of all encumbrances and restrictions (other than those
created by the Subscriber), except for restrictions on transfer set forth herein or imposed by applicable securities laws. Assuming the
accuracy of the representations and warranties of the Subscriber in Section 6.1 hereof, the Pre-Funded Warrant Shares will be issued in
compliance with all applicable federal and state securities laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Warrant Shares have been duly and validly authorized and reserved for issuance and, upon exercise
of the applicable Warrants in accordance with their terms, including the payment of any exercise price therefor, will be validly issued,
fully paid and nonassessable and will be free and clear of all encumbrances and restrictions (other than those created by the Subscriber),
except for restrictions on transfer set forth herein or imposed by applicable securities laws. Assuming the accuracy of the representations
and warranties of the Subscriber in Section 6.1 hereof, the Warrant Shares will be issued in compliance with all applicable federal and
state securities laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">The authorization, execution, delivery and performance by the Corporation of the Subscription Agreements
and the issue and sale of the Purchased Securities do not and will not conflict with and do not and will not result in a breach of any
of the terms, conditions or provisions of its constating documents or any agreement or instrument to which the Corporation is a party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">The Corporation has complied in all material respects with the requirements of applicable securities laws
in the jurisdictions in which the Purchased Securities will be distributed and the legislation pursuant to which it was incorporated,
and its regulations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">This Subscription Agreement has been duly executed and delivered by the Corporation and is a valid agreement
enforceable in accordance with its terms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Purchased Securities are not being sold by the Corporation to the Subscriber with knowledge of any
material fact about the Corporation that has not been generally disclosed.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">5.2</TD><TD STYLE="text-align: justify"><U>Registration Rights </U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Corporation shall use commercially reasonable efforts to prepare and file with the United States Securities
and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;), within thirty (30) days after the Closing Date, and cause the SEC to declare effective,
as promptly as possible, after the filing thereof, the Resale Registration Statement, covering the resale of all the Registrable Securities
for an offering to be made on a continuous basis pursuant to Rule 415 promulgated under the U.S. Securities Act (&ldquo;<B>Rule 415</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding the registration obligations set forth in Section 5.2(a), if the SEC informs the Corporation
that all of the Registrable Securities cannot, as a result of the application of Rule 415 or other applicable regulations, be registered
for resale as a secondary offering on a single registration statement, the Corporation agrees to promptly inform the Subscriber thereof
and use its reasonable efforts to file amendments to the registration statement as required by the SEC, covering the maximum number of
Registrable Securities permitted to be registered by the SEC. If the SEC or any publicly available written or oral guidance of the SEC
staff sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular registration statement
as a secondary offering, the Corporation shall reduce the Registrable Securities on a pro rata basis among the participating Subscribers
(the &ldquo;<B>Holders</B>&rdquo;) in this Offering, in proportion to the aggregate amount of Registrable Securities to be registered
on behalf of each.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">In connection with the Corporation&rsquo;s registration obligations hereunder, the Corporation shall,
as promptly as reasonably possible under the circumstances, taking into account the Corporation&rsquo;s good faith assessment of any adverse
consequences to the Corporation and its stockholders of the premature disclosure of such event, prepare a supplement or amendment, including
a post-effective amendment, to a registration statement or a supplement to the related prospectus or any document incorporated or deemed
to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, neither a registration
statement nor such prospectus, included therein, will contain an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading. If the Corporation notifies the Holders to suspend the use of any prospectus until the requisite changes to such prospectus
have been made, then the Holders shall suspend use of such prospectus.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE&nbsp;6
<U><BR>
ACKNOWLEDGEMENTS, COVENANTS, REPRESENTATIONS AND WARRANTIES<BR>
OF THE SUBSCRIBER</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">6.1</TD><TD STYLE="text-align: justify"><U>Representations, Warranties and Covenants of the Subscriber</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber, on its own behalf and, if applicable,
on behalf of others for whom it is acting hereunder, hereby represents and warrants to, and covenants with, the Corporation as follows
and acknowledges that the Corporation is relying on such representations and warranties in connection with the transactions contemplated
herein:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Subscriber and each Beneficial Purchaser, if any, is resident in the jurisdiction set out on the face
page of this Subscription Agreement. Such address was not created and is not used solely for the purpose of acquiring the Purchased Securities
and the Subscriber and any Beneficial Purchaser was solicited to purchase in such jurisdiction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Subscriber has the legal capacity and competence to execute this Subscription Agreement and to take
all actions required pursuant hereto and all necessary approvals by directors, shareholders and members of the Subscriber, or otherwise,
have been given to authorize it to execute and deliver this agreement and to take all actions required pursuant hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Subscriber has properly completed, executed and delivered within applicable time periods to the Corporation
the applicable certificate(s) and/or form(s) (dated as of the date hereof) set forth in Schedule &ldquo;A&rdquo; and the information contained
therein is true and correct.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The representations, warranties and covenants contained in the applicable Schedules will be true and correct
both as of the date of execution of this Subscription Agreement and as of the Closing Time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">If the Subscriber, and each Beneficial Purchaser, if any, for whom it is acting as trustee or agent, is
a corporation or a partnership, syndicate, trust, association, or any other form of unincorporated organization or organized group of
persons, the Subscriber or such Beneficial Purchaser was not created or being used solely to permit purchases of or to hold securities
without a prospectus in reliance on a prospectus exemption.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">The Subscriber, and each Beneficial Purchaser, if any, for whom the Subscriber is acting as trustee or
agent, was not created or used solely to purchase or hold securities as an accredited investor as described in paragraph (m) of the definition
of &ldquo;accredited investor&rdquo; provided in Schedule &ldquo;A&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">The Subscriber or any person for whom it is acting is neither a U.S. Person nor subscribing for the Purchased
Securities for the account of a U.S. Person or for resale in the United States and the Subscriber confirms that the Purchased Securities
have not been offered to the Subscriber in the United States and that this Subscription Agreement has not been signed in the United States.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">Neither the Subscriber nor any person for whom it is acting will offer, sell or otherwise dispose of the
Units or the Underlying Securities in the United States or to a U.S. Person unless the Corporation has consented to such offer, sale,
or disposition, and such offer, sale, or disposition is made in accordance with an exemption from the registration requirements under
the U.S. Securities Act and the securities laws of all applicable states of the United States or in accordance with the registration and
prospectus delivery requirements of the U.S. Securities Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The execution and delivery of this Subscription Agreement, the performance and compliance with the terms
hereof, the subscription for the Purchased Securities and the completion of the transactions described herein by the Subscriber will not
result in any material breach of, or be in conflict with or constitute a material default under, or create a state of facts which, after
notice or lapse of time, or both, would constitute a material default under any term or provision of the constating documents, by-laws
or resolutions of the Subscriber, applicable securities laws or any other laws applicable to the Subscriber, any agreement to which the
Subscriber is a party, or any judgment, decree, order, statute, rule or regulation applicable to the Subscriber.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">The Subscriber is subscribing for the Purchased Securities as principal for its own account and not for
the benefit of any other person (within the meaning of applicable securities laws) and not with a view to the resale or distribution of
all or any of the Purchased Securities, or if it is not subscribing as principal, it acknowledges that the Corporation may be required
by law to disclose to certain regulatory authorities the identity of each Beneficial Purchaser for which it is acting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">In the case of a subscription for the Purchased Securities by a Subscriber acting as trustee or agent
(including, for greater certainty, a portfolio manager or comparable adviser) for a principal, the Subscriber is duly authorized to execute
and deliver this Subscription Agreement and all other necessary documentation in connection with such subscription on behalf of each Beneficial
Purchaser, each of whom is subscribing as principal for its own account, not for the benefit of any other person and not with a view to
the resale or distribution of the Purchased Securities or the Underlying Securities, and this Subscription Agreement has been duly authorized,
executed and delivered by or on behalf of and constitutes a legal, valid and binding agreement of, such principal, and the Subscriber
acknowledges that the Corporation may be required by law to disclose the identity of each Beneficial Purchaser.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">In the case of a subscription for the Purchased Securities by the Subscriber acting as principal, this
Subscription Agreement has been duly authorized, executed and delivered by, and constitutes a legal, valid and binding agreement of, the
Subscriber. This Subscription Agreement is enforceable in accordance with its terms against the Subscriber and any Beneficial Purchaser.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">If the Subscriber is:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">a corporation, the Subscriber is duly incorporated and is validly subsisting under the laws of its jurisdiction
of incorporation and has all requisite legal and corporate power and authority to execute and deliver this Subscription Agreement, to
subscribe for the Purchased Securities as contemplated herein and to carry out and perform its obligations under the terms of this Subscription
Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">a partnership, syndicate or other form of unincorporated organization, the Subscriber has the necessary
legal capacity and authority to execute and deliver this Subscription Agreement and to observe and perform its covenants and obligations
hereunder and has obtained all necessary approvals in respect thereof; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">an individual, the Subscriber is of the full age of majority and is legally competent to execute this
Subscription Agreement and to observe and perform his or her covenants and obligations hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">There are no arrangements or persons acting or purporting to act in connection with the transactions contemplated
herein which creates any entitlement to any brokerage or finder&rsquo;s fee. If any person establishes a claim that any fee or other compensation
is payable in connection with this subscription for Units due to action by the Subscriber other than as provided for herein, the Subscriber
covenants to indemnify and hold harmless the Corporation with respect thereto and with respect to all costs reasonably incurred in the
defence thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">The Subscriber is not, with respect to the Corporation or any of its affiliates, a Control Person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">If required by applicable securities laws or the Corporation, the Subscriber will execute, deliver and
file or assist the Corporation in filing such reports, undertakings and other documents with respect to the issue of the Purchased Securities,
as may be required by any securities commission, stock exchange or other regulatory authority.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">The Subscriber covenants and agrees to comply with applicable securities legislation in Canada, and any
other relevant securities legislation, rules, regulations, orders, or policies concerning the purchase, holding of, and resale of the
Purchased Securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD STYLE="text-align: justify">The Subscriber, and each Beneficial Purchaser, if any, has been advised to consult its own legal advisors
with respect to trading in the Purchased Securities or the Underlying Securities and with respect to the resale restrictions imposed by
applicable securities laws of the province in which the Subscriber resides and other applicable securities laws, and acknowledges that
no representation has been made respecting the applicable hold periods imposed by applicable securities laws or other resale restrictions
applicable to such securities which restrict the ability of the Subscriber (or others for whom it is contracting hereunder) to resell
such securities, that the Subscriber (or others for whom it is contracting hereunder) is solely responsible to find out what these restrictions
are and the Subscriber is solely responsible (and the Corporation not in any way responsible) for compliance with applicable resale restrictions
and the Subscriber is aware that it (or Beneficial Purchasers for whom it is contracting hereunder) may not be able to resell such securities
except in accordance with limited exemptions under applicable securities laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD STYLE="text-align: justify">The Subscriber has not received or been provided with a prospectus, offering memorandum, within the meaning
of applicable securities laws, or any sales or advertising literature in connection with the Offering and the Subscriber&rsquo;s decision
to subscribe for the Purchased Securities was not based upon, and the Subscriber has not relied upon, any verbal or written representations
as to facts made by or on behalf of the Corporation. The Subscriber&rsquo;s decision to subscribe for the Purchased Securities was based
solely upon the information about the Corporation which is publicly available.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD STYLE="text-align: justify">The Subscriber is not purchasing the Purchased Securities with knowledge of material information concerning
the Corporation which has not been generally disclosed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(u)</TD><TD STYLE="text-align: justify">No person has made any written or oral representations:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">that any person will resell or repurchase the Purchased Securities or the Underlying Securities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">that any person will refund the Subscription Price; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">as to the future price or value of the Purchased Securities or the Underlying Securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">The subscription for the Purchased Securities has not been made through or as a result of, and the distribution
of the Purchased Securities is not being accompanied by any advertisement, including without limitation in printed public media, radio,
television or telecommunications, including electronic display, or as part of a general solicitation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(w)</TD><TD STYLE="text-align: justify">The Subscriber shall promptly provide evidence of the foregoing representations, warranties and covenants
at any time or times as the Corporation reasonably requires.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD STYLE="text-align: justify">There are risks associated with the purchase of and investment in the Units and the Subscriber has such
knowledge and experience that it is capable of evaluating the merits and risks of an investment in the Units and the securities issuable
thereunder and fully understands the restrictions on resale of the Units, and is capable of bearing the economic risk of the investment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(y)</TD><TD STYLE="text-align: justify">The Subscriber confirms that it:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">has such knowledge in financial and business affairs as to be capable of evaluating the merits and risks
of its investment in the Purchased Securities, including the potential loss of its entire investment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">is aware of the characteristics of the Purchased Securities and understands the risks relating to an investment
therein; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">is able to bear the economic risk of loss of its investment in the Purchased Securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(z)</TD><TD STYLE="text-align: justify">The funds representing the Subscription Price which will be advanced by the Subscriber to the Corporation
hereunder will not represent proceeds of crime for the purposes of the <I>Proceeds of Crime (Money Laundering) and Terrorist Financing
Act</I> (Canada) (the &ldquo;<B>PCMLTFA</B>&rdquo;), the United Kingdom&rsquo;s <I>Proceeds of Crime Act 2002</I> (the &ldquo;<B>POCA</B>&rdquo;)
or the <I>Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act</I> (the &ldquo;<B>PATRIOT
Act</B>&rdquo;), and the Subscriber acknowledges that the Corporation may in the future be required by law to disclose the Subscriber&rsquo;s
name and other information relating to this Subscription Agreement and the Subscriber&rsquo;s subscription hereunder, on a confidential
basis, pursuant to the PCMLTFA, POCA or the PATRIOT Act. To the best of its knowledge (a) none of the subscription funds to be provided
by the Sub-scriber (i) have been or will be derived from or related to any activity that is deemed criminal under the laws of Canada,
the United States, or any other jurisdiction, or (ii) are being tendered on behalf of a person or entity who has not been identified to
the Subscriber, and (b) the Subscriber shall promptly notify the Corporation if the Subscriber discovers that any of such representations
ceases to be true, and to provide the Corporation with appropriate information in connection therewith.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(aa)</TD><TD STYLE="text-align: justify">The Subscriber is not a person or entity identified in the Regulations Implementing the United Nations
Resolutions on the Suppression of Terrorism, the United Nations Al- Qaida and Taliban Regulations, the Regulations Implementing the United
Nations Resolution on the Democratic People&rsquo;s Republic of Ko-rea, the Regulations Implementing the United Nations Resolution on
Iran, the United Nations Cote d&rsquo;Ivoire Regulations, the United Nations Democratic Republic of the Congo Regulations, the United
Nations Liberia Regulations, the United Nations Sudan Regulations, the Special Economic Measures (Zimbabwe) Regulations or the Special
Economic Measures (Bur-ma) Regulations, the Special Economic Measures (Ukraine) Regulations, the Special Economic Measures (Russia) Regulations,
or the Freezing Assets of Corrupt Foreign Officials Act (collectively, the &ldquo;<B>Trade Sanctions</B>&rdquo;). The Subscriber acknowledges
that the Corporation may in the future be required by law to disclose the name and other information of the Subscriber related to the
acquisition of the Purchased Securities hereunder pursuant to the Trade Sanctions.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">6.2</TD><TD STYLE="text-align: justify"><U>Acknowledgments and Further Covenants of the Subscriber</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber, on its own behalf and, if applicable,
on behalf of others for whom it is acting hereunder, acknowledges and agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">No securities commission, agency, governmental authority, regulatory body, stock exchange or other regulatory
body has reviewed or passed on the merits of the Purchased Securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Purchased Securities will be subject to statutory resale restrictions under securities laws of the
province in which the Subscriber resides and under other applicable securities laws, and the Subscriber covenants that it will not resell
the Purchased Securities or the Underlying Securities except in compliance with such laws and the Subscriber acknowledges that it is solely
responsible (and Corporation not in any way responsible) for such compliance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Subscriber&rsquo;s ability to transfer the Purchased Securities and the Underlying Securities is limited
by, among other things, applicable securities laws and the Corporation shall refuse, and shall instruct its transfer agent to refuse,
to register any transfer that does not comply with applicable securities laws.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">Neither the Corporation nor any of its respective officers, directors, employees, shareholders, representatives,
affiliates, related entities and associates, or any persons acting on its or their behalf, including Cassels Brock &amp; Blackwell LLP,
legal counsel to the Corporation only, will in any circumstances be liable to the Subscriber under, arising out of or in any way connected
with this Subscription Agreement for any indirect or consequential loss or damage whether arising in contract or tort (including for negligence
or statutory duty), and Cassels Brock &amp; Blackwell LLP is not acting for the Subscriber, and the Subscriber should obtain its own independent
legal advice in connection with the transactions contemplated hereby.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Subscriber and each Beneficial Purchaser, if any, are solely responsible for obtaining such legal
advice and tax advice as they consider appropriate in connection with the execution, delivery and performance by it or them of this Subscription
Agreement and the completion of the transactions contemplated hereby and, without limiting the generality of the foregoing:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.25pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 28.35pt">(i)</TD><TD STYLE="text-align: justify">the Subscriber confirms that it is responsible for obtaining its own legal, tax, investment and other
professional advice with respect to the execution, delivery and performance by it of this Subscription Agreement and the transactions
contemplated hereunder including the suitability of the Units as an investment for the Subscriber, the tax consequences of purchasing
and dealing with the Units and the resale restrictions and &ldquo;hold periods&rdquo; to which the Shares, Pre-Funded Warrants, if any,
and Warrants comprising the Units are or may be subject under applicable securities laws. The Subscriber has not relied upon any statements
made by, or purporting to have been made on behalf of, the Corporation or its counsel with respect to such matters; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.25pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.25pt; text-align: justify; text-indent: -28.35pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.25pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 70.9pt"></TD><TD STYLE="width: 28.35pt">(ii)</TD><TD STYLE="text-align: justify">the Subscriber acknowledges that the Corporation&rsquo;s counsel is acting solely as counsel to the Corporation
and not as counsel to the Subscriber.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">The certificates or DRS statements representing the Underlying Securities will bear, as of the Closing
Date, legends substantially in the following form:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><B>&ldquo;THE OFFER
AND SALE OF THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE RULES AND REGULATIONS
THEREUNDER (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (I) THE RESALE OF SUCH SECURITIES HAS BEEN
REGISTERED PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144 OR ANOTHER APPLICABLE EXEMPTION FROM
THE REGISTRATION REQUIREMENTS UNDER THE SECURITIES ACT, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY
TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NOTWITHSTANDING THE FOREGOING,
THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN AGREEMENT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.&rdquo;
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">In addition, if required by the authorities of any state in connection with the issuance or sale of the
Units, the certificates or DRS statements representing the Underlying Securities may also bear the legend required by such state authority.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">The Subscriber and each Beneficial Purchaser shall execute, deliver, file and otherwise assist the Corporation
and with filing all documentation required by the applicable securities laws to permit the subscription for the Purchased Securities and
the issuance of the Underlying Securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Corporation is relying on the representations, warranties and covenants contained herein and in the
applicable Schedules attached hereto to determine the Subscriber&rsquo;s eligibility to subscribe for the Purchased Securities under applicable
securities laws and the Subscriber agrees to indemnify the Corporation, and each of its directors and officers against all losses, claims,
costs, expenses, damages or liabilities which any of them may suffer or incur as a result of or arising from reliance thereon. The Subscriber
undertakes to immediately notify the Corporation of any change in any statement or other information relating to the Subscriber set forth
in such applicable Schedules which takes place prior to the Closing Time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">The Corporation is relying on an exemption from the requirement to provide the Subscriber with a prospectus
under applicable securities laws and, as a consequence of acquiring the Purchased Securities pursuant to such exemption, certain protections,
rights and remedies provided by applicable securities laws, including statutory rights of rescission or damages, will not be available
to the Subscriber.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">The Purchased Securities are being offered pursuant to an exclusion from the registration requirements
of the U.S. Securities Act pursuant to Regulation S promulgated thereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">The Subscriber acknowledges that the Pre-Funded Warrants, if any, and the Warrants may not be exercised
in the United States by or on behalf of a U.S. Person, unless the Underlying Securities are registered under the U.S. Securities Act and
applicable state securities law or unless the Corporation has consented to such offer, sale or distribution and such exercise is made
in accordance with an exemption from the registration requirements under the U.S. Securities Act and the securities laws of all applicable
states of the United States.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">The Subscriber, and each Beneficial Purchaser, if any, is responsible for obtaining such legal and tax
advice as it considers appropriate in connection with the execution, delivery and performance of this Subscription Agreement and the transactions
contemplated under this Subscription Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">There is no government or other insurance covering the Purchased Securities or Underlying Securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">The Subscriber acknowledges and understands that in connection with the issue and sale of the Purchased
Securities pursuant to the Offering, the Corporation may pay certain finder&rsquo;s fees, commissions or other broker fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">There are risks associated with the purchase of the Purchased Securities, and the Subscriber acknowledges
that it has had access to such information concerning the Corporation as it has considered necessary in connection with its investment
decisions to invest in the Purchased Securities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD STYLE="text-align: justify">The Subscriber has had an opportunity to ask questions of and receive answers from the Corporation, or
a person or person acting on the Corporation's behalf, concerning the terms and conditions of an investment in the Purchased Securities
and the business and affairs of the Corporation, and all such questions have been answered to the full satisfaction of the Subscriber.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD STYLE="text-align: justify">The Subscriber acknowledges that this Subscription Agreement and the Schedules hereto require the Subscriber
to provide certain personal information to the Corporation. Such information is being collected by the Corporation for the purposes of
completing the Offering, which includes, without limitation determining the Subscriber&rsquo;s eligibility to purchase the Purchased Securities
under applicable securities laws. The Subscriber&rsquo;s personal information may be disclosed by the Corporation to: (i) stock exchanges
or securities regulators, (ii) the Canada Revenue Agency or other taxing authorities, and (iii) any of the other parties involved in the
Offering, including legal counsel to the Corporation and may be included in record books in connection with the Offering. By executing
this Subscription Agreement, the Subscriber is deemed to be consenting to the foregoing collection, use and disclosure of the Subscriber&rsquo;s
personal information. The Subscriber also consents to the filing of copies or originals of any of the Subscriber&rsquo;s documents described
herein as may be required to be filed with any stock exchange or securities regulators in connection with the transactions contemplated
hereby. The Subscriber represents and warrants that it has the authority to provide the consents and acknowledgements set out in this
paragraph on behalf of each Beneficial Purchaser, as applicable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD STYLE="text-align: justify">The information provided by the Subscriber on pages 1 and 2 of this Subscription Agreement identifying
among other things, the name, address, telephone number and email address of the Subscriber, the number of Purchased Securities being
purchased hereunder, the Subscription Price, the Closing Date and the exemption that the Subscriber is relying on in purchasing the Purchased
Securities will be disclosed to the securities regulators, and such information is being indirectly collected by the securities regulators
under the authority granted to it under applicable securities laws. This information is being collected for the purposes of the administration
and enforcement of applicable securities laws. Each Subscriber (and for certainty, including each Beneficial Purchaser) hereby authorizes
the indirect collection of such information by the securities regulators. In the event the Subscriber has any questions with respect to
the indirect collection of such information, the Subscriber should contact the applicable securities regulator(s) at the contact details
provided in Schedule &ldquo;B&rdquo;.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">6.3</TD><TD STYLE="text-align: justify"><U>Reliance on Representations, Warranties, Covenants and Acknowledgements</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber acknowledges and agrees that the
representations, warranties, covenants and acknowledgements made by the Subscriber in this Subscription Agreement are made with the intention
that they may be relied upon by the Corporation and in determining the Subscriber&rsquo;s eligibility (and, if applicable, the eligibility
of others for whom the Subscriber is contracting hereunder) to purchase the Purchased Securities under applicable securities laws. The
Subscriber further agrees that by accepting the Purchased Securities, and/or an ownership statement with respect to the Subscriber&rsquo;s
Units, the Subscriber shall be representing and warranting that such representations, warranties, acknowledgements and covenants are true
as at the Closing Time with the same force and effect as if they had been made by the Subscriber at the Closing Time and that they shall
survive the purchase by the Subscriber of the Purchased Securities and shall continue in full force and effect notwithstanding any subsequent
disposition by the Subscriber of any of the Purchased Securities or Underlying Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE&nbsp;7
<U><BR>
SURVIVAL OF REPRESENTATIONS, WARRANTIES AND COVENANTS</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">7.1</TD><TD STYLE="text-align: justify"><U>Survival of Representations, Warranties and Covenants of the Corporation</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The representations, warranties and covenants
of the Corporation contained in this Subscription Agreement shall survive the Closing and, notwithstanding such Closing or any investigation
made by or on behalf of the Subscriber with respect thereto, shall continue in full force and effect for the benefit of the Subscriber.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">7.2</TD><TD STYLE="text-align: justify"><U>Survival of Representations, Warranties and Covenants of the Subscriber</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The representations, warranties and covenants
of the Subscriber contained in this Subscription Agreement shall survive the Closing and, notwithstanding such Closing or any investigation
made by or on behalf of the Corporation with respect thereto, shall continue in full force and effect for the benefit of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE&nbsp;8
<U><BR>
COLLECTION OF PERSONAL INFORMATION</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">8.1</TD><TD STYLE="text-align: justify"><U>Collection of Personal Information</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber (on its own behalf and, if applicable,
on behalf of any person for whose benefit the Subscriber is subscribing) acknowledges and consents to the fact the Corporation is collecting
the Subscriber&rsquo;s (and any Beneficial Purchaser&rsquo;s) personal information for the purpose of completing the Subscriber&rsquo;s
subscription. The Subscriber (on its own behalf and, if applicable, on behalf of any Beneficial Purchaser) acknowledges and consents to
the Corporation retaining the personal information for as long as permitted or required by applicable law or business practices. The Subscriber
(on its own behalf and, if applicable, on behalf of any Beneficial Purchaser) further acknowledges and consents to the fact the Corporation
may be required by applicable securities laws, stock exchange rules, and the Independent Investor Regulatory Organization of Canada rules
to provide the securities regulators any personal information provided by the Subscriber respecting itself (and any Beneficial Purchaser).
The Subscriber represents and warrants that it has the authority to provide the consents and acknowledgements set out in this paragraph
on behalf of all Beneficial Purchasers<B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE&nbsp;9
<U><BR>
General</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.1</TD><TD STYLE="text-align: justify"><U>Further Assurances</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each of the parties hereto upon the request of
each of the other parties hereto, whether before or after the Closing Time, shall do, execute, acknowledge and deliver or cause to be
done, executed, acknowledged and delivered all such further acts, deeds, documents, assignments, transfers, conveyances, powers of attorney
and assurances as may reasonably be necessary or desirable to complete the transactions contemplated herein.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.2</TD><TD STYLE="text-align: justify"><U>Notices</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Any notice, document or other communication required or permitted by this agreement to be given by a party
hereto shall be in writing and is sufficiently given if delivered personally, of if sent by prepaid ordinary mail posted or if transmitted
by any form of recorded telecommunication tested prior to transmission, to such party addressed to such party as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 107.7pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 90.45pt"></TD><TD STYLE="width: 17.55pt">(i)</TD><TD STYLE="text-align: justify">if to the Corporation, to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">Modular Medical,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">10740 Thornmint
Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">San Diego, California
92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">Attention: James
E. Besser</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="white-space: nowrap; width: 106.35pt"></TD><TD STYLE="white-space: nowrap; width: 3.65pt">E-mail:</TD><TD STYLE="white-space: nowrap; text-align: justify">ir@modular-medical.com</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">With a copy (which
shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">Cassels Brock
&amp; Blackwell LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Suite 3200, Bay Adelaide Centre &ndash;
North Tower</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">40 Temperance St</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Toronto, ON M5H 0B4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 106.35pt"></TD><TD STYLE="width: 3.65pt">Attention:&nbsp;</TD><TD STYLE="text-align: justify">Sean Maniaci</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2">Email smaniaci@cassels.com</TD></TR>
                                                                                                                                      </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">And a copy (which
shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">Lucosky Brookman
LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">101 Wood Avenue
South</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: -3.65pt">Woodbridge, New
Jersey 08830</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 106.35pt"></TD><TD STYLE="width: 3.65pt">Attention:</TD><TD STYLE="text-align: justify">&nbsp;Lawrence Metelista</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD COLSPAN="2">Email: lmetelista@lucbro.com</TD></TR>
                                                                                                                                      </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: 34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: 34pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 110pt; text-align: justify; text-indent: 34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">in the case of notice to the Subscriber, to the Subscriber&rsquo;s residential address as set forth on
the face page to this Subscription Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Any such notice, direction or other instrument, if delivered personally, shall be deemed to have been
given and received on the day on which it was delivered, provided that if such day is not a Business Day then the notice, direction or
other instrument shall be deemed to have been given and received on the first Business Day next following such day and if transmitted
by email, shall be deemed to have been given and received on the day of its transmission, provided that if such day is not a Business
Day or if it is transmitted or received after the end of normal business hours then the notice, direction or other instrument shall be
deemed to have been given and received on the first Business Day next following the day of such transmission.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Any party hereto may change its address for service from time to time by notice given to each of the other
parties hereto in accordance with the foregoing provisions.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.3</TD><TD STYLE="text-align: justify"><U>No Revocation.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber and each Beneficial Purchaser agree
that this offer is made for valuable consideration and may not be withdrawn, cancelled, terminated or revoked by the Subscriber without
the consent of the Corporation. Further, the Subscriber expressly waives and releases the Corporation from all rights of withdrawal or
rescission to which the Subscriber might otherwise be entitled pursuant to applicable securities laws or otherwise at law.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.4</TD><TD STYLE="text-align: justify"><U>Modification.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the terms hereof, neither this Subscription
Agreement nor any provision hereof shall be modified, changed, discharged or terminated except by an instrument in writing signed by the
party against whom any waiver, change, discharge or termination is sought.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.5</TD><TD STYLE="text-align: justify"><U>Survival.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All representations, warranties, agreements, covenants
and acknowledgements made, or deemed to be made, by the Corporation herein shall survive the Closing and will continue in full force and
effect for the benefit of the Subscriber notwithstanding any subsequent disposition by the Subscriber of any of the Units. All representations,
warranties, agreements, covenants and acknowledgements made, or deemed to be made, by the Subscriber and the Beneficial Purchaser herein
will survive the execution and delivery, and acceptance, of this offer and the Closing notwithstanding any subsequent disposition by the
Subscriber of any of the Units.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.6</TD><TD STYLE="text-align: justify"><U>Time of the Essence</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Time shall in all respects be of the essence of
this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.7</TD><TD STYLE="text-align: justify"><U>Applicable Law</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Subscription Agreement shall be construed
and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the state of New York and the federal
laws of the United States applicable therein. Any and all disputes arising under this Subscription Agreement, whether as to interpretation,
performance or otherwise, shall be subject to the non-exclusive jurisdiction of the courts of the City of New York, Borough of Manhattan
and each of the parties hereto hereby irrevocably attorns to the jurisdiction of such courts.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.8</TD><TD STYLE="text-align: justify"><U>Entire Agreement</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Subscription Agreement, including the Schedules
hereto, constitutes the entire agreement between the parties with respect to the transactions contemplated herein and cancels and supersedes
any prior understandings, agreements, negotiations and discussions between the parties. There are no representations, warranties, terms,
conditions, undertakings or collateral agreements or understandings, express or implied, between the parties hereto other than those expressly
set forth in this Subscription Agreement or in any such agreement, certificate, affidavit, statutory declaration or other document as
aforesaid. This Subscription Agreement may not be amended or modified in any respect except by written instrument executed by each of
the parties hereto.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.9</TD><TD STYLE="text-align: justify"><U>Costs and Expenses</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All costs and expenses (including, without limitation,
the fees and disbursements of legal counsel) incurred in connection with this Subscription Agreement and the transactions herein contemplated
shall be paid and borne by the party incurring such costs and expenses.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.10</TD><TD STYLE="text-align: justify"><U>General Authorization to Correct Minor Errors</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber hereby authorizes the Corporation
to correct any minor errors in, or complete any minor information missing from any part of the Subscription Agreement and any other acknowledgements,
provisions, forms, certificates or documents executed by the Subscriber and delivered to the Corporation in connection with the Offering.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.11</TD><TD STYLE="text-align: justify"><U>Counterparts</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Subscription Agreement may be executed in
two or more counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same
Subscription Agreement. Counterparts may be delivered either in original or emailed form and the parties adopt any signature received
by email as original signatures of the parties.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.12</TD><TD STYLE="text-align: justify"><U>Assignment</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Subscription Agreement may not be assigned
by either party except with the prior written consent of the other parties hereto. For greater certainty, this Subscription Agreement
may only be transferred or assigned by the Subscriber subject to compliance with applicable laws (including, without limitation applicable
securities laws) and with the express written consent of the Corporation.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.13</TD><TD STYLE="text-align: justify"><U>Enurement</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Subscription Agreement shall enure to the
benefit of and be binding upon the parties hereto and their respective heirs, executors, successors (including any successor by reason
of the amalgamation or merger of any party), administrators and permitted assigns.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.14</TD><TD STYLE="text-align: justify"><U>Language.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Subscriber and each Beneficial Purchaser,
if any, acknowledge their consent and request that all documents evidencing or relating in any way to the purchase of the Units be drawn
up in the English language only. Nous reconnaissons par les pr&eacute;sentes avoir consent et demand&eacute; que tons les documents faisant
foi ou se rapportant de quelque mani&egrave;re &agrave; l&rsquo;achat des actions ordinaries soient r&eacute;dig&eacute;s en anglais seulement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify; text-indent: -42.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 42.55pt">9.15</TD><TD STYLE="text-align: justify"><U>Portable Document Format Subscriptions.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation shall be entitled to rely on delivery
by email or portable document format (&ldquo;<B>PDF</B>&rdquo;) of an executed copy of this Subscription Agreement, including the completed
Schedules hereto, and acceptance by the Corporation of such email or PDF copy shall be legally effective to create a valid and binding
agreement between the Subscriber and each Beneficial Purchaser, if any, and the Corporation in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[The remainder of this page has been left
intentionally blank. Signature page follows.]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Corporation hereby accepts the subscription
for the Units as set forth on the face page of this Subscription Agreement on the terms and conditions contained in this Subscription
Agreement (including all applicable Schedules) this _____ day of _______________, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>MODULAR MEDICAL, INC.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">per:</P></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Authorized Signing Officer</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Modular Medical, Inc. &ndash; Non-Brokered
Private Placement Subscription Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE &ldquo;A&rdquo;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACCREDITED INVESTOR CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>TO BE COMPLETED BY CANADIAN SUBSCRIBERS
WHO ARE SUBSCRIBING AS &ldquo;ACCREDITED INVESTORS&rdquo;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The categories listed herein contain certain
specifically defined terms. If you are unsure as to the meanings of those terms or are unsure as to the applicability of any category
below, please contact your broker and/or legal advisor before completing this certificate.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-left: 5.4pt; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid; border-left: Black 1.5pt solid; width: 0.5in"><B>TO:</B></TD>
  <TD STYLE="border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><B>MODULAR MEDICAL, INC.</B></TD>
  <TD STYLE="border-right: Black 1.5pt solid; border-top: Black 1.5pt solid; border-bottom: Black 1.5pt solid"><B>&nbsp;</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the purchase by the undersigned
Subscriber of the Units, the Subscriber, on its own behalf and on behalf of each of the Beneficial Purchasers for whom the Subscriber
is acting (collectively, the &ldquo;<B>Subscriber</B>&rdquo;), hereby represents, warrants, covenants and certifies to the Corporation
(and acknowledges that the Corporation and its counsel are relying thereon) that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Subscriber is resident in
or otherwise subject to the securities laws of one of the Provinces o</FONT>r Territories of Canada<FONT STYLE="font-size: 10pt">;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">the Subscriber is purchasing the Units as principal for its
own account and not for the benefit of any other person or is deemed to be purchasing as principal pursuant to NI&nbsp;45-106;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the Subscriber is an &ldquo;accredited investor&rdquo;, on
the basis that the undersigned fits within one of the categories of an &ldquo;accredited investor&rdquo; reproduced below beside which
the undersigned has indicated the undersigned belongs to such category;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">the Subscriber was not created or is not used solely to purchase
or hold securities as an accredited investor as described in paragraph (m) below; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">upon execution of this Schedule &ldquo;A&rdquo; by the Subscriber,
this Schedule &ldquo;A&rdquo; shall be incorporated into and form a part of the Subscription Agreement.</TD>
</TR></TABLE>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>(PLEASE CHECK THE BOX OF THE APPLICABLE CATEGORY OF ACCREDITED
INVESTOR)</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">(a) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(i) except in Ontario, a Canadian financial institution, or a Schedule III bank; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt"> </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(ii) in Ontario, a financial institution that is (A) a bank listed in Schedule I, II or III of the <I>Bank
Act </I>(Canada); (B) an association to which the <I>Cooperative Credit Associations Act </I>(Canada) applies or a central cooperative
credit society for which an order has been made under subsection 473(1) of that Act; or (C) a loan corporation, trust company, trust
corporation, insurance company, treasury branch, credit union, caisse populaire, financial services cooperative or credit union league
or federation that is authorized by a statute of Canada or Ontario to carry on business in Canada or Ontario, as the case may be;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> the Business Development Bank of Canada incorporated under the <I>Business Development Bank of Canada
Act </I>(Canada);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(c) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a subsidiary of any person or company referred to in paragraphs (a) or (b), if the person or company owns
all of the voting securities of the subsidiary, except the voting securities required by law to be owned by directors of that subsidiary;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> a person or company registered under the securities legislation of a jurisdiction (province or territory)
of Canada as an adviser or dealer (or in Ontario, except as otherwise prescribed by the regulations under the <I>Securities Act </I>(Ontario));</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(e) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an individual registered under the securities legislation of a jurisdiction of Canada as a representative
of a person referred to in paragraph (d);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(e.1) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> an individual formerly registered under the securities legislation of a jurisdiction of Canada, other
than an individual formerly registered solely as a representative of a limited market dealer under one or both of the <I>Securities Act
</I>(Ontario) or the <I>Securities Act</I> (Newfoundland and Labrador);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(f) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Government of Canada or a jurisdiction (province or territory) of Canada, or any crown corporation,
agency or wholly owned entity of the Government of Canada or a jurisdiction of Canada;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> a municipality, public board or commission in Canada and a metropolitan community, school board, the
Comit&eacute; de gestion de la taxe scolaire de l&rsquo;&icirc;le de Montr&eacute;al or an intermunicipal management board in Qu&eacute;bec;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(h) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any national, federal, state, provincial, territorial or municipal government of or in any foreign jurisdiction,
or any agency of that government;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(i) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a pension fund that is regulated by either the Office of the Superintendent of Financial Institutions (Canada),
a pension commission or similar regulatory authority of a jurisdiction (province or territory) of Canada;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left; width: 0.5in">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left; width: 0.5in"><FONT STYLE="font-size: 10pt">(j) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an individual who, either alone or with a spouse, beneficially owns financial assets having an aggregate
realizable value that, before taxes, but net of any related liabilities, exceeds $1,000,000;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(j.1) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an individual who beneficially owns financial assets having an aggregate realizable value that, before
taxes but net of any related liabilities, exceeds $5,000,000;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(k)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> an individual whose net income before taxes exceeded $200,000 in each of the two most recent calendar
years or whose net income before taxes combined with that of a spouse exceeded $300,000 in each of the two most recent calendar years
and who, in either case, reasonably expects to exceed that net income level in the current calendar year;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(l)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> an individual who, either alone or with a spouse, has net assets of at least $5,000,000;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(m) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a person, other than an individual or investment fund, that has net assets of at least $5,000,000 as shown
on its most recently prepared financial statements;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(n) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an investment fund that distributes or has distributed its securities only to (i) a person that is or was
an accredited investor at the time of the distribution, (ii) a person that acquires or acquired securities in the circumstances referred
to in sections 2.10 [<I>Minimum amount investment</I>] or 2.19 [<I>Additional investment in investment funds</I>] of NI 45-106, or (iii)
a person described in sub-paragraph (i) or (ii) that acquires or acquired securities under section 2.18 [<I>Investment fund reinvestment</I>]
of NI 45-106;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(o) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an investment fund that distributes or has distributed securities under a prospectus in a jurisdiction
of Canada for which the regulator or, in Qu&eacute;bec, the securities regulatory authority, has issued a receipt;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(p)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> a trust company or trust corporation registered or authorized to carry on business under the <I>Trust
and Loan Companies Act </I>(Canada) or under comparable legislation in a jurisdiction of Canada or a foreign jurisdiction, acting on
behalf of a fully managed account managed by the trust company or trust corporation, as the case may be;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(q) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a person acting on behalf of a fully managed account managed by that person, if that person is registered
or authorized to carry on business as an adviser or the equivalent under the securities legislation of a jurisdiction of Canada or a
foreign jurisdiction;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(r)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> a registered charity under the <I>Income Tax Act </I>(Canada) that, in regard to the trade, has obtained
advice from an eligibility adviser or an adviser registered under the securities legislation of the jurisdiction of the registered charity
to give advice on the securities being traded;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(s)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> an entity organized in a foreign jurisdiction that is analogous to any of the entities referred to
in paragraphs (a) to (d) or paragraph (i) in form and function;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(t)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> a person in respect of which all of the owners of interests, direct, indirect or beneficial, except
the voting securities required by law to be owned by directors, are persons that are accredited investors;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(u) </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an investment fund that is advised by a person registered as an adviser or a person that is exempt from
registration as an adviser;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> a person that is recognized or designated by the securities regulatory authority or, except in Ontario
or Qu&eacute;bec, the regulator as an accredited investor;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left">&#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">(w)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"> a trust established by an accredited investor for the benefit of the accredited investor&rsquo;s family
members of which a majority of the trustees are accredited investors and all of the beneficiaries are the accredited investor&rsquo;s
spouse, a former spouse of the accredited investor or a parent, grandparent, brother, sister, child or grandchild of that accredited
investor, of that accredited investor&rsquo;s spouse or of that accredited investor&rsquo;s former spouse; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="vertical-align: top; text-align: left"> &#9744;</TD>
    <TD STYLE="vertical-align: top; text-align: left">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(x)</P></TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;in
    Ontario, such other persons or companies as may be prescribed by the regulations under the <I>Securities Act</I> (Ontario).</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.85pt; text-align: justify; text-indent: -29.85pt"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">***</TD><TD STYLE="text-align: justify">If checking this category (x), please provide a description
of how this requirement is met.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purposes hereof, the following definitions
are included for convenience:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">&ldquo;<B>bank</B>&rdquo; means a bank named in Schedule I or II of the <I>Bank Act</I> (Canada);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">&ldquo;<B>Canadian financial institution</B>&rdquo; means (i) an association governed by the <I>Cooperative
Credit Associations Act</I> (Canada) or a central cooperative credit society for which an order has been made under section 473(1) of
that Act, or (ii) a bank, loan corporation, trust company, trust corporation, insurance company, treasury branch, credit union, caisse
populaire, financial services cooperative, or league that, in each case, is authorized by an enactment of Canada or a jurisdiction of
Canada to carry on business in Canada or a jurisdiction of Canada;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<B>company</B>&rdquo; means any corporation, incorporated association, incorporated syndicate or
other incorporated organization;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B>eligibility adviser</B>&rdquo; means:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">a person that is registered as an investment dealer and authorized to give advice with respect to the
type of security being distributed, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">in Saskatchewan or Manitoba, also means a lawyer who is a practicing member in good standing with a law
society of a jurisdiction of Canada or a public accountant who is a member in good standing of an institute or association of chartered
accountants, certified general accountants or certified management accountants in a jurisdiction of Canada provided that the lawyer or
public accountant must not</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">have a professional, business or personal relationship with the issuer, or any of its directors, executive
officer, founders, or control persons, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">have acted for or been retained personally or otherwise as an employee, executive officer, director, associate
or partner of a person that has acted for or been retained by the issuer or any of its directors, executive officers, founders or control
persons within the previous 12 months;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B>executive officer</B>&rdquo; means, for an issuer, an individual who is: (i) a chair, vice-chair
or president, (ii) a vice-president in charge of a principal business unit, division or function including sales, finance or production,
or (iii) performing a policy-making function in respect of the issuer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B>financial assets</B>&rdquo; means (i) cash, (ii) securities, or (iii) a contract of insurance,
a deposit or an evidence of a deposit that is not a security for the purposes of securities legislation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B>fully managed account</B>&rdquo; means an account of a client for which a person makes the investment
decisions if that person has full discretion to trade in securities for the account without requiring the client&rsquo;s express consent
to a transaction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">&ldquo;<B>investment fund</B>&rdquo; has the same meaning as in National Instrument 81-106 <I>Investment
Fund Continuous Disclosure</I>;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B>person</B>&rdquo; includes: (i) an individual, (ii) a corporation, (iii) a partnership, trust,
fund and an association, syndicate, organization or other organized group of persons whether incorporated or not, and (iv) an individual
or other person in that person&rsquo;s capacity as a trustee, executor, administrator or personal or other legal representative.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">&ldquo;<B>related liabilities</B>&rdquo; means (i) liabilities incurred or assumed for the purpose of
financing the acquisition or ownership of financial assets, or (ii) liabilities that are secured by financial assets;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">&ldquo;<B>Schedule III bank</B>&rdquo; means an authorized foreign bank named in Schedule III of the <I>Bank
Act</I> (Canada);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">&ldquo;<B>spouse</B>&rdquo; means, an individual who, (i) is married to another individual and is not
living separate and apart within the meaning of the <I>Divorce Act</I> (Canada), from the other individual, (ii) is living with another
individual in a marriage-like relationship, including a marriage-like relationship between individuals of the same gender, or (iii) in
Alberta, is an individual referred to in paragraph (i) or (ii), or is an adult interdependent partner within the meaning of the Adult
Interdependent Relationships Act (Alberta); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">&ldquo;<B>subsidiary</B>&rdquo; means an issuer that is controlled directly or indirectly by another issuer
and includes a subsidiary of that subsidiary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In NI 45-106 a person or company is an affiliate
of another person or company if one of them is a subsidiary of the other, or if each of them is controlled by the same person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In NI 45-106 and except in Part 2 Division 4 (Employee,
Executive Officer, Director and Consultant Exemption) of NI 45-106, a person (first person) is considered to control another person (second
person) if (a) the first person, beneficially owns or directly or indirectly exercises control or direction over securities of the second
person carrying votes which, if exercised, would entitle the first person to elect a majority of the directors of the second person, unless
that first person holds the voting securities only to secure an obligation, (b) the second person is a partnership, other than a limited
partnership, and the first person holds more than 50% of the interests of the partnership, or (c) the second person is a limited partnership
and the general partner of the limited partnership is the first person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned has executed this Accredited Investor
Certificate as of the day of ___________, 2025.</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 48%">If a Corporation, Partnership or Other Entity:</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 48%">If an Individual:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt"><I>Name of Entity</I></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><I>Signature</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt"><I>Type of Entity</I></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt"><I>Name of Individual</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt"><I>Signature of Person Signing</I></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt"><I>Title of Person Signing</I></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SCHEDULE &ldquo;B&rdquo;<BR>
CONTACT INFORMATION FOR CANADIAN SECURITIES COMMISSIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="6" STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Alberta Securities Commission </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Suite 600, 250 &ndash; 5th Street SW</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Calgary, Alberta T2P 0R4</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (403) 297-6454</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Toll free in Canada: 1-877-355-0585</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (403) 297-2082</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>British Columbia Securities Commission</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">P.O. Box 10142, Pacific Centre</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">701 West Georgia Street</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Vancouver, British Columbia V7Y 1L2</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Inquiries: (604) 899-6854</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Toll free in Canada: 1-800-373-6393</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (604) 899-6581</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Email: inquiries@bcsc.bc.ca</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>The Manitoba Securities Commission</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">500 &ndash; 400 St. Mary Avenue</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Winnipeg, Manitoba R3C 4K5</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (204) 945-2548</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Toll free in Manitoba 1-800-655-5244</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (204) 945-0330</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Financial and Consumer Services Commission (New
    Brunswick)</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">85 Charlotte Street, Suite 300</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Saint John, New Brunswick E2L 2J2</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (506) 658-3060</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Toll free in Canada: 1-866-933-2222</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (506) 658-3059</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Email: info@fcnb.ca</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Government of Newfoundland and Labrador</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Financial Services Regulation Division</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">P.O. Box 8700</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Confederation Building</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">2nd Floor, West Block</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Prince Philip Drive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">St. John&rsquo;s, Newfoundland and Labrador A1B 4J6</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Attention: Director of Securities</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (709) 729-4189</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (709) 729-6187</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Government of the Northwest Territories</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Office of the Superintendent of Securities</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">P.O. Box 1320</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Yellowknife, Northwest Territories X1A 2L9</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Attention: Deputy Superintendent, Legal &amp; Enforcement</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (867) 920-8984</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (867) 873-0243</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Nova Scotia Securities Commission</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Suite 400, 5251 Duke Street</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Duke Tower</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">P.O. Box 458</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Halifax, Nova Scotia B3J 2P8</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (902) 424-7768</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (902) 424-4625</P></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Government of Nunavut</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Department of Justice</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Legal Registries Division</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">P.O. Box 1000, Station 570</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">1st Floor, Brown Building</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Iqaluit, Nunavut X0A 0H0</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (867) 975-6590</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (867) 975-6594</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Ontario Securities Commission</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">20 Queen Street West, 22<SUP>nd</SUP> Floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Toronto, Ontario M5H 3S8</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (416) 593- 8314</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Toll free in Canada: 1-877-785-1555</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (416) 593-8122</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Email: exemptmarketfilings@osc.gov.on.ca</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Public official contact regarding indirect collection
    of information: Inquiries Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Prince Edward Island Securities Office</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">95 Rochford Street, 4th Floor Shaw Building</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">P.O. Box 2000</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Charlottetown, Prince Edward Island C1A 7N8</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (902) 368-4569</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (902) 368-5283</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Autorit&eacute; des march&eacute;s financiers</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">800, Square Victoria, 22e &eacute;tage</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">C.P. 246, Tour de la Bourse</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Montr&eacute;al, Qu&eacute;bec H4Z 1G3</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (514) 395-0337 or 1-877-525-0337</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (514) 873-6155 (For filing purposes only)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (514) 864-6381 (For privacy requests only)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Email: financementdessocietes@lautorite.qc.ca (For
    corporate finance issuers); fonds_dinvestissement@lautorite.qc.ca (For investment fund issuers)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Financial and Consumer Affairs Authority of Saskatchewan</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Suite 601 - 1919 Saskatchewan Drive</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Regina, Saskatchewan S4P 4H2</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (306) 787-5879</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (306) 787-5899</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Government of Yukon</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Department of Community Services</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Law Centre, 3rd Floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">2130 Second Avenue</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Whitehorse, Yukon Y1A 5H6</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Telephone: (867) 667-5314</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Facsimile: (867) 393-6251</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex10-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ,! # # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^Q"BBBO\
M@%_\#/ZH"BBBC_P, HHHH_\  P"BBBC_ ,# ****/_ P"BBBC_P, HHHH_\
M P"BBBC_ ,# ****/_ P"BBBC_P, HHHH_\  P"BBBC_ ,# ****/_ P"BBB
MC_P, HHHH_\  P"BBBC_ ,# ****/_ P"BBBC_P, HHHH_\  P"BBBC_ ,#
M****/_ P"BBBC_P, HHHH_\  P"BBBC_ ,# ****/_ P"BBBC_P, HHHH_\
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MD^!6,R["K-*DGF.(Q%+,,=2P;KX:*HQP&#>&C4]M6ACO93C:,%4F[57]*_\
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MA9J<J-"5:M&'++GE2C'EES6?*V/[:?['.IV%IJ6G?M8?LUWEC?VL%Y8WEO\
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M^#M<^V7$%YH]I9F40_ZU>'7#_P"TEXLR+_7_ ,3/I,>(7T<_"NG1JYAB^/\
MQO\ $;,N$G7R^A3IXK%XCA[@9X"/'7$-6&'K1K4J&$X=RRC*-7#N\,/.%5?
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M.E3]E24(325.":BBOFK]LG0M<\3_ +(?[5'AKPUH^J>(?$?B#]G#XVZ'X?\
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M28+?Q1\3(GT&^EN=+AMO"LEQIFC:V_EZA<^-=?LKV.2>XL]4N+:E_P &U/\
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M$;PWJ-Q<G[%IVF:A.\8F^#K'_@O7_P $B=0L;._B_;<^'%O'>6L%VD-]X?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>modd-20250320.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kk5s7xRiXhun8uNbHcsWaGNaaPtzp95KYlBuGl6fcnKPyonDuD/myP/LREWccwM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:MODD="http://modularmedical.com/20250320" elementFormDefault="qualified" targetNamespace="http://modularmedical.com/20250320">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://modularmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="modd-20250320_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="modd-20250320_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>modd-20250320_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>modd-20250320_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://modularmedical.com/role/Cover" xlink:href="modd-20250320.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://modularmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 20, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 20,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODULAR MEDICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0620495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10740 Thornmint Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-3500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MODD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &6(>EI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( &6(>EI;(CBM[@   "L"   1
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M=O\:R'X4@2'JF],!>8'KR)LH)\,E[11[9+Z62D S,F0J:82Q%O[OH_;] ^O
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M%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3),
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M/UY_ 5!+ 0(4 Q0    ( &6(>EI&QTU(E0   ,T    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 98AZ6ELB.*WN
M*P(  !$              ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ 98AZ6IE<G",0!@  G"<  !,              ( !X $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " !EB'I:_V'@P38$  !C$   &
M            @($A"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ 98AZ6I^@&_"Q @  X@P   T              ( !C0P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !EB'I:EXJ[',     3 @  "P
M    @ %I#P  7W)E;',O+G)E;'-02P$"% ,4    " !EB'I:JL0B%C,!   B
M @  #P              @ %2$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ 98AZ6B0>FZ*M    ^ $  !H              ( !LA$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 98AZ6F60>9(9 0  SP,
M !,              ( !EQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  X1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0235502-8k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modularmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0235502-8k_modular.htm">ea0235502-8k_modular.htm</File>
    <File>modd-20250320.xsd</File>
    <File>modd-20250320_lab.xml</File>
    <File>modd-20250320_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0235502-8k_modular.htm": {
   "nsprefix": "MODD",
   "nsuri": "http://modularmedical.com/20250320",
   "dts": {
    "inline": {
     "local": [
      "ea0235502-8k_modular.htm"
     ]
    },
    "schema": {
     "local": [
      "modd-20250320.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "modd-20250320_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "modd-20250320_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://modularmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235502-8k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0235502-8k_modular.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001013762-25-002793-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001013762-25-002793-xbrl.zip
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M.9)&PG0WZ:"78;(*?VOL4982*3]K9?8^[%YX-^NC*+1O-L\]\P[MQ#EP-Z,
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MGU,1V 00BZK;DO<[)N8UZ.U#QW@T40Q;LX+O<;)@][B\4O=MYPZ@K$ :F\Q
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M]D$-#$ZR%V\YG(C;!-.\^@G[>.!-QCZ#/C1I'[>5$"6+Y)+?NT-# L5 %%W
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MPBTR43*[N=Q?2QW'(=/;ZZSTWC&J89),X9BDY%7W)3J(9]I@"UO^=\ROQ&W
M\I:>IEN5'IODK,SX[=M;+'?MHK%UE:#D#M8F&N@2G@CNDB@?=.TWCOX41BK1
M7#9$J7&IYEAD+M(@*<44%:V7BW:ZPJA!4Q4W8&XAF0D,,5"(?=C4GU>G9>L;
MI6$^@G1OX0QD7E3Y"A>PQ61/J0WI@M"J8KA!D4I&[R*66;F5<*(DX<JI+0Z$
M*1<ZSAL.[/=ER:!D: "I-T)CG68"/=VI:NVL4>"$S,#(I<SG-)N7[CIC(QC/
M-EB\+'*,QBVE[,V2F!F'<6POPS\50_;#%D,F&+(?MABR[?D)E<F4E$G8'L=5
M.0.9U!H7J-.?8G>OLJ STG002MN[X._2J8;O]]CY.^E-AB>=K\4+4_;HX5I8
M-*"$I15',M$GGTM8$R_6J4R2U $$=86=+\QY[D1^YV9WRM*(SR7Z*BX7N*3I
MG@SZ&(L5K3I)XOQ#0C1'Y;$XADQC*ID2';%;R4)*UR"(C$INP_>WY(V89%.L
MZN5:VX^$K)W-?%=F#^YVI^JH1UL+H%G?E'K(L$_L(.OJ1O -EO,C#QO.2,,L
M\ZPJX,-4Z4IF#\1>F9)W O=KFS]*<Z;>BPS=>I+B<9(BM:!6947FW4I3W'&%
MN-7V5(M5] 1/4CP\10@2CSN%OW9W6,N)M)Q6["J<\?HRDPI[!C*,U1,3!M.U
M+&R-/._Y\(<F4!&]=EP1;(T?D>U)?BWVD^,T=U-]L49=M2S).<7ZFF#W6/_I
M[G[O;8)W>B^DK#5LX!AA.IE#O-#:")+G]V5Z)5.CZAC+&07XJ,<?YD6\%-+N
MM%K6-!4C"**Q:=&<L3V/AIEE*>NI);L;6QN<8 T318#O?K,?CTYK]#FS^E+5
M=3TH A%Q1O*T0,:-1E1?54%C=K&@?UB]@M%G. 5AF4;\25L5].%7:$97Z!OR
ME,%+CRV(ZTA!7,.A#UP_6P)#"C-(WEM#_E7.9XR=)\!$*%*BG(A9,N*/1'IC
M+4%$W"8?^>.9\^(QV5,M1@O?$,&AXF,G!R..Z%#$5.G6.U['3I[[_@QV%GO>
MAQ(Y'ZQ6C(3R8GDK\61JEJ$.>29^+S]L'A.)VD[U$<*6DG&IV*9G!X>'>OJX
M79 B#G_-;:]%E_;0J#WHJI:X%T% -PG)(YB'DB2@]I%UD^U)??A)G=%)/1U%
M2GK5EY</MB66T>SXX;RWR,3.,6).D>X1MY&Q^$<V,2F:$WT=-!E&Z.&B]+%Y
M\>N5/CH?#V$(H$'"$$3Y?%$U/;^7"UC-JN"F;<BEJ)PVYK=^$(@<#"Y*GK8.
MEUO7EVD&%<XG58NMD0F,IM!H_/%P*47;$U.=;&CJ\YH=9!8&R_[2E;J@4,)T
M2FW1::,ZPKHNG>6(PM7 3(:R Y;07PZO#*AXR_FD3@C.('/@5V#/R#0&Z)(N
M[=?0Y\[OVW5$3]W(0@98SW%@1#6RY%W5Z" Z@IF8ZW0F"%Q-IBJJL1]WY7EW
M $YAZ:RG!T_P.$;J76W[VTOG5XXA73>8..N7GU),S!",PA<-ZGL;(5V_ 4EZ
M19+TF(%&HI-XZ3D-/N^%:(?S]'/"/?0VZ<7)<71.N3X=4 %CA5HOA%<=X!.G
MNJ&#?%XU+9$-E@3AXAP2T#;R*LVGDDEDP"(G6A[M"%,(S$$,:[)E@51"=T*U
M@H,NJ*N%#0,/. /0X/ /1HLBP7AXX/ 8+]%HBXZ=P2_E1&A$F.)WTA\'7JND
ME@JY2(J6)*8.R#&3=CT6#KR&<X=:)O63;[S.9/B*X5I!TDY/T/T3:!7$*8L;
M V%+/#5^:@C2@^6+/F_U1B90-HU&-64Z$#\BOX9=0D%ORBG#0$/)Q:LYDVZ2
M^4_"F8N5;\*1=0_MXW>5ZLBXBYTG [LYRVL:[6S9@ *^N^.1=OQ,[!]=D ,I
M7SC+FL/[%HI'8 ;W6.:TS <5=$.O6]*Z@T<7.UDGZ0'..MY =YS@6)C1G=;1
M,J"UM/E6LN<2N"S2)KI"B2^%MMR6WMVY>T]'G[6E8[[Q"0-95L&NE*,<Z^T%
M_T)DXT*\3W1V/-H1;2\PE@K!KV#M!KE7Q7T! X6))7;WI&TJ+!5KXU@Q@RU\
M\H[ZN.H@\LVGK<V9?!Q-1[CZY<#154?GC_<R7WVHR[ 731.=9 OZ[3<$VTRF
M9'^PF3A6JI6=C"T.#!?'##OFDZF3R2X^G,:KS(73!]TU9+^NU-/(#A3HG]3G
M]8;6R ''Z1B3.7R/#/F5._: =_[*U&=!+UUW1ON@06VC91">PLU]J.8%6AWU
M<GA'FN8JZSOL<?>Q$F1=TW*&V?G9!+=8;$1X;&J$DFT AYH58^6>D3ZLPAZH
M<S>\Q'QW0P.$T?)?.$8:C[ $\5X&)6^^Z+I[?3S6Y>VY%Q.MH>S>Z$_<O-BS
M;([D0&[R@K%LA/;Y;=KV]PD$_WT;")9 \-^W@>#M^0DMNFO.A?&ZVH^F(,V%
MNDR;H20G4/I8*4>W1JV:7H.T^\L"1X!>W2;VCE>#\1NO!<U-=OS 7LVWR;1'
M4Q]F#M5_[_*Q:J'Z& XI<Q6$]>%S#(0[))=JINUM%>T]V8]665*C1@\FB',?
M6=.5JC@O,7+37%<4E67S1/'<[CI. N =9:VS4U[B2]@Y'#=?L0H[WF=[#X_=
M546<%?)%SZ>5?:),=M+4I5@U(A_=% >Y%9.53ZCAL><8><Z8\; HF+>QD*=D
M882$3P9FZE[[C1-6N.Y!I7'$US010OZ?"$H.=F56JF>=)H##JC-UYN-8S&93
M*+-Y=<AUDGU:Y+5W0;@?N!>A"TNNX+RV7)6XN&*-V]8=+QM3AO9PX4TG3T2S
MI7N*Y;HMBP:A\U@I@K/TVJFUIL@+3=,1&Z)$/BC$'.AC'41*Z#J,A)FD(U=4
M6XZ6EAUBW8<ZIY(>2G6[X%IZ/"K]G7+*.<6>*&#B#[W;8V(8%FK(DK]PFM>P
M3;EHK/I-G'(%9P?5-618C$DAG^=-P>4[6)OWZ0'FA=U +)V509.<EW9%%-=K
M5M:X$M'3#)/,J9QFK751,?+="Q^;'FD4B=K5O )W:AN"4$B^0N*2Z<UI.(@N
M<"\/CMO0"H(X3J2T2]<W'I+9&,Z?*9KGN(_<$-$-X2&C"SX$=++1\L;R,;##
M^'2GL,75PTY"$*7.#0))TVC/RXM?CH[.PB2&S'D0!"_I,> "XQ14;C,Z;A';
ML#^R)K(24-HF4V%9)B P<7R#;>#+<8,YBP)VPZRJ6FY43P-%"7$,?$!G25YC
M,( =WN/BH0UVZJ)J\@$@L%*(EJF[B$@>Z?WDMQCGU)!P\TDU[!!)&IBCHKKU
M!#>Z&BW*#&)HBA43X4ZDPA#\'/F9H7H^)<9GBQBK',C@8KH='V48 J$?66#-
M1A@TWX#RE9/RY; 9QW0=@ ;V >S.9EI0,.;DAE?A;<X 9\UX?9W!)5TMO'86
M780<;[*[T+_7P.JLV_Q.0J* &'+?27@=1+'#WJ/Y3"BR6&GF2@:0I;YCD7,<
M7B?L0V6C'3$L7X1;"8+S'EKA8@-,G,)78N$G+MK#XPURBF[&$%5%[A&Z:^2-
MG2HW%FQPM,^49!A,)$85#@6"X*S1O8R#*1'%X_HA<PIR&*:_9MP%'SF;BZ@2
ME<3T @L]+M YD8NS:N_5?C"8+HJ$O-.S@N;10?&Z;M#!];=*,DHW6D:W _-2
M[AZA.O;4W.XZ<XY@E3KJ!W*.?>-=NRMIR%Q[]%6',#F7;M!60[2^4P\BV8\Z
M2:N8=!G0D8R.$4.71O<K;B E3617:MY(;+2Q.]9N5Z;NT8<[%WMG#W$I-9?U
MB/>K@B#CP01)OUP^)Y)S5=W5@A!.06=VMX-?PT%[:DU<_X&K$/4C!8OE!%X"
M<^8[,U;'%&O;DLKA=?F4G:_4F]%.;,1U\XW:_[_3%?065O[*1'-]6,>* 8%?
MVXN!+P6"M$F6&6H7.:D6N!57L8,6SSQ6-#8YJ^SFO8$[2O.CD$>2OXAU&WPL
MJUNP=JXR9S:8O#4"2)0LJ)3[7_*HNJ=/,&6=!'UV;0G"T\'BX!#68%13OE,<
M8M^PI12)+1E<1FP85Y@Q9<QZY'GS&+F]+K2.5.R5@=A)HOL^WE'>"$<]TYC;
M1U-=(Q?S95N)TK_XBL10-^--&P&,0W.H5[ Z\!F9W^O0=ZIT7P3^>D&B@S1"
M]CIQ1[ -!^-8EK/DIB(.,D3\YAQQ^#I UB&2!'$<,-LH":/VVA>1D$$>*5T
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MR.E/,-!P3K-T(%=<<<8^22H6=H8!</]P0I6I5C28B(4V?.^'(=7-4$C==OH
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MJKN3\6-8$O$).F"T?F0D(%HRYT-EO:LS*4MM[B9G/129X\3)VZ&.4/P&.^+
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M]KPM18#+-F1F\2Y8T3))K7#3B+$>"<>WA6%;XU[<YO&!(!$4R8$F32EG-&L
MMFXV  -MW--9E_<J?3VIT(:$<9A+<;==_(ZL$]DX#4<N[P06V'AK2P#G ]83
M 587YM/][*X?3@'&:D$SA>!M#?/@&:CD9J7]FF7EU_0BS[E!5UT+<:_<0;RV
M@X,!OG751-_61+.:9.!OYJ0XM]"TIT:ZPD6W5#:C/>%0^6"5J+"4.YD2G2A9
M,'I1X'H2;F#47VAU: OB2PS\K(3S^88>I:8/M3&@[KB!L/FA+4B?;P-)OM:9
M0#OE2$U&,?S-YA3Q#,!#R) TTT+@ZCM-#5XPQK8-9*LQBLJ 5TO4Z@J3A'P
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M%*)771_5#5NC#H9!%4:S&&-*E!T\+H?B\AR%X+,)?!3RU'([RIPHDC/WJG6
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M<6@8?;EF7V(9E9 $&PA63$*O-CBY47*CHA9:Z<;4;&>M/"8)W?*3BO@WI3&
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MSUQ:K.>BY06JC8K-4-XJ+Q$4/!V ^!8V]VG8UEB(-IA.\>M MPC'XT)#-1T
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M 0'999)*OTXBM#$5'IHV>8J?/,&;YS[[^!HOQ)UBDM2T,S.&FP?'0I8'_-:
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M+@WBED]=D?!G6WLUF$I_HOR>LHN;&V7&1G.$&&15KF"@-< ""\M0-D@R*6=
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M= A5'&"2/Z9KK4J7C/APX,!05%3VI\ 995K1JUA!HKGX$>Z@;2.\'\%3/AI
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M/BBQ%%PQD6(!$7&P+#!H3X0N49#G@:[Y0>:5S0T8#BZ2GR'V),RY6,AG5O5
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MV$!H-IRJAW[&<S@A>D7@0(18=0Z]9RG7IZ1M)S>F?C:&;9-<9I7+7:[X4RB
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M[FCH+C<C_<1V&%)D>@?Z:@?HB X8*PN$UQ"M;Y1]3)XTLL71G4V^0Q-A*3E
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M@24A%+BIXUJ8P8>S>+$4@!.]FTMT)L7]]&%/IFDP2L5N@B+.SW(\><<FB\L
MU"F@L;L:R&D.AUZ\V-K8\,0NG,@.;)0,X?;:@_T GO%SY,MT^ Z$H1A4.W$6
M7R+\S=V,;7M#G 5CH"IR#9]F=]7O69Q N[$GC@[%EYU/8F-W^Y:[?C!TV,DP
M_9TD993THPA1!/M E/UA>%=CZ(YE.'HKTE3U^X\^'XYUX"1+&>5.;X#^G=P
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MTZO*OW%3:9Q81Q+W4[3[3="<QU2?9\,XH0C*6,27K*0AYB VS)H]DS*[M-)
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M;=S8;YZ=&WO)B:_!B8=-.?$L7(/447U8>*G$(M;(*\3K\$(F?<->YB#C8_6
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MWQS=!=\L!P0:SEG@:>B6O>Z9F0X2Y-W\C)1TUG4Q"[,(?FD*,@3=2,06O$Z
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MQGD062N:BJQR<7 -%/TX&,-!B?Q\[-2R,)&HY!&=Q5B5OHC'A+,2?%H3PG4
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M^3!UBKRB)6(\ 0W2^EVT8AB4:M@(#6[FE.*B E,A08:PA@+JJ!]*3Z"],O9
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MKWOP3Y@5[.O1\<$AD<='>.3KX6GW,_S<.3TZA*$ /4"'IQ^AM:.3WV$@1^(
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M('ZM?J(0/2J7433;M@,:*+UIG4D1%3A$#JP'=F4U/HLH4F-L4/D US2=K-3
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M+_*_%K)H(S8VPVF?G.NH<WHSR7=A_&U"=H;+I1]E.0SW;<N7!_TX-(:R$S"
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MX,W@;]W.\<D%@ !&?46[AQV=GQS1;H>G%\'IV[/SMX/CB^#B), %PU/[%X<
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MY4N^?V7V_6+&(XL9YA[1!]\7/,*>!@ 2)L50MP/]!2!,MV,)&0E$!?#3.1!
ME)XGP6CI$ZU9N$22-0LG0)O@$MQ<94E$W#8-YF%>5MA:3O\6-?XF3"SP>%BW
MXQC7*()+QU>QRGIP39,H 8Z/&)]YMP.V% ; 5);(D,<+W,$T'!? JQ-DR?,E
MCGUZ\(I_!P8!3%RV&3V<A7$2;&5YMR._AV49CJ_PKO8$6,%Q5@JQMTN/652
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M.><(5UJ--DF:AFM0O@1&A6&(FW$5<1J65B]LVR^XGA,.D5-67^_D>UKX\]H
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M,,O#ZY1RX<(*% 6!04V<K>Z8L4G8ZXENP8=PY?O'H*?".0)"LX$81HW4*+(
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MN,[Q#BP>^EI 4Z8JDPN8"W4CARFI%(Z"&*=-?"DA+'V=OBJ%T\#012918;K
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M0E?RV51A3,W*)5*2NA#8P+:SN'5XSIO!=@ZQ!%D2D>::Q%.L$((GBJY4$1B
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M__WR>[SQSG7 S4;W)H/3+LR[G3<1GF0)"-%TNJ6^2V=A<?G"EI%5 ^R:8O#
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M#+P2J:C@+:=2*CN <"P\RL<MYV'H?AI>=3H.N+QX^P:8I_G.=<$U)<QK@+;
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M$.5*+_W_&;,GL7W.HOV=X!$AZBFKM!JM^JZ_#8QVR\R;FM2D:5!H0)R]Q2]
MX*$*5*OC0VW&\GDQ3STTKK*Y\>AI\8CE ;S=9JF:0:4Q^"IX9Y#CVPL#&F#<
M9.B(" B] 3:A&PYY),I#/Z B&-6B/9V?I8<L@"3^O+\G#T2H]PZ69)=]ECMZ
MZCC#&!#K^NQM<'/,D[G>P" @?*M;Z%0O1?4*T$H](U96@7Y7E:"\%MOOE]<W
M7<M/<K/>)/]:X93(+?\%4$L#!!0    ( &6(>EIQTKBV6P<  .!7   5
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MK3*&LV8JFW 6#[DDP>OR/1F4+V(66F$+!>][(AY5MC#Q^D[)F%+W^$1OCS9
M0@2L !H2Q/ST62AP;A?(-'6+B63\.)Y;T_HV,_F+3&W_@C<-@N6@H<%<Q DP
MCG05I'\N]*+)^_4]G5+EIBD\T)5Y;QMZ#%\4 8I#XX/Z1B$PAHHP772.?-W8
M#>Y=M<4W[I=['ZO=\C]02P$"% ,4    " !EB'I:)4'^R1,;   [A0  &
M            @ $     96$P,C,U-3 R+3AK7VUO9'5L87(N:'1M4$L! A0#
M%     @ 98AZ6C_UO<>/V0  OZL% !T              ( !21L  &5A,#(S
M-34P,C Q97@Q,"TQ7VUO9'5L87(N:'1M4$L! A0#%     @ 98AZ6H^).VF%
M=@  I9$# !T              ( !$_4  &5A,#(S-34P,C Q97@Q,"TR7VUO
M9'5L87(N:'1M4$L! A0#%     @ 98AZ6@IIL#2U10  YET! !P
M     ( !TVL! &5A,#(S-34P,C Q97@T+3%?;6]D=6QA<BYH=&U02P$"% ,4
M    " !EB'I:::PN_E)4   TLP$ '               @ '"L0$ 96$P,C,U
M-3 R,#%E>#0M,E]M;V1U;&%R+FAT;5!+ 0(4 Q0    ( &6(>EJT[AO5+0,
M /0+   1              "  4X& @!M;V1D+3(P,C4P,S(P+GAS9%!+ 0(4
M Q0    ( &6(>EKEB#\M_0H  '^&   5              "  :H) @!M;V1D
M+3(P,C4P,S(P7VQA8BYX;6Q02P$"% ,4    " !EB'I:<=*XMEL'  #@5P
M%0              @ ':% ( ;6]D9"TR,#(U,#,R,%]P<F4N>&UL4$L%!@
0   (  @ -0(  &@< @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>ea0235502-8k_modular_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="modd-20250320.xsd" xlink:type="simple"/>
    <context id="AsOf2025-03-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2025-03-20</startDate>
            <endDate>2025-03-20</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-03-20" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-03-20" id="Fact000004">0001074871</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-03-20" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-03-20" id="Fact000010">2025-03-20</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-03-20" id="Fact000011">MODULAR MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityFileNumber contextRef="AsOf2025-03-20" id="Fact000012">001-41277</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-03-20" id="Fact000013">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-03-20" id="Fact000014">87-0620495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-03-20" id="Fact000015">10740 Thornmint Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-03-20" id="Fact000016">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-03-20" id="Fact000017">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-03-20" id="Fact000018">92127</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-03-20" id="Fact000019">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-03-20" id="Fact000020">800-3500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-03-20" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-03-20" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-03-20" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-03-20" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-03-20" id="Fact000025">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-03-20" id="Fact000026">MODD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-03-20" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-03-20" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
